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1. Summary 
 
Mismatch repair (MMR) is primarily involved in the correction of replication errors. As 
MMR reduces the mutation frequency up to three orders of magnitude, it makes a major 
contribution towards accurate transmission of genetic information. Mammalian MMR 
proteins are conserved through evolution. In human cells, recognition is mediated by two 
homologues of the E.coli MutS protein, hMutSα, a heterodimer of hMSH2 and hMSH6, or 
hMutSβ, a heterodimer of hMSH2 and hMSH3. Subsequently hMutLα, a heterodimer of 
hMLH1 and hPMS2, both homologues of the bacterial MutL protein, is thought to couple 
mismatch recognition with downstream events that include strand discrimination, 
exonucleolytic degradation of the mismatch-containing strand (by an exonuclease such as 
EXO1) and final resynthesis mediated by the DNA polymerase δ. Defects in MMR lead to 
increased mutagenesis, and were linked to colorectal cancer. Hereditary Non-Polyposis 
Colon Cancer (HNPCC) occurs with a very high frequency in individuals carrying germline 
mutations in one allele of primarily hMLH1 or hMSH2. In addition, epigenetic inactivation 
of hMLH1 through promoter hypermethylation can result in sporadic cancer. Together, 
these mechanisms account for about 15% of colorectal cancer cases worldwide. In addition, 
cells lacking MMR are resistant to several types of DNA damaging agents, including those 
used in cancer chemotherapy, such as the methylating drug temozolomide and the 
crosslinking agent cisplatin.  
Although the role of hMutSα and hMutSβ in mismatch recognition and binding has been 
extensively described, the exact function of the MutL proteins remains mostly unclear. I set 
out to gain a better understanding of the function of these polypeptides in MMR and/or 
related processes. In human cells, hMLH1 can bind to three MutL homologues, hPMS2, 
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hPMS1 or hMLH3, to form the heterodimers hMutLα, hMutLβ and hMutLγ respectively 
(Fig.1). 
Fig.1 MutL heterodimers in human cells. 
 
Of the three human heterodimers, only hMutLα is absolutely required for MMR. The role 
of hMutLβ is still unknown; although it was shown to bind hMutSα, it lacks any MMR 
activity in vitro. Similarly, the function of hMutLγ in MMR remained unknown, although it 
participates in meiotic recombination. 
The first part of my studies was aimed at the characterization of the function of the hMutLγ 
heterodimer in human cells with respect to its possible role in MMR. The results obtained 
represent the first report on the expression of hMLH3 in human cells and its possible role in 
MMR. We could show that hMLH3 is present at very low amounts in human cell extracts 
and that it physically interacts with hMLH1. The presence of hMLH1 is essential for the 
stability of hMLH3 in Sf9 cells. However, this interaction is not necessary for the 
stabilization of hMLH3 in human cells, since we found several hMLH1-deficient cell lines 
expressing hMLH3. In this respect hMLH3 differs from the other major hMLH1-
interacting partners, hPMS2 and hPMS1, which are highly unstable in the absence of 
hMLH1. Our finding suggested that hMLH3 might have an alternative interacting partner 
that can mediate its stability. Interestingly, hMLH3 expression can be silenced by promoter 
hypermethylation. To test the role of hMutLγ in MMR, we used cell extracts from Sf9 cells 
expressing hMLH3 to complement the repair defect of extracts prepared from hMutLα-
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deficient cells. Our in vitro MMR assays showed that hMLH3 can play a minor role in 
MMR, acting together with hMutSα in the repair of single mismatches and small insertion-
deletion loops. Nevertheless, hPMS2-deficient cells expressing hMLH3 still show a strong 
MMR-defect, suggesting that a major role of hMLH3 at physiological concentrations in 
vivo is unlikely. However, even a marginal role of hMLH3 in MMR, in partial redundancy 
with hPMS2, and its different expression levels in vivo, might help to explain the low 
penetrance of hPMS2-mutations in HNPCC, compared to hMLH1-mutations. 
MMR is critically dependent on the assembly of multimeric complexes involved in 
mismatch recognition and signal transduction to downstream repair events. Although the 
human MMR was reconstituted in vitro and thus the minimal protein requirements are 
known, the mechanism taking place in vivo is still not fully understood, especially in terms 
of regulation, redundancy and the link to other pathways such as recombination or 
activation of apoptosis. Moreover, the exact biological function of the heterodimer hMutLα 
(hMLH1 and hPMS2) is still enigmatic. The second part of my graduate studies was 
focused on the analysis of proteins interacting with hMutLα. We believe that the 
identification of novel interacting partners of hMLH1 and hPMS2 could yield essential 
information about the role of these two proteins in MMR and/or in other DNA repair-
related mechanisms. To this aim we used Tandem Affinity Purification (TAP), a recently 
developed two-step technique that allows the purification of interactors under native 
conditions and has been shown to be superior to one-step pulldown methods in terms of 
accuracy and specificity. We stably transfected two cell lines deficient for hMLH1 or 
hPMS2, namely 293T and HeLa12, with a vector expressing the N-terminally TAP-tagged 
hMLH1 or C-terminally TAP-tagged hPMS2, respectively. We could show that the tagged 
constructs corrected the MMR-defect of the two respective cell lines both in vitro and in 
vivo. Whole cell extracts from these cell lines were used for TAP, the eluates were loaded 
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on a polyacrylamide gel and the bands were cut out and analyzed by Mass Spectrometry 
(MS). We validated the technique by the detection of the bait proteins and their major 
known interacting partners. We could identify a number of proteins specifically present in 
the respective TAP eluate. Some of these interactors had already been described, but the 
majority of them represented novel findings. Most notably, the recently identified FancJ 
factor BACH1 (or BRIP1), was specifically present at high amounts in our pulldowns. We 
could confirm this interaction by independent techniques and currently are actively 
investigating its role in MMR. Moreover, since there are no hPMS1-deficient cell lines to 
allow for the complementation of the defect by TAP-tagged hPMS1 construct, we 
performed a large-scale immunoprecipitation coupled to MS analysis to identify the 
interacting partners of hPMS1. Interestingly, among the proteins that we identified we 
found a number of factors belonging to the ubiquitin pathway.  In summary, using the TAP 
technique and the large-scale immunoprecipitation, we identified numerous polypeptides 
that are specifically present in complexes with hMLH1, hPMS2 and hPMS1 that we listed 
according to their known biological functions. We started to validate the most interesting 
interactions and characterize their biological roles in the hope to better understand the 
MMR process in vivo. 
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2. Zusammenfassung 
 
Die Fehlpaarungs-Reparatur (Mismatch Repair, MMR) ist hauptsächlich für die Korrektur 
von Replikationsfehlern verantwortlich. Da sie die Mutationsrate um das Tausendfache 
reduziert, spielt dieses Reparatursystem eine Hauptrolle in der fehlerfreien Übertragung 
von genetischer Information. Die MMR-Proteine von Säugetieren sind hochkonserviert. In 
menschlichen Zellen wird die Erkennung einer Basen-Fehlpaarung durch zwei Homologe 
des E. coli MutS-Proteins, hMutSα (ein Heterodimer aus hMSH2 und hMSH6) oder 
hMutSβ (ein Heterodimer aus hMSH2 und hMSH3) gewährleistet.  hMutLα, ein 
Heterodimer bestehend aus den zwei bakteriellen MutL-Proteinhomologen hMLH1 und 
hPMS2, verknüpft dann den Fehlpaarungs-Erkennungsschritt mit nachfolgenden 
Ereignissen, zu welchen Strang-Diskriminierung, exonukleolytische Degradierung des 
fehlgepaarten Stranges (durch eine Exonuklease wie zum Beispiel EXO1) und die 
Resynthese durch DNA-Polymerase δ gehören. Defekte in der MMR führen zu erhöhter 
Mutagenese und nachweislich zu kolorektalem Krebs. Träger von Keimbahnmutationen in 
einem Allel des hMLH1- oder hMSH2-Gens erkranken mit sehr grosser Wahrscheinlichkeit 
an hereditärem nicht-polypösem Dickdarmkrebs (Hereditary Non-Polyposis Colon Cancer, 
HNPCC). Zusätzlich kann hMLH1 durch Promotor-Hypermethylierung epigenetisch 
inaktiviert werden und als Folge davon vereinzelt (sporadisch) Krebs entstehen. Zusammen 
machen diese Mechanismen etwa 15% der weltweit auftretenden kolorektalen Krebsfälle 
aus. Nennenswert ist zudem, dass Zellen ohne MMR Resistenzen gegenüber verschiedenen 
Arten von DNA-schädigenden Wirkstoffen entwickeln, auch gegenüber solchen, welche in 
der Krebs-Chemotherapie eingesetzt werden, wie zum Beispiel Temozolomid 
(methylierender Wirkstoff) und Cisplatin (quervernetzendes Agens). 
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Obgleich die Rolle von hMutSα und hMutSβ im Prozess der Erkennung und Bindung einer 
Basen-Fehlpaarung ausführlich beschrieben ist, bleibt die genaue Funktion des MutL-
Proteins mehrheitlich unklar. Mein Ziel war es, ein besseres Verständnis über die Funktion 
dieser Polypeptide in der MMR und/oder verwandten Prozessen zu gewinnen. In 
menschlichen Zellen kann hMLH1 an die drei MutL-Homologe hPMS2, hPMS1 oder 
hMLH3 binden und bildet so die Heterodimere hMutLα (hMLH1-hPMS2), hMutLβ 
(hMLH1-hPMS1) oder MutLγ (hMLH1-hMLH3) (Fig. 1). 
 
 
 
 
 
 
Fig.1 MutL-Heterodimere in menschlichen Zellen 
 
Von den drei menschlichen Heterodimeren wird nur hMutLα zwingend für die MMR 
benötigt. Die Rolle von hMutLβ ist nach wie vor unbekannt; obschon gezeigt wurde, dass 
hMutLβ an hMutSα bindet, konnte keine MMR-Aktivität in vitro nachgewiesen werden. 
Unbekannt bleibt auch die Funktion von hMutLγ in der MMR, wobei man weiss, dass 
dieses Heterodimer an der meiotischen Rekombination beteiligt ist. 
Der erste Teil meiner Doktorarbeit befasste sich mit der Charakterisierung der Funktion 
von hMutLγ in menschlichen Zellen und der Frage, welche mögliche Rolle dieses 
Heterodimer in der MMR spielen könnte. Meine Resultate demonstrierten zum ersten Mal 
die Expression von hMLH3 in menschlichen Zellen und dessen mögliche Rolle in der 
MMR. Wir konnten zeigen, dass hMLH3 in sehr geringen Mengen in menschlichen Zell-
Extrakten vorhanden ist und physisch mit hMLH1 interagiert. Die Anwesenheit von 
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hMLH1 ist essenziell für die Stabilität von hMLH3 in Sf9-Zellen. In menschlichen Zellen 
ist diese Interaktion jedoch nicht notwendig für die Stabilisierung von hMLH3, da wir in 
einigen hMLH1-defizienten Zell-Linien die Expression von hMLH3 beobachten konnten. 
Demzufolge unterscheidet sich hMLH3 von den beiden anderen hMLH1-
Hauptinteraktionspartnern hPMS2 und hPMS1, welche im höchsten Masse instabil sind in 
der Abwesenheit von hMLH1. Wir vermuten, dass hMLH3 möglicherweise alternative 
Interaktionspartner hat, welche die Stabilität des Proteins gewährleisten. Interessanterweise 
kann die hMLH3-Expression durch Promotor-Hypermethylierung ausgeschaltet werden. 
Um die Rolle von hMutLγ in der MMR zu testen verwendeten wir Zellextrakte von 
hMLH3-exprimierenden Sf9-Zellen und komplementierten damit den Reparaturdefekt von 
hMutLα-defizientem Extrakt. Unser in vitro-MMR-Ansatz zeigte, dass hMLH3 zusammen 
mit hMutSα eine untergeordnete Rolle bei der Reparatur von Einzel-Fehlpaarungen und 
kleinen Insertions-Deletionsschlaufen spielt. Nichtsdestotrotz zeigen hMLH3-
exprimierende, hPMS2-defiziente Zellen immer noch einen starken MMR-Defekt, was 
darauf hindeutet, dass hMLH3 bei physiologischen Konzentrationen in vivo keine 
bedeutende Rolle zukommt.  Jedoch kann nicht ausgeschlossen werden, dass hMLH3 in 
teilweiser Redundanz mit hPMS2 eine marginale Rolle in der MMR spielt und die 
unterschiedlichen hMLH3-Expressions-Levels in vivo erklären möglicherweise die tiefe 
Penetranz von hPMS2-Mutationen in HNPCC im Vergleich zu hMLH1-Mutationen. 
Für die MMR ist die Assemblierung von multimeren Komplexen, welche in die Basen-
Fehlpaarungs-Erkennung und Signal-Weiterleitung an nachgeordnete Reparaturprozesse 
involviert sind,  von entscheidender Wichtigkeit. Obschon die menschliche MMR in vitro 
rekonstituiert wurde und die minimalen Protein-Anforderungen bekannt sind, ist der in 
vivo-Mechanismus nach wie vor nicht vollständig entschlüsselt. Insbesondere fehlen 
Informationen über die Regulation, die Redundanz und die Verbindung zu anderen Pfaden 
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wie Rekombination oder Apoptose-Aktivierung. Zudem bleibt die genaue biologische 
Funktion des Heterodimers hMutLα ein Mysterium.  
Der zweite Teil meiner Doktorarbeit befasste sich mit der Analyse von hMutLα-
interagierenden Proteinen. Wir glauben, dass die Identifikation von neuen 
Interaktionspartnern von hMLH1 und hPMS2 essenzielle Informationen über die Rolle 
dieser beiden Proteine in der MMR und/oder in anderen DNA-reparaturverwandten 
Mechanismen aufdecken könnte. Zu diesem Zweck nutzten wir die kürzlich entwickelte 
Zwei-Schritt-Technologie der Tandem-Affinitäts-Reinigung (TAP), welche die 
Aufreinigung von Interaktoren unter nativen Bedingungen erlaubt und sich, vorallem in 
Bezug auf Genauigkeit und Spezifität, als ausgezeichnete one-step pulldown-Methode 
erwiesen hat. Wir transfektierten zwei entweder hMLH1- (293T) oder hPMS2-defiziente 
(HeLa12) Zell-Linien mit einem Vektor, welcher entweder hMLH1 mit N-terminalem 
TAP-Anhang oder hPMS2 mit C-terminalem TAP-Anhang exprimierte. Wir konnten 
zeigen, dass die TAP-gekennzeichneten Konstrukte den MMR-Defekt in der jeweiligen 
Zell-Linie in vitro und in vivo korrigierten. Total-Zellextrakte von obig genannten Zell-
Linien wurden für die TAP gebraucht, die Eluate wurden auf ein Polyacrylamid-Gel 
geladen und die Banden ausgeschnitten und mittels Massen-Spektrometrie (MS) analysiert. 
Wir validierten die Technik durch Detektierung der Köder-Proteine und deren 
Hauptinteraktions-Partner. So konnte eine Anzahl Proteine identifiziert werden, welche 
jeweils spezifisch für das jeweilige TAP-Eluat waren. Einige dieser Interaktoren wurden 
beschrieben, der Grossteil jedoch repräsentierte neue Befunde. Besonders bemerkenswert 
ist, dass der kürzlich identifizierte FancJ factor BACH1 (BRIP1) spezifisch und in grossen 
Mengen in unseren pulldowns vorhanden war. Wir konnten diese Interaktion durch 
unabhängige Techniken bestätigen und untersuchen zur Zeit intensiv die Rolle dieser 
Inteaktion in der MMR. Da zudem keine hPMS1-defizienten Zell-Linien existieren, um die 
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Komplementation des Defektes mit einem TAP-gekennzeichneten hPMS1-Konstrukt zu 
erlauben, führten wir grossangelegte (large-scale) Immunopräzipitationen, gekoppelt an 
MS-Analysen zur Identifizierung der hPMS1-Interaktionspartner durch. Interessanterweise 
fanden wir unter den identifizierten Proteinen eine Anzahl von Faktoren, welche zum 
Ubiquitin-Pfad gehören.  
Zusammengefasst kann man sagen, dass wir durch die Anwendung der TAP-Technik und 
mittels Durchführung von large-scale Immunopräzipitationen zahlreiche Polypeptide 
identifizierten, welche spezifisch in Komplexen mit hMLH1, hPMS2 und hPMS1 
vorhanden sind. Nach Auflistung der identifizierten Proteine entsprechend ihrer 
biologischen Funktion beginnt nun die Validierung der interessantesten Interaktionen und 
die Charakterisierung der biologischen Rollen derselben, in der Hoffnung, ein besseres 
Verständnis des in vivo-MMR-Prozesses zu erlangen. 
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3. Introduction 
 
DNA molecules can be damaged in numerous ways. In addition to misincorporation errors 
arising during replication, spontaneous damage including deamination, depurination and 
oxidation, together with exogenous effects of radiation and chemical agents all accumulate 
in DNA and threaten genomic integrity. Most kinds of DNA damage are harmful and its 
effects are diverse, ranging from disturbed DNA metabolism to triggering of cell cycle 
arrest or cell death. Long-term effects include irreversible mutations contributing to 
oncogenesis. For these reasons, it is essential for the cell to have efficient repair 
mechanisms able to reduce this damage to a tolerable level. The importance of repair can be 
seen from the fact that DNA is the only biomolecule that is specifically repaired while all 
others are replaced. More than 100 genes participate in various aspects of DNA repair, 
even in organisms with very small genomes, and many repair pathways are highly 
conserved during evolution. Although cells from various organisms  possess a large number 
of different types of repair systems, each relatively specific for a certain kind of DNA 
damage, the repair pathways  can be grouped into four broad categories: direct reversal of 
damage, double-strand break repair, translesion synthesis and excision of damaged region, 
followed by replacement (reviewed in Hoeijmakers J.H., 2001). 
The Direct Reversal (DR) pathway consists of repair proteins that act directly on damaged 
bases and correct the damage without removing the damaged nucleotide. Typical examples 
of DR are repair of UV-induced cyclobutane pyrimidine dimers by the enzyme CPD 
photolyase and the removal of alkyl groups from the O6-position of guanine by 
methylguanine-methyltransferase, MGMT.  
Double-strand breaks (DSB) are a very disruptive form of DNA damage that, if left 
unrepaired, can lead to broken chromosomes and cell death whereas, if repaired 
improperly, to chromosome translocations and cancer. Two independent pathways carry out 
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the repair of DSBs: homologous recombination (HR) and non-homologous end joining 
(NHEJ). HR relies on the use of homologous DNA sequences as templates for resynthesis, 
whereas NHEJ provides a faster, but error-prone pathway of repair of DSBs by joining of 
ends even if there is not significant sequence similarity between them. 
Translesion synthesis is carried out by a class of polymerases that lack exonuclease activity 
and possess a more flexible active site, which allows them to synthesize DNA through a 
variety of lesions present in the template molecule. This kind of mechanism should not, 
strictly speaking, be considered as an example of repair, because the damage is left in the 
DNA, nevertheless it is an important component of the overall cellular response to DNA 
damage. 
Excision repair is the major DNA repair mechanism. In cases where the damage is present 
in just one DNA strand, it can be repaired by cutting it out and replacing it with new DNA 
synthesized using the complementary strand as a template. All organisms employ at least 
three excision mechanisms: base excision repair (BER), nucleotide excision repair (NER) 
and mismatch repair (MMR). 
BER deals with small modifications of individual bases, often arising spontaneously 
through oxidation, methylation, depurination or deamination. The specificity of the reaction 
is given by the DNA glycosylases that recognize a subset of base alterations and cleave the 
N-glycosylic bond between the base and the deoxyribose, creating thus an abasic site. This 
step is followed by the nicking of the damaged strand by an endonuclease and nucleotide 
replacement by a DNA polymerase. 
The NER pathway removes DNA lesions that cause a structural deformation of the DNA 
helix. Repair is achieved trough a damage recognition step (binding of a multi-protein 
complex at the site of damage), a double incision of the damaged strand on both sides of the 
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damage and by the subsequent removal of the damage-containing stretch of nucleotides. 
The resulting gap is then refilled by a DNA polymerase followed by religation. 
The MMR system is responsible for the removal of biosynthetic errors. It removes mispairs 
(non Watson-Crick basepairs) in the newly synthesized strand that were missed by the 
proofreading activity of the polymerase and thus lowers the mutation rate by a factor of 
100-1000 to one error per 1010 nucleotides synthesized (Modrich P. and Lahue R., 1996).  
MMR will be the subject of the following discussion. I will briefly review our knowledge 
of the mechanism of MMR, the biological function of the proteins involved in MMR and 
the link between MMR and human cancer. 
 
3.1. MMR in E. coli 
 
The function of the E. coli MMR system has been well characterized and has served as a 
paradigm for the eukaryotic MMR. The entire reaction has been reconstituted in vitro 
(Lahue R.S. et al., 1989) and involves three dedicated proteins: MutS, MutL and MutH. 
The MMR reaction can be divided into three steps: initiation, excision and resynthesis 
(reviewed in Iyer R.R. et al., 2006). In the first step, the mismatch is detected by a 
homodimer of MutS. MutS can bind to insertion-deletion loops (IDLs) 1-4nt in length and 
to all the possible base-base mismatches with the exception of C/C. The crystal structures 
of MutS from E.coli and T. aquaticus have been solved (Lamers M.H. et al., 2000; 
Obmolova G. et al., 2000); the structures are very similar and provide invaluable insight 
into protein function. MutS appears as a modular protein, consisting of separate domains. It 
embraces the DNA and dimerizes at the top and bottom, leaving two channels of 
approximately 30Å and 40Å in the centre with the DNA kinked by 60° and accommodated 
in the latter (Fig.1). 
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Fig.1 E. coli MutS structure. The    
mismatch-binding monomer is shown in 
domains: N-terminal mismatch-recognition 
domain, dark blue; connector domain, light 
blue; core domain, red; clamp, orange; 
ATPase domain, green with red ADP; helix-
turn-helix domain, yellow. The other 
monomer is shown in grey. DNA is shown in 
red, with a yellow      mismatch. (Sixma T.K., 
2001) 
 
 
It is notable that even though MutS is a homodimer, only one subunit actually binds the 
mismatch, although both contact the DNA to form a clamp. This functional asymmetry is 
an interesting preview of the heterodimers that are found in eukaryotes. 
In the presence of ATP and a mismatch, MutS recruits a homodimer of MutL and together 
they activate MutH. MutH is a latent endonuclease that preferentially cleaves the hemi-
methylated dam (GATC) sites that transiently exist after a replication fork passes. Thus, in 
E. coli, DNA methylation is used as the strand discrimination signal: the nicking of the 
unmethylated DNA strand by MutH ensures that MMR targets the repair to the error-
containing newly synthesized strand. The nick serves as a point of entry for Ssb (single-
strand DNA binding protein) and helicase II, whose loading at the nick is facilitated via 
protein-protein interactions with MutL. A hallmark of MMR is the bidirectionality of the 
process. The MutH-generated nick can occur either 5' or 3' to the mismatch at distances up 
to 1kb away. Depending on which side the cleavage occurs, one of several single-strand 
specific 5'-3' (RecJ or ExoVII) or 3'-5' (ExoI , ExoX or ExoVII) exonucleases (ExoVII 
supports excision in both directions) degrade the DNA tract between the nicked, 
hemimethylated site and the mismatch. The resynthesis is then mediated by DNA 
polymerase III holoenzyme, Ssb and DNA ligase (Fig.2). 
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Fig.2 Mechanism of E.coli MMR. Although not shown, the ligation step is carried out by DNA ligase 
after DNA polymerase III holoenzime fills in the gap (Iyer R.R. et al., 2006). 
 
3.2. MMR in eukaryotic cells 
 
Genes encoding homologues of the MutS and MutL bacterial proteins have been identified 
in several eukaryotes, including yeast, plants, insects, nematodes and mammals. Although 
the principle repair mechanism is conserved, the eukaryotic MMR system is more complex. 
In contrast to the situation in prokaryotes, where MutS and MutL function as homodimers, 
all eukaryotic organisms characterized to date possess multiple MutS and MutL 
homologues with the active form being heterodimers. 
The best characterized eukaryotic MMR system is that of the yeast S. cerevisae, where six 
MutS (scMsh1p-6p) and four MutL homologs (scMlh1p-3p and scPms1p) have been 
identified through a combination of genetic, molecular biological and genome-based 
techniques (reviewed in Kolodner R.D. and Marsischky G.T., 1999). Of the six MutS 
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members, scMsh1p appears to solely promote repair and stability of mitochondrial DNA 
(Reenan R.A.G. and Kolodner R.D., 1992) and although a predicted MSH1-like protein 
was found in the A. thaliana genome, similar homologues have not been found in other 
organisms.  
There are five MutS homologues in humans: hMSH2, hMSH3, hMSH6 that play a role in 
MMR, and hMSH4 and hMSH5 that are exclusively involved in meiotic recombination. 
Similarly, four MutL homologues are known: hMLH1, hMLH3, hPMS2, and hPMS1 (the 
latter two named after the yeast homologues, originally identified in a screening for post-
meiotic segregation genes). As mentioned above, the eukaryotic MMR proteins function as 
heterodimers. Thus, human hMSH2 interacts with hMSH6 or hMSH3 to form the 
complexes named hMutSα and hMutSβ, respectively. Similarly, human hMLH1 can 
combine with three different MutL homologues: hPMS2, hPMS1 and hMLH3 to form the 
complexes hMutLα, hMutLβ or hMutLγ. The various complexes perform specialized 
functions: hMutSα binds and supports the repair of all base-base mismatches, as well IDLs 
of 1-4 unpaired nucleotides, although with different efficiency (G/T, A/C, and A/A 
mismatches and 1nt IDL being the best substrates; reviewed in Marra G. and Jiricny J., 
2005). hMutSβ is responsible for the repair of larger IDLs. The activities of the two hMutS 
heterodimers are thus partially redundant on the repair of small IDLs. Large IDLs, ≥ 10 
bases, are repaired by a pathway independent of MMR (Littman S.J. et al., 1999). An 
interesting feature of the hMutS and hMutL complexes is that although hMSH2 and 
hMLH1 are stable per se, hMSH6, hPMS2 and hPMS1 require the presence of the 
corresponding interacting partner to be stabilized. The function of the MutL heterodimers is 
not as well characterized as that of the MutS proteins and will be the subject of further 
discussion. The most studied heterodimer has been hMutLα that is an essential component 
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of human MMR and supports the repair initiated by both hMutSα and hMutSα. The identity 
and functions of E.coli and eukaryotic MMR proteins are summarized in Table 1. 
 
Eukaryotic 
homologues 
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Table 1 E.coli and eukaryotic proteins required for MMR (adapted from Kunkel T.A. and Erie D.A., 
2005) 
 
3.2.1. Overview of the MMR process 
 
The repair reaction must be targeted to the mismatch-containing newly synthesized strand. 
MutH, which confers strand specificity in E. coli, is not present in eukaryotes, which must 
therefore discriminate strands in a different way. Given that the in vitro MMR reaction is 
nick-dependent, it was suggested that the gaps between Okazaki fragments on the lagging 
strand or the free 3' terminus on the leading strand could provide an appropriate strand 
discrimination signal (Fang W.H. and Modrich P., 1993; Holmes J. et al., 1990; Thomas 
D.C. et al., 1991). However, although strand discontinuities are sufficient to direct MMR in 
vitro, the natural signal that directs the reaction in vivo is still undetermined. Similarly, it is 
still unclear what couples mismatch recognition by the MutS heterodimer with downstream 
events. Central to this question is how MSH proteins bound to a mismatch recruit other 
partners. The C-terminus of all MutS homologues is highly conserved and contains an 
Eukaryotic 
homologues 
Ssb 
RPA, replication protein A 
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ATP-binding site. Several reports show a strict connection between nucleotide binding and 
DNA binding. Heteroduplex DNA has been shown to increase the rate of ATP hydrolysis 
by hMutSα several fold (Gradia S. et al., 1999 and 2000). Conversely, the addition of ATP 
reduces the relative affinity of these proteins for DNA, resulting in an apparent dissociation 
of hMutSα from the mismatch-containing substrate (Blackwell L.J. et al., 1998; Iaccarino I. 
et al., 1998; Gradia S. et al., 1997; Hughes M.J. and Jiricny J., 1992). Although ATP 
binding and hydrolysis is indisputably important in this process, its exact function(s) is still 
under investigation and several models have been suggested. In the “active translocation” 
model, based on electron-microscopy studies of E.coli MutS (Allen D.J. et al., 1997), it is 
proposed that ATP promotes bidirectional translocation of hMutSα by drawing flanking 
DNA toward the protein complex after its initial mismatch binding, yielding a Ω-like loop 
(Blackwell L.J. et al., 1998). In a second model (the “sliding clamp” model), it is proposed 
that mismatch recognition by hMutSα provokes an ADP→ATP exchange. The nucleotide 
switch results in a conformational transition of the protein that allows it to act as a 
diffusible clamp, and to slide along the DNA in an ATP-hydrolysis independent manner, 
signalling to additional components of the MMR machinery (Gradia S. et al., 1999). Both 
models suggest that, upon ATP binding, hMutSα moves away from the mismatch site in 
search of a strand discrimination signal before activating the repair process. A third model 
has been proposed more recently on the basis of the crystal structure of bacterial MutS 
bound to mismatches, which challenges the idea that the proteins leave the mismatch. 
Based on the sharp kinking of mismatched DNA (Obmolova G. et al., 2000; Lamers M.H. 
et al., 2000) the “transactivation model” argues that MutS remains in the vicinity of the 
mismatch and that communication between the mismatch and subsequent repair factors is 
promoted via protein-protein interactions (Junop M.S. et al., 2001). A critical observation 
in support of this model in bacteria came from the observation that, in the presence of MutL 
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and ATP, MutS can activate MutH-mediated cleavage in trans (Junop M.S. et al., 2001). 
The fact that human MMR can be initiated despite the presence of blockades between the 
mismatch and the nick (Wang H. and Hays J.B., 2004) speaks in favor of this model also 
for eukaryotic MutS proteins. Finally, based on atomic force microscope images and DNA 
binding assays, a fourth model was suggested, where the mismatch-bound scMutSα 
homologue serves as a nucleation site for polymerization of a second protein (i.e. scMutLα 
homologue) along the helix (Hall M.C. et al., 2001). Clearly, additional biochemical, 
biophysical and structural studies are necessary to further establish the merit of these 
models and so to clarify the exact mechanism involved in MMR initiation. The proteins 
involved in the MMR steps of excision and resynthesis have been recently identified. These 
include exonuclease EXO1 (Tishkoff D.X. et al., 1998; Genschel J. et al., 2002), single-
strand DNA binding protein RPA (Lin Y. et al., 1998; Ramilo C. et al., 2002), proliferating 
cellular nuclear antigen (PCNA) (Umar A. et al., 1996; Gu L. et al., 1998) and DNA 
polymerase δ (Longley M.J. et al., 1997). An additional replicative DNA polymerase, Pol ε, 
has been implicated in MMR, but its specific role in the process is still unclear (Pospiech 
H. and Syvaoja J.E., 2003). The yeast DNA helicase, scRrm3p, has been postulated to be 
involved in MMR, based on its interaction with scPCNAp (Schmidt K.H. et al., 2002), but 
its human equivalent has not been identified. 
Identification of these factors made it possible to reconstitute the MMR system in vitro 
from purified proteins and to suggest a model for MMR in human cells (Fig. 3). According 
to the latest in vitro studies (Dzantiev L. et al., 2004; Constantin N. et al., 2005), upon 
ATP-driven conformational change of hMutSα and  recruitment of hMutLα, the ternary 
complex encounters a strand discontinuity, possibly bound to PCNA. 
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This event triggers the loading of EXO1 and 
stimulates its activity so that it starts to degrade 
the nicked strand in 5'-3' orientation, toward the 
mismatch. The region of single stranded DNA 
exposed by EXO1 is stabilized by the binding of 
RPA. The process continues in the direction of 
the mismatch through several cycles of binding 
of EXO1, degradation of several hundreds 
nucleotides, dissociation of EXO1 followed by 
its further stimulation by an additional 
hMutSα/hMutLα/ATP complex, until the 
degradation passes the mismatch. The repair is 
then completed with the filling of the gap by the 
replicative DNA polymerase δ and the sealing of 
the nick by a yet unidentified ligase. This model 
accounts for a 5'-3' mismatch–provoked excision 
due to the 5'-3' activity of EXO1 and although a 
recent publication shows a bi-directional in vitro 
repair mediated by an additional 3'-5' cryptic 
activity of EXO1 (Dzantiev L. et al., 2004), more 
data are necessary to clarify this point. It is however 
important to note that the situation in vivo might be 
dramatically different and involve several additional factors, with possible functional 
redundancies. 
 
Fig. 3 Schematic representation of 
human MMR (see text for details). 
Blue circle: PCNA; blue diamonds: 
RPA. (Stojic L. et al., 2004) 
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3.2.2. MutL proteins and MMR 
 
While MutS homologues are responsible for mismatch recognition, the function of MutL 
homologues is more difficult to characterize. These proteins seem to play an essential role 
in MMR by coordinating various protein-protein interactions, thereby earning the 
pseudonym “molecular matchmakers”, but their exact biological role remains enigmatic. 
Human hMLH1 can form heterodimers with either hPMS2, hPMS1 or hMLH3 to form 
three complexes designated hMutLα, hMutLβ or hMutLγ. Although a structure is not yet 
available for full length MutL, crystal structures for the N-terminal 40-kDa of E.coli MutL 
(LN40) and hPMS2 (NhPMS2) in free form and bound to ADP or ATP analogs, as well as 
for a C-terminal dimerization domain fragments of MutL have been obtained (Ban C. and 
Yang W., 1998; Ban C. et al., 1999; Guarne A. et al., 2001; Guarne A. et al., 2004). MutL 
proteins share sequence homology at their N termini over the first 300-400 residues. LN40 
bound to ATP is a monomer in solution however, when bound to a non-hydrolysable ADP, 
it undergoes a large conformational change and forms a dimer. On the basis of sequence 
and structural analyses, MutL is a member of the GHKL superfamily of ATPases, which 
includes also DNA gyrase, a type II topoisomerase, Hsp90 and histidine kinase (Dutta R. 
and Inouye M., 2000). The ATPase activity of MutL and its human homologues is 
substantially less robust than that of ATP-driven motor proteins, which suggests that ATP 
is used to modulate conformational changes in the protein that facilitate interactions with 
other factors and/or DNA. The integrity of the ATPase domain is required for MMR 
(Rashle M. et al., 2002; Tomer G. et al., 2002). Mutational studies of the ATP binding sites 
of scMutLα showed that both subunits have intrinsically different ATPase activities both of 
which are important for MMR (Hall M.C. et al., 2002; Welz-Voegele C. et al., 2002). Thus, 
similarly to MutS, also MutL proteins are functionally asymmetric and likely bind and 
hydrolyse ATP in a sequential or alternating manner during MMR. The structure of 
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NhPMS2 is overall quite similar to that of LN40 and similarly the hPMS2 fragment 
hydrolyses ATP, although slowly. An interesting difference is that the hPMS2 40-kDa 
fragment is the first example of a GHKL ATPase active as a monomer (Guarne A. et al., 
2001). The C-terminal regions of MutL homologues share little sequence similarity. The C-
terminal dimerization domain of MutL has been modelled as a V-shaped dimer with a large 
cavity that has been postulated to accommodate DNA (Guarne A. et al., 2004). 
Similarly to MutS, E.coli MutL is a DNA-binding protein with affinity for both single- and 
double-strand DNA (Junop M.S. et al., 2003), and the MutL ATPase is dramatically 
activated by ssDNA and to a lesser extent by dsDNA (Spampinato C. and Modrich P. 2000; 
Ban C. et al., 1999). In contrast, the ATPase activity of hMutLα doesn’t respond to DNA, 
although the N-terminal ATPase of hPMS2 subunit binds DNA with a preference for 
duplex molecules (Hall M.C. et al., 2001). Also yeast scMutL homologues bind DNA and 
mutations in the DNA binding domain of scMlh1p result in a mutator phenotype and loss of 
heteroduplex repair, suggesting that scMlh1p-DNA binding is important for MMR (Hall 
M.C. et al., 2001; Hoffmann E.R. et al., 2003). 
As mentioned above, hMLH1 can interact with two additional MutL homologues, hPMS1 
and hMLH3. hMutLβ (heterodimer of hMLH1 and hPMS1) does not appear to have a role 
in MMR in vitro (Raschle M. et al., 1999) and other functions of this protein have not been 
discovered yet. With the exception of hMLH1 (Raschle M. et al., 1999) and hMutSα (Plotz 
G. et al., 2002), additional proteins interacting with hPMS1 are at the moment not known. 
hMLH3, the third hMutL protein able to heterodimerise with hMLH1 in a complex called 
hMutLγ, was first identified in S. cerevisiae, where it binds yeast scMlh1p (Wang T.F. et 
al., 1999). Trough mutation analyses it was suggested to be involved in the repair of a 
subset of IDLs, working in concert with scMsh3p (Harfe B.D. et al., 2000; Flores-Rozas H. 
and Kolodner R.D., 1998). The human hMLH3 protein was shown to interact with hMLH1 
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by far-western and mammalian two-hybrid experiments (Lipkin S.M. et al., 2000; Kondo E. 
et al., 2001). Based on the phenotype of Mlh3-/- mice (see chapter 3.2.3.4), a possible role 
of the mouse Mlh3 in MMR was suggested (Chen P.C. et al., 2005), however the 
heterodimer hMutLγ was not characterized and its role in MMR was not clear. A better 
understanding of the role of hMLH3 in human was the aim of the first part of my work that 
resulted in the first data showing the expression levels of this protein in human cells and its 
possible role in MMR (Cannavo E. et al., 2005 and Results). 
 
3.2.3. MMR defects and cancer 
 
MMR defects are linked to both hereditary and sporadic forms of colorectal cancer. 
The hallmark of MMR–deficient tumours is microsatellite instability (MSI), which is 
manifested by gain or loss in the number of mainly mono- and di-nucleotides repeats. To 
standardize testing, a set of five short DNA repeats has been recommended for sensitive 
detection of MSI. If two or more of the five sequences show repeat length variation, the 
sample is considered MSI positive. 
 
3.2.3.1. Hereditary Non-Polyposis Colon Cancer (HNPCC) 
 
The importance of MMR is underlined by the fact that germline mutations of human MMR 
genes cause susceptibility to HNPCC. HNPCC is the most common form of hereditary 
colon cancer, accounting for about 5% of all colon cancers (Lynch H.T. and de la Chapelle, 
1999; Truninger K. et al., 2005) one of the most common neoplasias in Western 
populations. HNPCC is a heritable autosomal dominant disease, which is defined, 
according to the international diagnostic criteria (Amsterdam Criteria I), by the presence of 
colorectal cancer in at least three family members in two successive generations, with one 
affected member having been diagnosed at less then 50 years of age (Vasen H.F.A. et al., 
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1991). In addition to colon cancer, HNPCC patients have higher risk to develop cancers of 
the endometrium, and to a lesser extent of the small bowel, urethra and renal pelvis; the 
diagnostic criteria were later revised to take these extra-colonic cancers into account 
(Amsterdam Criteria II; Vasen H.F.A. et al., 1999). 
Germline mutations in MMR genes are detected in up to 70-80% of HNPCC families (Liu 
B. et al., 1996; Wijnen J. et al., 1997). Individuals with HNPCC carry heterozygous 
germline mutations in MMR genes however, when tumours arise, they have usually lost the 
second wild-type allele through somatic events. Since the initial identification of HNPCC-
linked genes in 1993, HNPCC families have been extensively screened for mutations in 
MMR genes. Mutations of hMSH2 and hMLH1 account for about two-thirds of all HNPCC 
kindreds tested. This percentage reflects the relative importance of the functional role of the 
products of these genes in MMR, as judged by the fact that they are essential components 
of all hMutS and hMutL heterodimers. Due to the partial functional redundancy of hMSH6 
and hMSH3, germline mutations in hMSH3 have not been found and mutations in hMSH6 
are less frequent (~10%) and associated usually with a low degree of MSI. Moreover, these 
mutations occur often in clinically atypical HNPCC families. Surprisingly, although in a 
recent study (Truninger K. et al., 2005) the percentage of HNPCC-associated germline 
mutations in hPMS2 was reported to be similar to that of hMSH2, mutations in hPMS2 
show a low penetrance and occur in atypical HNPCC families. Considering that the 
heterodimer hMutLα (consisting of hMLH1 and hPMS2) is an essential player in MMR, a 
clear connection between mutations in hPMS2 and HNPCC would be expected. One 
possible explanation is the existence of two additional hMLH1-containing heterodimers in 
human cells that could account for a partial redundancy in MMR. In the case of hMutLβ, 
the heterodimer does not seem to participate in MMR in vitro (Raschle M. et al., 1999) and 
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there is no evidence that hPMS1 is an HNPCC-associated gene, even though the possibility 
that this gene is implicated in the susceptibility to non-HNPCC cancers cannot be excluded.  
Although hMLH3 germline mutations have been described in familial colorectal cancer, the 
involvement of hMLH3 in tumorigenesis of HNPCC is controversial. hMLH3 germline 
mutations were found in families carrying a second MMR gene mutated in some cases, 
whereas other groups reported somatic mutations of the gene as the primary event in 
HNPCC patients. Similarly, the MSI status of the tumour in case of hMLH3 mutations is 
contradictory (Liu H.X. et al., 2003; Hienonen T. et al., 2003; de Jong M.M. et al., 2004; 
Wu Y. et al., 2001). We could show (Cannavo E. et al., 2005 and Results) that hMutLγ 
(hMLH1 and hMLH3 heterodimer) has a marginal role in MMR in vitro and that hMLH3 
can be epigenetically silenced in vivo so that a role of hMLH3 in human cancer, possibly in 
combination with additional factors, cannot be excluded. 
Finally, a controversy also exists in terms of whether germline mutations of hEXO1 are 
linked to HNPCC. Several germline mutations of hEXO1 have been reported in HNPCC 
families, but the same alterations were also identified in normal populations, suggesting 
that the alterations represent polymorphisms (Wu Y. et al., 2001; Jagmohan-Changur S. et 
al., 2003). Nevertheless, the creation of the Exo1-/- mice (see chapter 3.2.3.4) suggests that 
a role of hEXO1 mutations in colon cancer predisposition is possible. 
 
3.2.3.2. Sporadic colorectal cancer 
 
MSI occurs in 15% approximately of sporadic tumours of colorectum and other organs 
(Boland C.R. et al., 1998). The majority of sporadic colorectal cancers with high MSI are 
caused by inactivation of hMLH1. Whereas in HNPCC the MMR genes are inactivated 
mainly by somatic mutations or loss of heterozygosity, in sporadic hMLH1-deficient 
colorectal cancers, the inactivation mostly results from gene silencing through promoter 
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hypermethylation (Kuismanen S.A. et al., 2000). hMLH1 promoter inactivation seems to be 
often biallelic, as suggested by studies in cell lines (Veigl M.L. et al., 1998) and it is 
present already in non-neoplastic precursor lesions of colon cancer, indicating that it is an 
early event in tumorigenesis (Toyota M. et al., 1999). 
 
3.2.3.3. Tumorigenesis and MMR deficiency 
 
The mutation rates in tumour cells with MMR deficiency are 100-1000 fold higher then in 
normal cells (Bhattacharyya N.P. et al., 1994). As mentioned above, these mutations occur 
with especially high frequency in genes containing microsatellites. As numbers of these 
genes are tumour suppressors, their mutational inactivation is believed to promote 
cancerogenesis. A selection of these genes is shown in table 2.  
Table 2 Selection of target genes for frameshift mutations in MSI colon cancers (Adapted from 
Peltomaki P., 2001) 
 
Moreover, functional MMR was shown to suppress recombination between homeologous 
sequences. As a result, MMR-deficient cells might have higher rates of gene conversion, 
which might expose tumour suppressor genes to loss of heterozygosity (Ciotta C. et al., 
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1999). Finally, MMR-deficient cells fail to promote apoptosis upon exposure to certain 
genotoxic agents (see chapter 3.3.1). This might allow cells with damaged DNA to survive 
and potentially give rise to tumours, rather then die (Bardelli A. et al., 2001). 
 
3.2.3.4. Mouse models of human MMR defects 
 
The development of mouse cell lines with targeted inactivation of all known MMR genes 
has critically helped the understanding of the relationship between MMR and tumorigenesis 
in HNPCC (reviewed in Wei K. et al., 2002). In general, the phenotype of MMR mutant 
mice correlates well with mutation analysis in HNPCC patients and repair defects of cell 
lines lacking the corresponding protein. A major difference is that, unlike HNPCC patients, 
only homozygous and not heterozygous mice develop tumours. This feature is most likely 
due to the short life span and small size of the mice, which make the somatic loss of the 
second allele less probable. The spectrum of tumours in these mice includes mainly 
gastrointestinal (GI) and skin cancers, with a particular susceptibility to lymphomas. In 
addition, MMR deficient mice do not develop colorectal cancer, but rather tumours of the 
small intestine. The phenotype of the MMR deficient knock-out mice is shown in table 4. 
 
Table 4: Phenotype of MMR-deficient knock-out mice (Adapted from Li G.M., 2003 and Chen P.C. 
et al., 2005) 
 
A striking feature of the Mlh1, Pms2 (males only) and Mlh3 knock-out mice is sterility, 
which does not appear in Msh2- and Msh6-deficient animals. This implies additional 
Lymphoma, GI 
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functions for MutL homologue proteins in meiosis, which will be discussed in chapter 
3.3.2. 
Moreover, the tumour spectrum of Mlh1-/- animals differs from that of Pms2-/- mice, 
suggesting that other proteins might have redundant roles with Mlh1. Indeed Chen P.C. et 
al. (2005) recently reported that Mlh3-/- animals develop GI cancers and lymphomas, albeit 
at a later age. 
 
3.3. Additional roles of MMR  
 
 
3.3.1. MMR deficiency and drug resistance 
 
While MMR is well characterized for its role in correcting replication errors, other 
important roles of MMR proteins have been discovered. Most notably, MMR was shown to 
mediate cell killing upon treatment with several genotoxic agents (reviewed in Stojic L. et 
al., 2004). MMR-deficient cells have been shown to be around 100-fold more resistant to 
methylating agents (SNI-type) and two to three folds to cisplatin, than cells with functional 
MMR. 
Upon treatment with low doses of SNI -type alkylating agents such as MNNG (N-methyl-
N'-nitro-N-nitrosoguanidine) or its close relative Temozolomide used in cancer 
chemotherapy, MMR-proficient cells usually undergo growth arrest at the G2-phase of the 
cell cycle, which is followed by apoptosis. MMR-deficient cells treated with the same 
doses do not respond to the treatment, thus the apoptotic response only occurs in the 
presence of functional MMR (reviewed in Stojic L. et al., 2004). The molecular events 
involved in the MMR-dependent apoptotic response have not been established yet, 
however, two models have been proposed. 
SNI -type alkylating agents give rise to O6-methylguanine (O6-MeG), which templates 
thymidine during replication. If demethylation is not carried out by the methyltransferase 
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MGMT, the MMR machinery will recognise the O6-MeG/T mismatch. However, because 
MMR is always targeted to the newly synthesized strand, adducts in the template strand 
cannot be removed and thus the unusual base pair re-forms upon DNA resynthesis. As a 
result, the repair cycle might be perpetually reinitiated. Such a futile repair cycle may signal 
cells to switch on the apoptotic machinery (Karran P., 2001). A second model suggests the 
possibility that MMR proteins might act as damage sensors and directly transduce the 
damage signal to downstream components (Fishel R., 1999). 
As mentioned above, MMR-deficient cells show a two to three fold higher resistance also 
to cisplatin compared to MMR-proficient cells. Although this difference is well 
documented (reviewed in Stojic L. et al., 2004), the role of MMR in the sensitivity to 
cisplatin is less critical than in the case of alkylating agents. It is clear that the lesions 
produced by cisplatin (mainly intra- and inter-strand cross-links) cannot possibly be 
mistaken for a simple mismatch by the MMR machinery; this kind of lesions would rather 
block the progression of the replication fork. The mechanism underlying the MMR-
dependent response to cisplatin must therefore differ from that controlling the response to 
alkylating agents. Clearly, more experiments are needed to clarify this point. 
The role of MMR in the response to other DNA damaging agents, such as ionizing 
radiation, UV radiation, topoisomerase inhibitors or interstrand cross-linking agents is more 
controversial. Although a differential response to those agents was reported to be MMR-
dependent, when those agents were tested using strictly isogenic MMR-proficient and 
deficient cells, no differences were observed (Papouoli E. et al., 2004 and references 
within). 
 
 
 
 32 
3.3.2. Role of MMR proteins in meiosis 
 
Some MMR proteins have meiosis-specific functions that appear to operate independently 
of mismatch binding/repair. In meiosis, homologous recombination serves to promote 
genetic diversity and to create a physical link between homologous chromosomes that is 
crucial for assuring their proper segregation during the first meiotic division. A subset of 
MMR proteins is required for the formation of crossovers and the proper segregation of 
homologues (reviewed in Kolas N.K. and Cohen P.E., 2004; Hoffmann E.R. and Borts 
R.H., 2004). The MutS homologues MSH4 and MSH5 (that interact to form a heterodimer) 
appear to have completely lost the ability to participate in MMR instead, the loss of either 
is associated with approximately 50% reduction in meiotic crossing over (Hollingsworth 
N.M. et al., 1995; Ross-Macdonald P. et al., 1994). Mice deleted for Msh4 or Msh5 are 
sterile, show asynapsis of homologous chromosomes but do not develop tumours 
(Edelmann W. et al., 1999; de Vries S.S. et al., 1999; Kneitz B. et al., 2000). 
MutL homologues MLH1, MLH3 and PMS2 appear also to have a role in meiotic 
recombination, in addition to their function in MMR. Knock-out mice for Mlh1 are sterile 
and the complex Mlh1-Mlh3 is formed during murine meiosis (Kolas N.K. et al., 2005). In 
addition, Mlh3 interacts with Msh4 in mammalian meiotic cells (Santucci-Darmanin S. et 
al., 2002), suggesting that MLH1-MLH3 might act during meiosis together with MSH4-
MSH5 (Kolas N.K. et al., 2005). As would be expected if Mlh3 functioned together with 
Mlh1, Mlh3-/- mice are infertile. Mlh3 seems to be required for the localization of Mlh1 to 
meiotic chromosomes and for the formation of late recombination nodules (Lipkin S.M. et 
al., 2002). The absence of Pms2 in mice causes abnormal chromosome synapsis and 
sterility but, intriguingly, only in males (Baker S.M. et al., 1995). The data available up to 
date point to a role of PMS2 in mammalian meiosis (Kolas N.K. et al., 2005), but the exact 
function and mechanism remains unclear. Finally, mice carrying an inactivating mutation in 
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Exo1 are infertile (Wei K. et al., 2003), but the role of this protein in crossing over remains 
elusive. 
 
3.3.3. Further roles of MMR proteins 
 
MMR proteins participate in several other mechanisms that involve heterodouplex 
formation and/or recombination. For instance they have important anti-recombination 
functions. MutS and MutL proteins suppress recombination between quasi-homologous 
sequences, so called homeologous recombination. The anti-recombination activity of MMR 
in prokaryotes is thought to constitute a barrier to DNA transfer between different species 
(Vulic M. et al., 1997). Studies in yeast and mammalian cells have demonstrated similar 
functions of the eukaryotic MutS and MutL proteins (reviewed in Surtees J.A. et al., 2004). 
Studies in S.cerevisae have identified a specialized role of scMsh2p-scMsh3p in 
homologous recombination and a type of recombination known as single strand annealing 
(SSA) (reviewed in Paques F. and Haber J.E., 1999). In homologous recombination, a 
single-stranded tail with a 3'-end invades a homologous duplex DNA molecule, and the 
invading 3'-end is then used to prime DNA synthesis. If the 3'-end itself is not homologous 
to the invaded duplex, the nonhomologous segment must be removed before DNA 
synthesis can be initiated. In the SSA recombination pathway, a double strand break 
between directly repeated sequences is acted on by a 5'-3' exonuclease to yield long tails 
with 3' ends. Genetic studies have demonstrated that scMsh2p and scMsh3p cooperate with 
scRad1p-scRad10p endonuclease to effect the removal of nonhomologous 3'-tails generated 
during mitotic homologous recombination and SSA (Saparbaev M. et al., 1996; Sugawara 
N. et al., 1997). 
The recombinational functions of MMR seem also to be responsible for the emerging role 
of MMR proteins in telomere elongation by a telomerase-independent recombination-based 
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mechanism, called ALT (Alternative Lengthening of Telomeres; Nguyen B. et al., 2004 and 
references within). The precise role of MMR defect for the engagement of this ALT 
telomere elongation remains unclear, although work in yeast suggest that a hyper-
recombinogenic phenotype, which is associated with the MMR defect, might facilitate ALT 
engagement (Rizki A. et al., 2001). 
Paradoxically, some MMR proteins also participate in specialized processes that destabilize 
genetic information. An example is the expansion of trinucleotide repeat sequences that 
underlie a number of neurodegenerative diseases, such as myotonic dystrophy, 
Huntington’s disease, fragile X-syndrome and Friedreich’s ataxia (Wells R.D. et al., 1998). 
MMR proteins seem to actively contribute to the formation of large expansions, maybe in a 
replication–independent manner. In particular, a specific role of hMSH2 and hMSH3 in this 
pathway has been postulated, but the molecular mechanisms responsible for the expansion 
remains to be established (Owen B.A. et al., 2005).  
Finally, two examples where MMR proteins alter genetic information in a positive way are 
somatic hypermutation (SHM) and class-switch recombination (CSR) (reviewed in Martin 
A. and Scharff M., 2002). These processes occur in B cells and are required for the 
development of a normal and highly diverse repertoire of immunoglobulin genes. There are 
different postulated roles for MMR in SHM and CRS, but additional data are needed to 
draw any conclusions at the moment. 
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Abstract
The human mismatch repair (MMR) proteins hMLH1 and
hPMS2 function in MMR as a heterodimer. Cells lacking either
protein have a strong mutator phenotype and display micro-
satellite instability, yet mutations in the hMLH1 gene account
for f50% of hereditary nonpolyposis colon cancer families,
whereas hPMS2 mutations are substantially less frequent and
less penetrant. Similarly, in the mouse model,Mlh1/ animals
are highly cancer prone and present with gastrointestinal
tumors at an early age, whereas Pms2/ mice succumb to
cancer much later in life and do not present with gastro-
intestinal tumors. This evidence suggested that MLH1 might
functionally interact with another MutL homologue, which
compensates, at least in part, for a deficiency in PMS2. Sterility
of Mlh1/, Pms2/ , and Mlh3/ mice implicated the Mlh1/
Pms2 and Mlh1/Mlh3 heterodimers in meiotic recombination.
We now show that the hMLH1/hMLH3 heterodimer, hMutL;,
can also assist in the repair of base-base mismatches and single
extrahelical nucleotides in vitro . Analysis of hMLH3 expression
in colon cancer cell lines indicated that the protein levels
vary substantially and independently of hMLH1. If hMLH3
participates in MMR in vivo , its partial redundancy with
hPMS2, coupled with the fluctuating expression levels of
hMLH3, may help explain the low penetrance of hPMS2
mutations in hereditary nonpolyposis colon cancer families.
(Cancer Res 2005; 65(23): 10759-66)
Introduction
Mismatch repair (MMR) proteins are a highly conserved group of
polypeptides that play key roles in the correction of mispairs
arising during DNA replication. They also prevent recombination
between nonidentical sequences and participate in the signaling of
certain types of DNA damage. The importance of MMR proteins in
the maintenance of genomic integrity is underscored by the finding
that germ line mutations in MMR genes predispose to hereditary
nonpolyposis colon cancer, a common familial cancer predisposi-
tion syndrome (reviewed in refs. 1, 2). The principal MMR players
in human cells are homologues of the bacterial MutS and MutL
proteins. hMutSa, a heterodimer of the MutS homologues hMSH2
and hMSH6, binds base-base mismatches and small insertion/
deletion loops, whereas hMutSh (a heterodimer of hMSH2 and
hMSH3) binds only insertion/deletion loops. This in vitro evidence
could be corroborated by analysis of the phenotypes of MMR-
deficient cells: Those lacking hMSH2 are fully MMR deficient and
display a mutator phenotype and microsatellite instability that is
consistent with the loss of repair of both base-base mismatches
and insertion/deletion loops. Cells lacking hMSH6 retain a strong
mutator phenotype but their microsatellite instability is limited to
mononucleotide repeats due to the functional redundancy with
hMutSh in insertion/deletion loop repair. This situation is mirrored
in hereditary nonpolyposis colon cancer families, where the
penetrance of hMSH2 mutations is substantially higher than that
of alterations in the hMSH6 locus (reviewed in ref. 2).
Whereas it is generally accepted that hMutSa and hMutSh are
the mismatch recognition factors that initiate MMR (reviewed in
ref. 3), the function of the MutL homologues remains speculative.
The human genome contains numerous genes that have significant
sequence homology to mutL and to yeast MutL homologue and
postmeiotic segregation genes; however, to date, only hMutLa,
a heterodimer of hMLH1 and hPMS2, could be shown to be
involved in MMR. Correspondingly, hMLH1- or hPMS2-deficient
cells have a strong mutator phenotype and high microsatellite
instability (reviewed in ref. 1). In in vitro studies, hMutLa could
be shown to associate with hMutSa on a mismatch-containing
substrate (4) and was suggested to act as a ‘‘molecular matchmaker’’
between these protein complexes and the downstream effectors of
repair (reviewed in ref. 3). hMutLh, a heterodimer of hMLH1 and
hPMS1, has been biochemically characterized but could not be
shown to participate in MMR in vitro (5). This finding was
substantiated by in vivo evidence: Mice carrying a disruption in
the Pms1 gene display neither microsatellite instability nor cancer
predisposition (6). hMLH3 was identified through its interaction
with hMLH1 on Far Western blots (7); however, this heterodimer,
hMutLg, has not been biochemically characterized and its role
in mammalian MMR has not been established. MLH3 was first
identified in Saccharomyces cerevisiae and its gene product,
scMlh3p, was shown to bind scMlh1p (8, 9) and to be involved in
meiotic recombination (reviewed in refs. 10, 11). As mlh3 mutants
display amutator phenotype similar to that ofmsh3-deficient strains
(8, 12), it was suggested that the two polypeptides are involved in the
repair of a subset of insertion/deletion loops. hMLH3 seems to be
involved in meiotic recombination (13, 14) and the same is true for
the murine Mlh3 (14). As both Mlh1- and Mlh3-deficient mice are
sterile (reviewed in refs. 10, 11), it was suggested that the two
polypeptides function together. However, unlike Mlh1/ animals
(6), Mlh3/ mice did not succumb to cancer in the first 9 months
of life (15). The roles of the various MMR factors and the pheno-
types of mice with defects in MMR genes are listed in Table 1.
The involvement of MutL homologue malfunctions in human
cancer is not as clear cut as in the case of the MutS homologues.
Mutations in hMLH1 predominate in hereditary nonpolyposis
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colon cancer, accounting for nearly 50% of all known germ line
MMR gene mutations (2). Surprisingly, no germ line mutations
have been found in hPMS1 or hPMS2 , which was unexpected, given
the key role of the latter protein in MMR. Recent immunohisto-
chemical analysis of 1,048 unselected colon tumors revealed the
lack of hPMS2 in f1.5%, a proportion similar to that of MSH2-
deficient cancers (16). Genetic analysis identified germ line
mutations in hPMS2 in a number of these patients and it is likely
that the remainder will also be linked to genetic alterations once
the problems associated with sequencing of the hPMS2 locus are
overcome (there are f20 hPMS2 pseudogenes on chromosome 7,
which interfere with DNA sequencing). However, these patients do
not belong to typical hereditary nonpolyposis colon cancer families
and the penetrance of these mutations seems to be very low. One
possible explanation for this finding is that the defect in hPMS2 is
partially compensated for by another MutL homologue, such as
hMLH3. Germ line hMLH3 missense and frameshift mutations
have been described in familial colorectal cancer cases but the
implication of these alterations in carcinogenesis is ambiguous. In
some cases, the mutation in hMLH3 was identified in families
carrying a second MMR gene mutation, whereas no mutations in
the other MMR genes could be identified in other cases (17–19). A
similar discrepancy applies also to the microsatellite instability
status of the tumors (17, 20). The role of hMLH3 in MMR and of
hMLH3 mutations in cancer thus remains open to question. In an
attempt to provide answers to these questions, we examined the
role of hMLH3 in MMR in vitro .
Materials and Methods
cDNA Vectors
pFastBac1-His6-hMLH3. The cDNA of hMLH3 (Swiss-Prot entry
Q9UHC1) was used as template for a PCR reaction where (His)6 tag
was added at the NH2 terminus of hMLH3 using the primers hMLH3fo1
(5V-CGCGGATCCACCATGTCGTACTACCATCACCATCACCATCACG-
ATTACGATATCCCAACGACCGAAAACCTGTATTTTCAGGGCATCAAGTG-
CTTGTCAGTTGAAG-3V) and hMLH3re1 (5V-ATTTGCCTACTGGTGG-
GACC-3V). The fragment was then cleaved with BamH1 and PflM1 and
cloned between the corresponding sites in pFastBac1 (Invitrogen, San
Diego, CA).
pTXB1-hMLH3 (amino acids 961-1,453). The COOH-terminal part
of hMLH3 cDNA coding for amino acids 961 to 1,453 was amplified by
PCR from pFastBac1-His6-hMLH3 using the primers fMLH3-Ct (5V-GG-
GAATTCCATATGGAGAACTGTGTGATATCAGAAACTC-3V) and rMLH3-Ct
(5V-AAGGCCGCTCTTCCGCACATTGGTGGCTCACAGGGAGGCATG-3V). The
PCR product was subcloned between the NdeI/SapI sites of pTXB1 (New
England Biolabs, Beverly, MA).
Expression of hMutL;
The Bac-to-Bac baculovirus expression system (Life Technologies,
Gaithersburg, MD) was used according to the instructions of the manu-
facturer. Spodoptera frugiperda Sf9 cells (2  108; Life Technologies) were
infected with either a single recombinant baculovirus or with a combina-
tion of two viruses at a multiplicity of infection of 10. Cells were harvested
72 hours after infection and total extracts were prepared as described (21).
Partial purification of hMutLg from Sf9 extracts was done using Ni-NTA
agarose (Qiagen, Hilden, Germany), and the QIAexpressionist system was
used according to the instructions of the manufacturer using 5 mL of 50%
Ni-NTA slurry per 100 mg of protein extract.
hMutLg was expressed also in bacteria using a bicistronic vector
pET11b-His6-hMLH3/MLH1 (cloning information on request) in the BL21
strain of Escherichia coli . After induction of expression at 37jC for 4 hours
with 0.4 mmol/L isopropyl-h-D-thiogalactopyranoside, the heterodimer was
expressed but was insoluble. Nevertheless, the protein could be used to
quantify the relative abundance of hMLH3 in HeLa cells.
hMLH3 Antibody Production and Purification
The COOH-terminal polypeptide of hMLH3 (amino acids 961-1,453) was
expressed using the Impact-CN-System (New England Biolabs) in BL21
E. coli transformed with pTXB1-hMLH3 (amino acids 961-1,453). The
peptide was purified using fast protein liquid chromatography on a MiniQ
4.6/50 PE column (Amersham Pharmacia, Uppsala, Sweden) and used to
immunize rabbits at Eurogentec (Seraing, Belgium). The rabbit polyclonal
antibody was then affinity-purified using the COOH-terminal polypeptide
immobilized on a nitrocellulose membrane. In brief, 100 Ag of the purified
polypeptide were blotted onto a nitrocellulose membrane by standard elec-
trophoretic transfer, visualized by Ponceau S staining, and the correspond-
ing band was cut out. The membrane was blocked with 5% nonfat dry milk
in TBST [20 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, and 0.1% Tween
20] for 60 minutes, incubated with 700 AL of the polyclonal antibody for
4 hours at 4jC, and washed thrice with TBST for 15 minutes. The mem-
brane was then cut into small pieces (1  0.5 cm) and the antibody was
eluted from the membrane by incubation for 20 minutes at room tem-
perature in 0.1 mol/L glycine (pH 2.5). The supernatant was collected and
the pH was neutralized by an equal volume of 1 mol/L Tris-HCl (pH 8.0).
The purified antibody was stored at 20jC in 50% glycerol.
It was used to perform all the experiments described in this study except
for the immunoprecipitation of hMLH3 from human cell extracts.
Human Cell Lines and Preparation of Cell Extracts
All the colon cancer cell lines, HEK293, and HeLa cell lines used in this
study were obtained from the cell line repository of Cancer Network Zurich.
The hPMS2-deficient cell lines HeLa clone 12 (22) and Hec-1A (23) were kindly
provided by Dr. Margherita Bignami (ISS, Rome, Italy). The cell line HEK293T
was derived from HEK293 by immortalization with adenovirus 5 DNA and
transfection with SV40 large Tantigen (24). The hMLH1 gene in this cell line is
epigenetically silenced by promoter hypermethylation (25). The 293T La cell
line was developed in our laboratory (26). In these cells, the hMLH1 c-DNA
was stably integrated under the control of the tetracycline response promoter
Table 1. Overview of mammalian MutS and MutL homologues and their roles in MMR
Heterodimer Components MMR role Phenotype of knockout mice
hMutSa hMSH2 Repair of base-base mismatches and small loops Lymphomas, gastrointestinal, skin, and other tumors
hMSH6 Lymphomas, gastrointestinal, and other tumors
hMutSh hMSH2 Repair of loops Lymphomas, gastrointestinal, skin, and other tumors
hMSH3 Gastrointestinal tumors
hMutLa hMLH1 Repair of all MMR substrates Lymphomas, gastrointestinal, skin and other tumors; sterility
hPMS2 Lymphomas, sarcomas; male sterility
hMutLh hMLH1 ? Lymphomas, gastrointestinal, skin, and other tumors
hPMS1 No phenotype
hMutLg hMLH1 ? Lymphomas, gastrointestinal, skin, and other tumors
hMLH3 Sterility
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using the Tet-Off system (Clontech, Palo Alto, CA). In the absence of
doxycycline, these cells express hMLH1 and are MMR proficient. All the cell
lines were cultured at 37jC in a 5% CO2–humidified atmosphere and
maintained in the appropriate media. Whole cell extracts from these cell lines
were prepared as described (26) without modifications. The origin and MMR
status of the cell lines used in this study is listed in Table 2.
Western Blot Analysis
Western blots were done as previously described (26) using the following
primary antibodies: our rabbit polyclonal anti-hMLH3 (1:400), anti-hMLH1 and
anti-hPMS2 from BD PharMingen (San Diego, CA) (1:4,000 and 1:1,000, respec-
tively), and anti-h-tubulin (1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA).
Coimmunoprecipitation Analysis of hMLH1 and hMLH3
HeLa whole cell extract (1 mg) was incubated in a total volume of 500 AL in
NP40 Lysis Buffer [50 mmol/LTris-HCl (pH 8.0), 125 mmol/L NaCl, 1% NP40, 2
mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 1 complete pro-
tease inhibitory cocktail (RocheMolecular Biochemicals, Basel, Switzerland)]
for 3 hours at 4jC with the anti-hMLH1 (6 Ag; BD PharMingen) or anti-
hMLH3 (10 Ag; Santa Cruz Biotechnology) antibodies. The immunoprecipi-
tates were captured by incubation for 30 minutes at 4jC with 50 AL of 50%
slurry of Protein A/G PLUS agarose (Santa Cruz Biotechnology). The agarose
beads were then washed thrice with cold NP40 Lysis Buffer and the proteins
were eluted with SDS sample buffer and subjected to Western blot analysis.
Control experiments were done either in the absence of antibody or in the
presence of 25 units of Benzonase (Merck, Whitehouse Station, NJ).
Analysis of the hMLH3 Promoter and Treatment of Cells
with 5-Aza-2V-deoxycytidine
The hMLH3 5Vflanking region was analyzed for CpG content with the
CpG plot software of the European Bioinformatics Institute (http://
www.ebi.ac.uk/emboss/cpgplot/) and its methylation status was evaluated
with methylation-specific PCR as described previously (16). Primer
sequences for the unmethylated reactions were 5V-GTTGTGTGTAGTTTTT-
GGAGTTG-3V(sense) and 5V-CTCCCAACACCTAAAACTAACA-3V(antisense),
which amplified a 229 bp product. The methylation-specific primers were
5V-CGCGTAGTTTTCGGAGTC-3V (sense) and 5V CTAAAACTAACGAAACG-
CACG 3V(antisense), which amplified a 205 bp product. The PCR conditions
are available on request.
To reactivate the expression of hMLH1 and hMLH3 , 2,5  105 HEK293T
cells were seeded on a 78 cm2 dish on day 0 and treated with 3 Ag/mL of
5-aza-2V-deoxycytidine (Fluka, Buchs, Switzerland) on days 2 and 5. The
medium was changed 24 hours after each addition of the drug and the cells
were harvested on day 8.
Microarray Experiments
Microarray experiments were done as described previously (27). Gray
columns in the graphs represent mRNA levels based on raw signals detected
in the corresponding cell lines with the Affymetrix HG-U133A microarray.
Mismatch Repair Assays
The assays were done as described previously (28, 29).
Results
Expression of hMutL; in Sf9 cells and production of anti-
hMLH3 antibody. To produce the recombinant hMLH3 and
hMutLg factors, S. frugiperda Sf9 cells were infected with
baculoviruses carrying cDNAs encoding hMLH1 and/or hMLH3 .
Infection of Sf9 cells with the hMLH3 virus alone yielded the
protein in an amount that was hardly detectable by Western blott-
ing. The amount of expressed protein was significantly increased
when the cells were coinfected with both hMLH1 and hMLH3 vec-
tors (Fig. 1A), suggesting that the presence of hMLH1 is necessary
for the stabilization of hMLH3 in Sf9 cells. This is reminiscent of
hMSH6 and hPMS2, both of which require their heterodimeric
partners (hMSH2 and hMLH1, respectively) for stability. However,
the amount of the recombinant heterodimer obtained was too low
Table 2. Characteristics of the human cell lines used in this study
Cell lines Origin MMR status* MMR protein defect
c
Genetic complementation
293 Embryonic kidney epithelium +
293T Embryonic kidney epithelium  hMLH1, hPMS2, hMLH3
293T La+ Embryonic kidney epithelium + hMLH3 hMLH1 cDNA
CaCo2 Colon carcinoma +
CO115 Colon carcinoma  hMLH1, hPMS2
Colo741 Colon carcinoma +
CX-1 Colon carcinoma +
GP5D Colon carcinoma  hMSH2, hMSH6, hMSH3, hMLH3
HCT116 Colon carcinoma  hMLH1, hPMS2, hMSH3
HCT116+Ch.3 Colon carcinoma + hMSH3 Chromosome 3
HT29 Colon carcinoma +
Hec1A Endometrial adenocarcinoma  hPMS2, hMSH6
Hec1A+Ch.7 Endometrial adenocarcinoma  hMSH6 Chromosome 7
HeLa Cervical carcinoma +
HeLa clone 12 Cervical carcinoma  hPMS2
LS411 Colon carcinoma  hMLH1, hPMS2
SW48 Colon carcinoma  hMLH1, hPMS2
SW480 Colon carcinoma +
SW837 Colon carcinoma +
*+, MMR proficient; , MMR deficient (these cell lines are unable to repair both base-base mismatches and insertion/deletion loops, with the exception
of Hec1A+Ch.7, which is able to repair insertion/deletion loops).
cThe primary alteration of MMR protein expression is reported in bold. Lack of hMLH1 or hMSH2 lead to proteolytic degradation of hPMS2, or hMSH6
and hMSH3, respectively. The hMSH3 gene in HCT116 cells is mutated as a consequence of the MMR defect. The hMLH3 alterations are those described
in this study; other alterations have been reported elsewhere (see text).
Role of hMutLg in MMR
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to permit extensive purification. The reasons underlying the low
levels of expression are unknown at this time, but it is possible that
high amounts of the full-length protein may be toxic (7).
Commercially available antibodies could detect the recombinant
hMLH3 protein on Western blots but failed to detect the
endogenous protein in all the human cell lines used in this study
(data not shown). Therefore, we raised our own polyclonal rabbit
antiserum, directed against the COOH terminus of hMLH3, which
contains the hMLH1-interacting domain. The affinity-purified
antibody (Fig. 1B) detected a band of the expected size (f160
kDa) in Sf9 lysates infected with the hMLH1 and hMLH3 vectors,
whereas no signal was visible when we probed lysates of uninfected
cells (Fig. 1C). The purified antibody was then tested using extracts
of various human colon cancer cell lines. The antibody highlighted
a double band migrating at the expected size of hMLH3 (Fig. 1D,
bottom). As the faster migrating band was also observed in Western
blots done with the preimmune serum (data not shown), and as the
abundance of the slower-migrating band correlated with hMLH3
mRNA expression levels in the same cell lines (Fig. 1D, top), we
concluded that the latter is the specific band. As shown in Fig. 1D ,
the levels of hMLH3 fluctuate significantly in the tested cells lines
and seem to be independent of the amount of hMLH1 and hPMS2
expressed in the same cells.
Relative abundance of hMLH3 in human cells and its
interaction with hMLH1. Given that hMLH3, hPMS2, and hPMS1
interact with the same region of hMLH1 (30), we wanted to ask
whether the relative abundance of the three different heterodimers
can be correlated with the phenotype of the cells. Therefore, we did
semiquantitative Western blots where we compared the intensity
of bands due to endogeneous hMLH3 and hPMS2 proteins in
HeLa cells with that of bands due to known amounts of the
corresponding recombinant proteins (Fig. 2A). These experiments
revealed that hMLH3 is f60 times less abundant than hPMS2.
Considering that hPMS1 is f10 times less abundant than hPMS2
in human cells (5), hMLH3 exists in the cells at levels significantly
Figure 1. Expression of hMutLg in Sf9 cells, anti-hMLH3 antibody specificity,
and endogenous levels of hMLH3 in colon cancer cell lines. A, expression of
hMLH3 in Sf9 cells infected either with a baculovirus vector expressing hMLH3
or with a mixture of hMLH1- and hMLH3-expressing viruses. This Western blot
shows that hMLH3 is stabilized in this system by hMLH1. B, Coomassie blue
staining of rabbit polyclonal anti-hMLH3 serum before (Serum ) and after
(Anti-hMLH3 ) affinity purification. C, Western blot analysis of whole cell extracts
of Sf 9 cells uninfected (TE Ctrl , 2 Ag) or coinfected with the hMLH1/hMLH3
baculoviruses (TE MutLc , 2 Ag). The recombinant polypeptide (amino acids
961-1,453) used for the generation of the antibody was loaded in the third lane
(1 ng). Anti-hMLH3, affinity-purified serum used at 1:400 dilution; Pre-serum,
preimmune serum used at the same dilution. D, microarray analysis of mRNA
expression levels (top ) and Western blot analysis of protein levels (bottom ) of
hMLH3 in a series of colon cancer cell lines (50 Ag of whole cell extract per lane);
n.s., nonspecific band detected by the anti-hMLH3 antibody in human cell
extracts.
Figure 2. Relative abundance of hMLH3 and its interaction with hMLH1
in vivo. A, the recombinant hMLH3 and hPMS2 proteins were loaded onto a
denaturing polyacrylamide gel in the indicated amounts and visualized by
Western blotting with the respective antibodies. The relative abundance of the
two polypeptides was calculated by comparing the intensity of the hMLH3 and
hPMS2 bands with those of the endogenous proteins present in 50 Ag of HeLa
whole cell extract. The blot is representative of two independent experiments,
and the intensities of the bands were calculated by densitometry.
B, coimmunoprecipitation of hMLH3 and hMLH1 in HeLa cells. One milligram of
whole cell extract was incubated with or without 6 Ag of anti-hMLH1 antibody
(top ) or 10 Ag of anti-hMLH3 antibody (bottom ). DNase, reaction done in the
presence of 25 units of Benzonase. Ponceau staining for IgG is also shown to
show equal loading. Ctrl, 50 Ag of HeLa whole cell extract.
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lower than those of the other two hMLH1-interacting partners
hPMS2 and hPMS1. In spite of this difference, hMLH3 was found to
physically interact with hMLH1 in Far Western experiments (7)
and in mammalian two hybrid assays (30). We could confirm
this interaction using immunoprecipitation experiments in which
the anti-hMLH1 antibody could immunoprecipitate both hMLH3
and hPMS2 from human cell lysates (Fig. 2B, top) and the anti-
hMLH3 antibody precipitated the endogenous hMLH1 (Fig. 2B,
bottom). No proteins were detected in control experiments where
the precipitating antibody was omitted. The interaction between
hMLH3 and hMLH1 was not mediated by bound DNA because
treatment with DNase before incubation with the antibodies failed
to abolish the interaction between the two proteins (Fig. 2B, top).
hMLH1 is not required for the stability of hMLH3 in human
cells. hPMS2 and hPMS1 are stabilized by the presence of hMLH1
(1, 31). Considering this characteristic of these two MutL
homologues, together with the finding that hMLH1 was required
for the stabilization of hMLH3 in baculovirus-infected Sf9 cells
(Fig. 1A), we expected to observe substantially decreased levels of
endogenous hMLH3 in human cell lines lacking hMLH1. Surpris-
ingly, we could detect hMLH3 in hMLH1-deficient HCT116 cells,
and the restoration of hMLH1 expression by chromosome 3
transfer resulted in no appreciable increase in hMLH3 level (Fig. 3A,
bottom left). This shows that the presence of hMLH1 is not required
for hMLH3 stability in human cells. The relative amounts of intra-
cellular hMLH3 were also unaffected by hPMS2 levels, as shown by
comparison of hMLH3 band intensity in Western blots of extracts
of the hPMS2-deficient Hec-1A cells with those of a Hec-1A clone in
which the expression of hPMS2 was restored by chromosome 7
transfer (Fig. 3A, bottom right). hMLH3 protein levels failed to
correlate with hMLH1 and hPMS2 expression also in other colon
cancer cell lines, such as SW480 or Caco2, that express both
hMLH1 and hPMS2, or LS411, CO115, or SW48 that lack hMutLa
(Fig. 3B).
Having established that the level of hMLH3 in cells is not
dependent on hMLH1 but that it correlates well with hMLH3
mRNA levels (Fig. 3B), we wondered whether the fluctuation of
hMLH3 expression in the tested cell lines could be linked with
cytosine methylation, which is known to silence several key genes
in colon cancer (32). The human embryonic kidney cell line 293T is
deficient in both hMLH1 and hMLH3 (Fig. 3C) and it could be
shown that the CpG islands that constitute the promoters of
hMLH1 (25) and other genes (33) are silenced by hypermethylation
in these cells. As the hMLH3 promoter also contains a CpG island,
we reasoned that the lack of hMLH3 expression in this cell line
might also be linked to the transcriptional inactivation of its
promoter. This prediction was substantiated in two independent
experiments. First, treatment of 293T cells with the demethylating
agent 5-aza-2V-deoxycytidine partially restored the expression of
both hMLH1 and hMLH3 (Fig. 3C). In the second experiment, we
treated genomic DNA of 293T and the parental 293 cells (which
express both hMLH1 and hMLH3; Fig. 3C) with sodium bisulfite,
which deaminates cytosines to uracils, but leaves 5-methycytosines
unchanged. Methylation-specific PCR showed that the promoter of
the hMLH3 gene in 293T cells was indeed methylated (data not
shown). As expected, expression of high amounts of hMLH1 in the
293T-derived 293T La+ cells resulted in the stabilization of hPMS2
(26) but did not affect hMLH3 levels (Fig. 3C). The promoter of the
hMLH3 gene can thus be silenced by cytosine methylation, but this
is most likely not the only mechanism that results in the lack of
expression of the protein, as 5-aza-2V-deoxycytidine treatment
failed to induce the expression of hMLH3 in GP5D cells (Fig. 3D).
Figure 3. Expression of hMLH3 in vivo is
independent of hMLH1 and hPMS2 and can
be controlled by cytosine methylation.
A, microarray analysis of hMLH3 mRNA
(top ) and protein (bottom ) expression
in hMLH1-deficient HCT116 and
hPMS2-deficient Hec-1A cells. Correction of
the MMR defect by transfer of chromosome
3 or 7, which carry wild-type copies of the
hMLH1 and hPMS2 genes, respectively, had
no effect on hMLH3 expression. B, hMLH3
expression is independent of hMLH1/hPMS2
expression in a panel of MMR-proficient and
MMR-deficient cell lines. Legend as in (A).
C, the hMLH3 promoter in 293T cells in
silenced by methylation. Expression of
hMLH1 in 293T-La cells does not alter
hMLH3 levels but demethylation of the
promoter by 5-aza-2V-deoxycytidine
(5-Aza-dC ) treatment results in the
reappearance of hMLH3, together with
hMLH1, the promoter of which is also
methylated in these cells. D, down-regulation
of the hMLH3 gene in GP5D cells is not
mediated by cytosine methylation. The
promoter was shown by methylation-specific
PCR to be unmethylated and 5-Aza-dC did
not reactivate hMLH3 expression in these
cells. In the Western blot experiment, 50 Ag
of total extract were used per lane.
Role of hMutLg in MMR
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Role of hMutL; in in vitro mismatch repair. The observation
that extracts from 293T-La+ cells are MMR proficient (26)
despite their lack of hMLH3 suggested that hMutLg does not
play a major role in MMR in vitro . However, the possibility
that it acts as a backup to hMutLa in the absence of hPMS2
could not be excluded. Therefore, we tested extracts of the
human cell line HeLa clone 12, which expresses hMLH1, hPMS1,
and hMLH3 but lacks hPMS2. As shown in Fig. 4A , these extracts
were deficient in the repair of heteroduplex substrates containing
either a G/T mismatch or an insertion/deletion loop of one or
two nucleotides, but their repair proficiency on all tested
substrates could be restored by the addition of recombinant
hMutLa. Before concluding that hMutLg does not participate in
MMR, we considered the possibility that the expression level of
endogenous hMLH3 in the tested human cell lines might be too
low to be detectably active in our in vitro assay. Therefore, we
decided to test whether in vitro MMR activity may be detected in
the presence of higher amounts of the heterodimer. These
experiments were done with the hMutL a, h, and g deficient
extracts of 293T cells supplemented with whole cell extracts from
Sf9 cells expressing comparable amounts of hMutLa or hMutLg
(Fig. 4B, inset). As shown previously, extracts of Sf9 cells
overexpressing hMutLa could complement the MMR defect in
the 293T extracts very efficiently, whereas extracts of uninfected
Sf9 cells failed to do so (Fig. 4B ; ref. 26). Interestingly, when
extracts of Sf9 cells expressing hMutLg were used, we observed
an increase in repair activity of f20%. Similar results were
obtained when the hMutLg was enriched by Ni-agarose
chromatography, showing that the observed MMR activity was
specific to hMutLg. We detected similar repair activities on
substrates containing a G/T mismatch or a 1-base loop with a
nick located either 5V or 3V from the mismatch, but no activity
was observed on a substrate containing insertion/deletion loops
of two or four nucleotides (Fig. 4B ; data not shown). These
experiments show that although physiologic levels of hMutLg are
insufficient to mediate mismatch correction in our in vitro MMR
assays, the factor can participate, albeit with low efficiency, in
the correction of base-base mispairs and one-nucleotide inser-
tion/deletion loops.
Discussion
Like its S. cerevisiae homologue (8), the mammalian MLH3 gene
(7) could be shown to be involved in meiotic recombination
(13–15). However, whereas the S. cerevisiae (8) and Schizosaccharo-
myces pombe (12) proteins play a small but distinct role in the
repair of a subset of insertion/deletion loops, no similar evidence
existed for mammalian MLH3. In this present study, we set out to
search for this evidence.
We first wanted to study the expression of hMLH3 and confirm
the existence of hMutLg in vivo . Using a newly generated antibody,
we showed that hMLH3 is much less abundant than the other two
known hMLH1 interactors, hPMS2 and hPMS1. Despite this, we
could confirm the physical interaction between hMLH3 and
hMLH1 in HeLa cells by immunoprecipitation experiments.
Surprisingly, although hMLH1 was required for hMLH3 stability
in Sf9 cells (Fig. 1A), no such requirement was apparent in human
cells where no degradation of hMLH3 occurred in the absence of
hMLH1 (Fig. 3A and B). We also failed to observe any significant
competition between hMLH3 and hPMS2 for hMLH1, showing that
in human cells hMLH3 might be stabilized by interaction with
another, as yet unidentified, protein. This finding is supported by
evidence from meiosis in mice, where Mlh3 was seen to bind to
pachytene chromosomes before Mlh1 and, after Mlh1 recruitment
to these sites, foci containing Mlh3 alone persisted (11, 15). It was,
therefore, suggested that Mlh3 could either exist alone or interact
with a different partner (11). Immunoprecipitation experiments
revealed a direct interaction of scMlh3p with Sgs1 helicase in
meiotic S. cerevisiae cells (34) and hMLH3 was shown to bind
hMSH4 in meiotic human cells (14); however, the identification of
the putative hMLH3 partners that might help stabilize it in mitotic
cells must await the results of future experiments.
The ultimate objective of this work was to elucidate the role of
hMLH3 in human MMR. We first tested extracts of human HeLa
clone 12 cells, which lack hPMS2 (22) and thus contain only
hMutLh and hMutLg. As the former heterodimer is devoid of MMR
activity in our in vitro MMR assay (31), any observed repair activity
could be ascribed to hMutLg. The extracts were MMR deficient on
all tested substrates (Fig. 4A), which suggested that the hMutLg
heterodimer does not participate in MMR. However, as hMLH3 is
generally much less abundant in human cells than hPMS2, we
Figure 4. In vitro MMR assays. A, the MMR defect of cytoplasmic extracts
of the hPMS2-deficient cell line HeLa clone 12 can be corrected by the addition of
0.2 Ag purified hMutLa. The repair efficiencies were determined on heteroduplex
substrates containing a G/T mismatch, or +1 (D1) or +2 (D2) insertion/deletion
loops. B, cytoplasmic extracts of 293T cells, which lack hMLH1, hMLH3, and
hPMS2 were supplemented with 2 Ag of whole cell extract from Sf9 cells
coinfected with hMLH1/hPMS2 (Sf9-La ), hMLH1/hMLH3 (Sf9-Lc), or the latter
partially purified on Ni-agarose (Sf9-Lc-Ni ). MMR efficiency was tested on
heteroduplex substrates containing a G/T mismatch, or +1 (D1) or +2 (D2)
insertion/deletion loops. The amounts of hMutLa and hMutLg complexes used
for complementation were comparable (inset ). Whole cell extracts from
uninfected Sf 9 cells (Sf9 ) or Sf9 extract that underwent Ni-agarose (Sf9-Ni )
chromatography were used as negative controls. Columns, result of at least
three independent experiments; bars, SE. Cytoplasmic extract of the
MMR-proficient HeLa cells was used as the positive control.
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wanted to exclude the possibility that the lack of repair activity is
linked to insufficient amounts of hMutLg. Therefore, we tested the
MMR activity of extracts of 293T cells, which are deficient in all
three MutL homologues, supplemented either with recombinant
hMutLa or hMutLg (Fig. 4B). The former factor complemented the
MMR defect in the 293T extracts on all tested substrates. When
comparable amounts of hMutLg were used, we observed a small
but significant (f20%) repair with both G/T and +1 insertion/
deletion loop substrates. This repair activity was not due to an
intrinsic repair activity of the Sf9 extracts per se, as extracts from
uninfected Sf9 cells were repair deficient in the complementation
experiments. As there are no available functional assays to test the
activity of hMutLg, a possibility exists that this heterodimer was
isolated in a partially inactive form. However, we consider this
possibility unlikely because all the procedures used were identical
to those used for the preparation of the Sf9 extract expressing
hMutLa, which was fully active. Moreover, immunoprecipitation
experiments done with Sf9 extracts expressing hMutLg showed
that hMLH3 was able to bind hMLH1 (data not shown). The
sensitivity of the in vitro MMR assay remains, however, rather low
so that the contribution of hMutLg to the repair process in vivo
might be higher. Interestingly, the repair activity of hMutLg was
limited to G/T mismatch and 1-base loops, as we failed to observe
any repair activity using +2- and +4-base-loop substrates. The latter
result indicates that hMutLg seems to be involved in the repair of
substrates recognized by hMutSa rather than insertion/deletion
loops of more than one extrahelical nucleotide recognized by
hMutSh. This is in contrast to the data obtained in S. cerevisiae
where the role of scMlh3p seems to be in the repair of a subset of
insertion/deletion loops together with scMutSb . The role of hMLH3
in mammals thus might differ from that in lower eukaryotes.
Our findings, suggesting that hMutLg may play a backup role
in human MMR, are supported by evidence from the mouse
model. As noted above, Mlh3 null mice were not cancer prone in
the first 9 months of life and showed no gross defects in MMR
(15). However, a long-term study of these animals, coupled with a
highly sensitive analysis of their genomic DNA, provides evidence
for the involvement of Mlh3 defects in both MMR and
tumorigenesis. Mlh3/ mice have a shorter life span than the
wild-type controls and more than half of the animals develop
cancers, including gastrointestinal tumors after the 9-month time
span. Importantly, Mlh3 deficiency increased the levels of
mutations in long mononucleotide repeats, although to a lesser
extent than in Pms2/ mice (35). Taken together, our results and
the mouse model data suggest that the hMutLg heterodimer
functions in the repair of base-base mismatches and small
insertion/deletion loops.
Considering the possible involvement of hMLH3 in human
MMR, the identification of hMLH3 silencing through promoter
hypermethylation is of particular interest. We showed that the
hMLH3 promoter is methylated in 293T cells and that the protein
is consequently not expressed. In this particular cell line, the
methylation could be caused by the presence of the SV40 large T
antigen. However, using methylation-specific PCR, we could
detect partially methylated hMLH3 promoters in the colon
cancer cell line LS411 and in the ovarian cancer cell line
A2780/CP70, and fully methylated in the leukemia cell line Jurkat
(data not shown), which shows that hMLH3 silencing via
promoter hypermethylation can also be unrelated to the presence
of SV40 large T antigen.
Although recombinant hMutLg possessed detectable repair
activity in our in vitro MMR assays, hPMS2-deficient cells expressing
hMLH3 display a strong mutator phenotype (refs. 16, 23; this study).
This suggests that hMLH3, most likely in the form of hMutLg,
does not play a major role in MMR in vivo . However, the detection
of sequence variants of hMLH3 in the germ line of families
predisposed to colorectal cancer (17, 20), coupled with our detection
of epigenetic silencing of hMLH3 in human cell lines, suggests
that this gene may play a role in human cancer, possibly in
combination with other risk factors. If hMutLg does indeed play a
backup role for hMutLa in vivo , the fluctuating abundance of
hMLH3, such as that observed in the tested cell lines (Figs. 1 and 3),
might help explain the variable penetrance of hPMS2 mutations
in hereditary nonpolyposis colon cancer families (16).
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ABSTRACT 
 
Postreplicative mismatch repair (MMR) involves the concerted action of at least 20 
polypeptides. Although the minimal human MMR system has recently been reconstituted in 
vitro, genetic evidence from different eukaryotic organisms suggests that some steps of the 
MMR process may be carried out by more than one protein. Moreover, MMR proteins are 
involved also in other pathways of DNA metabolism, but their role in these processes is 
unknown. In an attempt to gain novel insights into the function of MMR proteins in human 
cells, we searched for interacting partners of two key MMR proteins, MLH1 and PMS2, by 
tandem affinity purification (TAP). Our approach was validated by the finding that most of 
the known interacting partners of MLH1 and PMS2 were present in our protein mixtures. 
However, we also identified a large number of other polypeptides, some of which bound to 
the MMR proteins with very high affinity, as shown in reciprocal immunoprecipitation 
assays. Whether these polypeptides represent novel members of the mismatch repairosome, 
or whether they interact with the MMR proteins during other metabolic transactions is 
currently the subject of intense study in our laboratory.  
 
 
INTRODUCTION 
The evolutionarily conserved human mismatch repair (MMR) system maintains genomic 
stability by removing replication errors from DNA (Marra G. and Jiricny J., 2005). Despite 
the fact that the human MMR pathway was recently reconstituted in vitro from purified 
individual components (Dzantiev L. et al., 2004; Zhang Y. et al., 2005), our knowledge of 
the molecular mechanisms of this process is still incomplete. The repair reaction requires a 
mismatch recognition step, which is mediated by the heterodimers hMutSα (hMSH2 and 
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hMSH6) or hMutSβ (hMSH2 and hMSH3). hMutSα preferentially recognizes single base 
mismatches and insertion-deletion loops (IDLs) of 1-4 bases, whereas hMutSβ recognises 
IDLs containing 1-8 bases. Upon mismatch binding, the hMutS heterodimer associates with 
the heterodimeric complex hMutLα (hMLH1 and hPMS2) that was shown to be essential 
for repair. However, the biochemical function of the MutL proteins remains enigmatic. 
hMutLα is believed to couple the mismatch recognition step to downstream processes that 
include the removal of the mismatch from the nascent DNA strand, resynthesis of the 
degraded region and ligation of the remaining nick (reviewed in Kunkel T.A. and Erie 
D.A., 2005; Marra G. and Jiricny J., 2005 ). 
hMutLα was shown to possess a weak ATPase activity, which most likely plays a role in 
signalling rather then in catalysis (Acharya S. et al 2003; Raschle M. et al., 2002). hMLH1 
can bind two other human MutL homologues, hPMS1 and hMLH3 to form the 
heterodimers hMutLβ and hMutLγ, respectively. In vitro studies failed to identify a role of 
hMutLβ in MMR (Raschle M. et al., 1999), whereas hMutLγ can participate in the repair of 
base-base mismatches and small IDLs, even though its in vivo role seems to be only 
marginal (Cannavo E. et al., 2005). A better understanding of the mechanism of human 
MMR and, in particular, of the function of hMLH1 is of particular importance due to the 
link between MMR and cancer. Mutations in MMR genes predispose to hereditary non 
polyposis colorectal cancer (HNPCC), with hMLH1 mutations being responsible for most 
(≈60%) of the cases (HNPCC mutation database at http://www.insight-group.org/). 
In addition to being involved in MMR, hMLH1 was shown to have a role in meiotic 
recombination; Mlh1-/- knock out mice develop a spectrum of tumours that resemble the 
tumour spectrum of the Msh2-/- mice, but the Mlh1-/- mice are, in addition, sterile. Sterility 
is also a feature that characterizes Pms2-/- male mice, suggesting that Mlh1 and Pms2 have 
different meiotic functions (reviewed in Wei K et al 2002; Jiricny J. and Marra G., 2003).  
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In conclusion, in spite of the enormous progress in the characterization of the human MMR 
machinery during the last decade, many unanswered questions remain. Among those, 
understanding the biochemical and biological role of hMutLα, hMutLβ and hMutLγ is of 
particular importance, as well as the identification of additional factors that might play a 
direct or regulatory role in the repair process. Nothing is known, for instance, about the 
regulation of the MMR machinery or the potential participation of DNA helicases in the 
repair process. In addition, the in vivo repair mechanism might be characterized by 
functional redundancies, such as in E. coli, where four different exonucleases are involved 
(reviewed in Schofield M.J. and Hsieh P., 2003). Reconstitution of MMR in vitro thus does 
not exclude the involvement of other, yet unidentified, factors in the repair process. 
In an attempt to clarify the function of hMutLα, we searched for new interacting partners of 
hMLH1 and hPMS2 using Tandem Affinity Purification (TAP). Several reports provide 
evidence that this technique, originally tested in S. cerevisae (Rigaut G.et al 1999; Puig O. 
et al 2001), represents a major improvement in the identification of protein-protein 
interactions. TAP represents a valuable method to identify interacting proteins in vivo, 
under native conditions and with a high degree of purity (Gingras A.C. et al., 2005). Our 
analysis resulted in the identification of a number of proteins in complex with hMLH1 or 
hPMS2. While some of these interactors were described previously, a majority of these 
proteins represent novel, either directly or indirectly interacting, partners. We started to 
analyse and validate some of these potentially interesting interactions and will focus on 
their role in human MMR or related pathways. 
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METHODS 
Plasmid construction 
The mammalian vector for the expression of N-terminally TAP-tagged hMLH1 was created 
by inserting the cDNA encoding the full-length hMLH1 into the EcoRI site of pZome-1-N 
(Cellzome), and the vector for the expression of C-terminally TAP-tagged hPMS2 was 
created by inserting the cDNA encoding the full-length hPMS2 into the BamHI site of 
pZome-1-C (Cellzome). 
 
Cell culture and transfection 
The 293T and HeLa cells were obtained from the cell line repository of Cancer Network 
Zurich and the HeLa12 cell line was kindly provided by Dr. M. Bignami (ISS, Rome, 
Italy). All the cell lines were cultured at 37°C in a 5% CO2-humidified atmosphere and 
maintained in the appropriate media. Transfection was performed using the Fugene 6 
transfection reagent (Roche Applied Science) according to the manufacturer’s 
recommendations. For generation of stable cell lines, 0.2 µg/ml of Puromycin (Invivogen) 
was added to the medium one day after transfection. After 2 weeks the surviving colonies 
were isolated and their extracts were screened by Western blotting using antibodies against 
hMLH1 and hPMS2. The clones showing the highest expression of the two tagged 
mismatch repair proteins were further subcloned.  
 
Western blot analysis and antibodies 
Western blot analysis was performed as described previously (Cejka P. et al., 2003) using 
the following antibodies: anti-hMLH1 and -hPMS2 from BD Pahrmingen (1:4000 and 
1:1000, respectively) and anti β-Tubulin from Santa Cruz, (1:2000). For the 
immunoprecipitation experiment, the anti-hPMS1 rabbit polyclonal antibody (Raschle M. 
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et al., 1999) was further affinity-purified. Briefly, 10 mg of purified (His)6-tagged internal 
peptide of hPMS1 (aa 335-64; Raschle M. et al., 1999) were coupled to 0.4 gr of CNBr-
activated Sepharose 4B (Amersham Pharmacia), according to the manufacturer’s 
instructions. 5 ml of rabbit polyclonal anti-hPMS1 serum diluted 10x in 50 mM Tris-HCl 
pH 7.5 was then bound to the CNBr-bound antigen for 4 h at 4°C. After two washes in 10 
mM Tris-HCl pH 7.5 and two additional washes in 10 mM Tris-HCl pH 7.5, 500 mM 
NaCl, the antibody was eluted with 100 mM Glycine-HCl pH 2.5 at 4°C. The elution step 
was repeated twice and the final eluates were pooled in new tubes containing Tris-HCl 1 M, 
pH 8.0 to a final concentration of 100 mM. 300 µl of the corresponding pre-immune serum 
were IgG/A purified by binding to 300 µl of Protein A/G Plus agarose (Santa Cruz 
Biotechnology). Elution of the IgG/A bound antibodies was then performed as above. 
 
Co-immunoprecipitation 
Co-immunoprecipitation analyses were performed as described previously (Cannavo E. et 
al., 2005) using 1 mg of whole cell extracts and 6 µg of anti-hMLH1 antibody (BD 
Pharmingen). Control experiments were done in the absence of the primary antibody. 
Large-scale immunoprecipitation of hPMS1 was performed using 10 mg of HeLa whole 
cell extract and 1.6 µg of affinity-purified rabbit polyclonal anti-hPMS1 or purified pre-
immune serum as negative control. 
 
Testing of MMR status 
In vitro MMR assay, MNNG sensitivity assay and FACS analysis were performed as 
described previously (Cejka P. et al., 2003) 
 
 
 59 
Tandem Affinity Purification (TAP)  
293T and HeLa12 cells stably transfected with plasmids expressing the N-terminally TAP-
tagged hMLH1 and the C-terminally TAP-tagged hPMS2 (TAP-hMLH1/293T and TAP-
hPMS2/HeLa12 cell lines respectively) were plated in 15 cm dishes. Cells were cultured to 
80% confluency, washed twice in cold PBS and lysed 30 min on ice in 50 mM Tris-HCl pH 
8.0, 125 mM NaCl, 1% NP40, 2 mM EDTA, 1 mM phenylmethylsulfonylfluoride (PMSF), 
1x complete inhibitory cocktail (Roche Molecular Biology), 0.5 mM sodium 
orthovanadate, 20 mM sodium fluoride and 5 nM okadaic acid. The lysates were cleared by 
centrifugation at 12000 xg for 3 min and the soluble material was collected. Protein 
concentration was determined using the Bradford assay (Bio-Rad). 
Batch Tandem Affinity Purification was performed according to the original protocol (Puig 
O. et al., 2001) with minor changes. All the following purification steps were performed on 
ice or at 4°C. For each experiment, 60 mg of whole cell extract was incubated for 4 h with 
gentle agitation with 100 µl of IgG Sepharose beads (Amersham Biosciences) equilibrated 
with lysis buffer. Beads were then washed 3x with 1 ml lysis buffer and 3x with 1 ml TEV 
buffer (10 mM Hepes-KOH pH 8.0, 150 mM NaCl, 0.1% NP40, 0.5 mM EDTA, 1 mM 
DTT, 1mM PMSF and 1x complete inhibitory cocktail). Bound TAP-tagged proteins were 
released by overnight incubation in TEV buffer containing 16 U of acTEV protease 
(Invitrogen) in tubes mounted on a rotating platform. The supernatant from the TEV 
reaction was collected and transferred to a new tube. 1 volume of Calmodulin Binding 
Buffer (CBB: 10 mM β-mercaptoethanol, 10 mM Hepes-KOH pH 8.0, 150 mM NaCl, 1 
mM MgOAc, 1 mM imidazole, 0.1% NP40, 2 mM CaCl2, 1 mM PMSF and 1x complete 
inhibitory cocktail) was added to the collected supernatant and centrifuged at 1500 rpm for 
3 min. The supernatant was then transferred to a new tube and the procedure described 
above was repeated two more times. 1/250 volume of 1 M CaCl2 was then added and the 
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supernatant was batch-purified by binding to 100 µl of calmodulin affinity resin 
(Stratagene) equilibrated in CBB, for 4 h on a rotating platform. Beads were washed 3x 
with 1.2 ml of CBB and 2X with 1.2 ml of Calmodulin Rinsing Buffer (CRB: 50 mM 
ammonium bicarbonate pH 8.0, 75 mM NaCl, 1 mM MgOAc, 1 mM imidazole and 2 mM 
CaCl2) and eluted with 100 µl of Calmodulin Elution Buffer (CEB: 50 mM ammonium 
bicarbonate pH 8.0 and 35 mM EGTA). One third of the eluate was separated by SDS-
PAGE and visualized by silver staining. As negative control, the purification was 
performed with extracts prepared from parental cells not expressing the tagged protein. 
 
Mass Spectrometry (MS) 
The eluate from two TAP experiments (total volume 200 µl) was concentrated using the 
Microcon YM-3 concentrator (Millipore) according to the manufacturer’s instructions, 
separated by 7.5% SDS-PAGE and visualized by Coomassie staining. The gel was then cut 
into 11 pieces and subjected to in-gel tryptic digestion. Briefly, the gel pieces were 
additionally cut into smaller fragments and subjected to two cycles of rehydration in 50 
mM ammonium bicarbonate and shrinking by dehydration in 80% acetonitrile. Proteins 
were then reduced with 37 mM DTT in 50 mM ammonium bicarbonate at 50°C, 30 min. 
After two rounds of dehydration in 80% acetonitrile, proteins were alkylated with 20 mM 
iodoacetamide in 50 mM ammonium bicarbonate, 15 min at room temperature in the dark. 
After 3 rounds of rehydration in 50 mM ammonium bicarbonate and shrinking in 80% 
acetonitrile the gel pieces were incubated with 200 ng of sequencing grade modified trypsin 
(Promega) for 4 hours at 37°C and then 25°C overnight. Peptides were extracted by one 
change of formic acid 0.1% and three changes of 80% acetonitrile and dried under vacuum. 
The hPMS1- or pre-immune serum-bound proteins from the large scale immunoprecipitation 
(see above) were analyzed by SDS-PAGE, stained with Coomassie blue, the gel was cut into 
15 pieces and subjected to tryptic digestion according to the same protocol.  
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Tryptic peptides were analyzed on a LTQ FT™ (Thermo Electron, Bremen, Germany). 
Peptides were separated on a nano-HPLC ( Agilent, Palo Alto, CA) online prior to MS 
analysis on a C18 reversed phase column using an acetonitrile/water system at a flow rate 
of 200 nl/min. Tandem mass spectra were acquired in a data dependent manner. Typically 4 
MS/MS were performed after each high accuracy survey scan. The human portion 
(taxonomy ID: 9606) of the UniProt database (http://www.uniprot.org) was interrogated 
using the Mascot search algorithm (Perkins D.N. et al., 1999). 
 
RESULTS 
Generation and characterization of stable mammalian cell lines expressing TAP-
tagged hMLH1 and hPMS2 
 
Tandem Affinity Purification (TAP) was shown to be a powerful method for identification of 
interacting partners of known proteins in various host cell lines (Puig O. et al., 2001; Gingras 
A.C. et al., 2005). In order to avoid competition, it is preferable to use cell lines lacking the 
corresponding endogenous protein. For this reason, we stably-transfected two human cell 
lines deficient for hMLH1 or hPMS2, namely the hMLH1-deficient embryonic kidney cell 
line 293T and the hPMS2-deficient ovarian carcinoma cell line HeLa12 with pZome-1-N-
hMLH1 and pZome-1-C-hPMS2, respectively. The resulting clones were analyzed by 
Western blot for the expression of the TAP-tagged protein hMLH1 or hPMS2 (see Methods 
for details). The clones exhibited various expression levels of the transfected proteins (data 
not shown). The two selected stable cell clones expressed the TAP-tagged protein at 
comparable levels to the amount present in the MMR-proficient cell line HeLa (Fig 1A). The 
TAP-tagged protein in both cases translocated into the nucleus as ascertained by 
immunofluorescence or immunoistochemistry (data not shown). 
To rule out the possibility that the TAP-tag impairs the function of hMLH1 or hPMS2, we 
performed in vitro MMR assay with cytoplasmic extracts from TAP-hMLH1/293T and TAP-
hPMS2/HeLa12 cells. As shown in Fig.1B, the MMR activity in both cell lines was 
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comparable to the repair activity of MMR-proficient HeLa cells. Treatment of mammalian 
cells with low doses of SN1 type alkylating agents, such as N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG), induces a G2 cell cycle arrest that is absolutely dependent on 
functional MMR. Thus, loss of MMR leads to increased resistance to killing by these drugs. 
We confirmed this hallmark of MMR proficient cells in our stable cell lines by FACS 
analysis. Both TAP-hMLH1/293T and TAP-hPMS2/HeLa 12 cell lines arrested in the G2 
phase of the cell cycle upon treatment with 0.2 µM of MNNG for 24 h (Fig. 1C). The arrest 
of cell growth upon treatment with MNNG was also confirmed by clonogenic assays (data 
not shown). In summary, we show that the TAP-tag does not impair the MMR function of 
hMLH1 or hPMS2, respectively. 
 
Tandem Affinity Purifications (TAP) 
Since its first description in 1999 (Rigaut G. et al., 1999) TAP has been successfully used in 
the identification of binding partners of various proteins (Puig O. et al 2001 and reviewed in 
Gingras A.C. et al., 2005). The TAP-tag consists of two IgG binding domains of the S. 
aureus protein A and a calmodulin binding peptide separated by a TEV protease cleavage site. 
The interaction of hMLH1 and hPMS2 is mediated via the C-terminus of the hMLH1 and the 
N-terminus of hPMS2 (Kondo E. et al., 2001). To avoid a possible impairment of the 
reciprocal binding, we placed the TAP-tag at the N-terminus of hMLH1 and at the C-terminus 
of hPMS2 (Fig.2A). The protein complexes were then isolated by chromatography on IgG-
Sepharose, followed by elution with TEV protease, and loading into a calmodulin Sepharose 
column. The final elution was carried out with EGTA (Fig. 2B). TAP was performed as 
described in Materials and Methods. Each experiment was repeated several times and the 
results were highly reproducible, as judged by comparing silver stained gels from independent 
experiments (data not shown). 
 
Identification of interacting partners of hMLH1 and hPMS2  
For each large-scale experiment, TAP was performed with 120 mg of whole cell extract and, 
upon concentration, the final eluate was subjected to electrophoresis on a polyacrylamide gel 
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and visualized by Coomasie staining. The lane containing the sample was then cut into 11 
pieces, and the identity of the proteins was established by MS analysis. In both cases, the bait 
protein and its principle interacting partners were detected as the most prominent bands, 
migrating at the predicted molecular size (Fig. 3A). The identity of these proteins was verified 
not only by MS analysis, where the corresponding Mascot score was always among the 
highest (Table 1 and 2), but also by Western blot analysis (Fig. 3B), therefore validating this 
approach for the identification of physiological binding partners. We could identify a number 
of proteins specifically present in the eluate from TAP-hMLH1 or TAP-hPMS2. First, we 
verified that the detected proteins were isolated from the gel area corresponding to the 
predicted molecular size. Next, we classified the proteins into several groups according to the 
known function. Selected hMLH1 interactors are shown in Table 1, and selected hPMS2 
interactors in Table 2. 
 
Co-immunoprecipitation of hPMS1 interacting partners. 
hPMS1 interacts in vivo with hMLH1 to form the heterodimer hMutLβ. hMutLβ was shown 
not to have a role in in vitro MMR (Raschle M. et al., 1999) and the physiological role of 
hPMS1 has yet to be identified. As expected, we found hPMS1 associated with hMLH1 in 
the TAP eluate from the cell line expressing TAP-tagged hMLH1 and not TAP-tagged 
hPMS2 (Table 1 and 2). It was indeed shown previously that hPMS2 and hPMS1 compete 
for the same interacting region of hMLH1 (Kondo E. et al., 2001). The relative abundance of 
hPMS1 found in complex with hMLH1 was instead a surprising finding. As shown in Fig. 
4A, the band corresponding to hPMS1 is one of the three major bands, the other two being 
the bait protein hMLH1 and its major interactor hPMS2. In Western blot analysis, the relative 
amount of hPMS1 present in the hMLH1-TAP eluate appeared comparable to the amount of 
hPMS2 in the whole cell extract (Fig. 4B). Given that the level of hPMS1 was reported to be 
lower than that of hPMS2 (Raschle M. et al., 1999), the fact that they were pulled down in 
similar amounts shows that the affinity of hMLH1 for hPMS1 is high. Considering the 
strength of the interaction and the relative amount of hPMS1 in the TAP eluate, it appears 
unlikely that hMutLβ has no biological role. We thus set out to identify additional interacting 
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partners of hPMS1, in the hope that they might point at the biological function of hMutLβ. 
Unfortunately, as no human cell lines lacking hPMS1 have been identified to date, we could 
not use the TAP approach as the tagged polypeptide might compete with the untagged protein 
in the cell. We were thus forced to use a large-scale co-immunoprecipitation coupled with MS 
analysis.  
We immunoprecipitated hPMS1 from 10 mg of HeLa whole cell extract, using an affinity-
purified anti-hPMS1 antibody or, as a negative control, the purified pre-immune serum.  The 
immunoprecipitates were analyzed by SDS-PAGE, the bands visualized by Coomassie 
staining (Fig. 5A), the lanes containing the sample were cut into 15 pieces, which were 
subjected to in-gel tryptic digestion and the peptides were analyzed by MS as described. The 
affinity-purified anti-hPMS1 antibody efficiently immunoprecipitated hPMS1 and its major 
partner hMLH1 from whole cell extracts while the pre-immune serum failed to do so (Fig. 
5B). We could identify a high number of additional specific interacting partners, a sub-set of 
which was divided into functional categories, and is listed in Table 3. 
 
DISCUSSION 
Human MMR has recently been the focus of intensive research efforts, however the precise 
function of the hMutlα heterodimer remains unclear. In order to elucidate the role of hMLH1 
and hPMS2 in MMR, we searched for interacting partners of the two proteins, using the dual-
purification strategy TAP which has proven to be an invaluable method for the 
characterization of protein complexes. This technique was first tested in S. cerevisiae (Rigaut 
G. et al., 1999), but has recently been successfully used in other organisms, including human 
cells. Several studies compared TAP with single-tag purification strategies, and/or 
immunoprecipitation experiments. TAP was shown to be significantly more specific, thereby 
dramatically reducing false positive identifications (reviewed in Gingras A.C. et al., 2005). In 
S. cerevisae, where large datasets are already available, the error rate of the TAP-tag method 
has been estimated at about 15%, while for a single-epitope tag method the error rate was 
about 50% (Dziembowski A. and Seraphin B., 2004). In addition, TAP uses mild washing 
conditions, thus allowing for the recovery of native complexes. When performing TAP the 
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expression level of the tagged protein is an important determinant for the success of the 
experiment. For this reason, is it preferable to avoid the use of extracts from transiently-
transfected cells, where the expression levels of the tagged proteins are often high, resulting in 
the identification of a large number of unspecific interactors binding to the overexpressed or 
misfolded protein and making the identification of low abundant binding partners more 
difficult. In contrast, performing stable transfections allows selection of clones expressing the 
recombinant protein at levels comparable to wild type.  Moreover, endogenous proteins might 
compete for binding partners with the stably-expressed TAP-tagged protein and so reduce the 
recovery of interactors. To avoid this problem, it is preferable to stably-transfect a cell line 
originally deficient for the target protein. This approach also enables testing the activity of the 
tagged protein in cell extracts, providing that an appropriate assay is available.  In this study, 
we used hMLH1-deficient 293T cells (Trojan J. et al., 2002) for transfection with TAP-tagged 
hMLH1 and hPMS2-deficient HeLa12 cells (Ciotta C. et al., 1998) for transfection with 
TAP-tagged hPMS2, generating two stable cell lines, TAP-hMLH1/293T and TAP-
hPMS2/HeLa12, respectively. The interaction domain between the two molecules is located at 
the C-terminus of hMLH1 and at the N-terminus of hPMS2 (Kondo E. et al., 2001). To avoid 
a disturbance in the reciprocal interaction, we located the TAP-tags at the N-terminus of 
hMLH1 and at the C-terminus of hPMS2. TAP was then performed using whole cell extracts 
from the newly-generated cell lines and, as negative control, from the parental untransfected 
cells.  
A high number of proteins in complex with both TAP-hMLH1 and TAP-hPMS2 were 
identified by MS analysis. We first validated the approach by demonstrating that hMLH1 
pulled down high amounts of its principal interacting partner hPMS2 and vice versa.  Both 
proteins were detected by MS with a very high score and were clearly visible on silver-stained 
SDS gel. Moreover, we could identify hPMS1, a well-known interacting partner of hMLH1 in 
our hMLH1-TAP pulldown. The interaction of hMLH1 with hMLH3, which form the third 
hMLH1-containing heterodimer, could not be confirmed, due to the lack of expression of 
hMLH3 in the 293T cell line because of promoter hypermethylation (Cannavo E. et al., 
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2005). Our analysis revealed several additional previously known interactors. Among 
those, the 5'-3' exonuclease EXO1, which was shown to interact with hMLH1/hPMS2 in 
co-immunoprecipitation and pulldown experiments (Schmutte C. et al.,2001; Nielsen F.C. 
et al., 2004), was specifically present also in both our hMLH1- and hPMS2-TAP 
pulldowns. The EXO1-binding proliferating cell nuclear antigen (PCNA) was shown to 
interact with hMLH1 in yeast two-hybrid and co-immunoprecipitation experiments (Umar 
A.et al., 1996; Gu L. et al., 1998). Although we did not identify peptides belonging to 
PCNA in the eluate from TAP-hMLH1 with a significant score, the protein was specifically 
present at significant levels in the complex bound to hPMS2. In addition to EXO1 and 
PCNA, we could detect other proteins involved in MMR, including hMSH2, hMSH6 and 
replication factor C (RFC), specifically among the hPMS2-bound proteins. Interestingly, all 
factors required for the recently reconstituted MMR reaction in vitro (Dzantiev L. et al., 
2004), with the notable exception of DNA polymerase δ and RPA, were specifically 
detected in our hMLH1- or hPMS2-TAP eluates. hMLH1 was also described to associate 
with the breast cancer susceptibility gene BRCA1 (Wang Y. et al., 2000) in the so-called 
BASC complex. The same group later described the binding of BRCA1 to SMC1 
(structural maintenance of chromosome protein 1) upon DNA damage (Yazdi P.T. et al., 
2002). The finding of both proteins, BRCA1 and SMC1, in our TAP-hMLH1 eluate is a 
further validation of our experimental conditions. Although several interactions between 
our bait proteins and known interacting factors could be confirmed with our TAP strategy, 
this was not always the case. For instance, we failed to detect interactions between hMLH1 
and the Bloom helicase (Pedrazzi G. et al., 2001), hMRE11 (Her C. et al., 2001) or MBD4 
(MED1) (Bellacosa A. et al., 1999). These interactions were identified using different 
methods in different cell lines, which might strongly influence protein recovery. In 
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addition, the strength of the interaction and the location of the TAP-tag at one extremity of 
the bait protein might have a significant influence on the binding of certain molecules.  
Although the interaction between hMLH1 and hPMS1 is very well known, we were 
puzzled by the amount of the latter protein in our pulldown and consequently by its high 
affinity to hMLH1. In order to identify interacting partners of this polypeptide, we 
performed a large-scale immunoprecipitation of hPMS1 in HeLa cells followed by MS 
analysis. This kind of approach is not comparable to TAP in terms of accuracy and 
specificity. Antibodies typically cross-react with more proteins than their respective 
antigens so that the immunoprecipitate contains multiple proteins that are pulled down by 
the antibody but are not related to the target complex. In the case of hPMS1, the TAP could 
not be used mainly due to the lack of a hPMS1-deficient cell line as discussed above. In 
addition, given that the function of hPMS1 is not yet known, it would not be possible to test 
whether the addition of the TAP-tag impairs the functionality of the protein and so the 
binding to some, maybe essential, binding partners. Identification of interacting partners by 
immunoprecipitation is a valid approach,but it requires even more accurate data verification 
than TAP.  
The main focus of this study was to detect novel interactions of proteins with human MutL-
homologue complexes, in an attempt to explain the role of these proteins in MMR and 
related processes. Our study clearly led to the identification of novel interactors (Table 1-
3); though it is essential to validate TAP or IP approaches with independent techniques in 
different cell lines, and ultimately, to eluycidate the biological roles of these interactions. 
Recently, we started to focus our attention on several potentially interesting molecules 
identified in our analysis. The presence of numerous proteins belonging to the Ubiquitin 
pathway in complex with hPMS1 and in particular the very high Mascot score associated to 
the ubiquitin-ligase EDD1 brought us to investigate the possibility that this molecule 
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undergos ubiquitylation. Preliminary data show that hPMS1 is indeed poly-ubiquitinated in 
the cells, in the absence of any treatment (data not shown). The biological significance of 
this modification, namely whether the poly-ubiquitination merely targets the protein for 
proteasome-mediated degradation, or whether it modulates hPMS1 activity, remains to be 
established. The presence of some deubiquitinating enzymes such as UBP5 and UBP5 
suggests that poly-ubiquitination is a dynamic process. Interestingly, we could not detect 
any biochemical activity of hPMS1 expressed in baculovirus infected Spodoptera 
frugiperda cells in our in vitro MMR assay (Raschle M. et al., 1999). It will be interesting 
to evaluate the possibility that ubiquitinated hPMS1 plays a role in postreplicative MMR or 
in other processes of DNA metabolism.  
The newly-identified protein Angiomotin appears to be in a stable complex with hMLH1 
(Table 1, score 4013). This protein was identified by a yeast two-hybrid assay in search for 
Angiostatin interactors. Angiomotin is involved in angiogenesis and is located at the 
cellular membrane (Troyanovsky B. et al., 2001). Two forms of Angiomotin were 
identified to date, a shorter form, Angiomotin p80, and a longer form, Angiomotin p130, 
containing an additional 490aa at the N-terminus, (Bratt A. et al., 2005). We confirmed the 
interaction between hMLH1 and Angiomotin p130 by immunoprecipitation and could 
detect Angiomotin in the cytoplasm of 293T cells by immunofluorescence experiments 
(data not shown). In summary, though hMLH1 is a nuclear protein, it is synthesized in the 
cytoplasm where it seems to bind Angiomotin. The biological significance of this 
interaction remains to be established. 
 Of particular interest appears the identification of the BRCA1-associated C-terminal 
helicase BRIP1 (BACH1), that was recently identified as FANCJ, in the hMLH1-, hPMS2- 
and hPMS1-bound complexes (Litman R. et al., 2005; Levran O. et al., 2005; Levitus M. et 
al., 2005). BRIP1 appears to be critical for homologous recombination and seems to 
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participate in DNA double strand breaks repair (Cantor S.B. et al., 2001; Litman R. et al., 
2005). We confirmed the binding of BRIP1 to hMLH1 by reciprocal immunoprecipitation. 
BRCA1 was also present in the in the complex (data not shown). It will be important to 
establish whether BRIP1 plays a role in MMR, or whether it could mediate the link 
between MMR and recombination. hMLH1 is known to be involved in both mitotic and 
meiotic recombination as evident from the phenotype of the Mlh1-/- knock out mice that are 
sterile (Backer SM et al., 1996 and reviewed in Wei K. et al., 2002) and from experiments 
in yeast cells (Hoffmann E.R. and Borts R.H., 2004). 
A number of additional proteins, the peptides of which were identified in our samples, are 
in our view of particular interest and will be the subject of our future studies. Among those, 
a complex of two proteins related to the bacterial ATP-dependent helicase RuvB, RuvBL1 
(TIP49a) and RuvBL2 (TIP49b), was identified specifically in association with both 
hMLH1 and hPMS2. RuvBL1 and RuvBL2 are highly conserved in evolution end essential 
for viability in yeast. The precise role of these ATPase-helicases is not known, but they 
were reported to be associated with transcription factors (Bauer A. et al., 1998; Cho S.G. et 
al., 2001), to modulate apoptosis (Dugan K.A. et al., 2002), oncogenic transformation 
(Wood MA et al., 2000; Feng Y. et al., 2003) and were shown to be in chromatin 
remodelling complexes in yeast ( Shen et al., 2000; Jonsson Z.O. et al., 2004) as well in a 
complex with the histone acetyltransferase TIP60 in human cells (Ikura T. et al., 2000; 
Frank S.R. et al., 2003). 
It is known that both hMLH1 and hPMS2 contain one monopartite nuclear localization 
signal (NLS) and that certain mutations within this NLS impair their nuclear import (Wu X 
et al., 2003; Brieger A.  et al., 2005). NLS are recognized by specialized transport factors, 
karyopherins or importins, which function as heterodimeric protein complexes, that dock 
NLS-containing substrates and mediate their import into the nucleus (reviewed in Goldfarb 
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D.S. et al., 2004). We identified importin α2 and its known binding partner importin β1 in 
the complex with both hMLH1 and hPMS2 (only importin α2 in complex with hPMS1). 
This finding suggests that importin α2/β1 heterodimer might be the transporter molecule for 
hMutLα. We also identified several proteins with unknown function. The presence of the 
protein KIAA1018 appears to be most significant, because of the numerous peptides 
observed in the complex bound to hMLH1, hPMS2 and hPMS1. KIAA1018 appears to be 
identical to the myotubularin-related protein 10 (MTMR10). In human, 13 myotubularin-
related proteins are known, although the function of many of them has not been identified 
yet. These proteins are mainly characterized by a tyrosine-phosphatase domain and have 
been involved in phosphoinositide metabolism, cellular growth and differentiation and 
found mutated in human genetic diseases (reviewed in Tronchere H. et al., 2003).  
In conclusion, we used the TAP technique to identify interacting partners of the MMR 
proteins hMLH1 and hPMS2. This technique proved to be a valuable tool that allowed us to 
validate known interactions and to discover new potential binding partners. The biological 
significance of the identified interactions will be evaluated for a selection of potentially 
interesting molecules that will hopefully help us to better understand the MMR mechanism 
and/or to discover novel functions of hMutLα in the cell. 
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FIGURE LEGENDS 
 
Fig.1 Characterization of mammalian cell lines stably expressing TAP-tagged 
hMLH1 and hPMS2 
A: Whole cell extracts of TAP-hMLH1/293T (left panel) and TAP-hPMS2/HeLa12 cells 
(right panel) were analyzed by Western blot (50 µg of extract/lane) for the expression of 
hMLH1 and hPMS2. In both cell lines, the expression of the TAP-tagged proteins and their 
respective major interacting partners is comparable to the amounts of these proteins present in 
50 µg of whole cell extract from the MMR-proficient cell line HeLa (first lane). Note that 
TAP-hMLH1 and TAP-hPMS2 migrate slower due to the presence of the TAP-tag. 
B: In vitro MMR assays. The repair efficiency of the extracts of TAP-hMLH1/293T (left 
panel) and TAP-hPMS2/HeLa12 (right panel) cells was compared with the repair efficiency 
of the extracts from corresponding parental MMR-deficient cell lines 293T or HeLa12.  The 
repair efficiencies were determined on hetroduplex substrates containing a G/T mismatch (see 
Methods for details). Extracts from the MMR-proficient HeLa cells were used as a positive 
control. 
C: FACS profiles of the MMR-proficient or -deficient HeLa or HeLa12 cells, (left panel), and 
293 and 293T (right panel) were compared with the profile of TAP-hMLH1/293T (left panel) 
and TAP-hPMS2/HeLa12 (right panel) cells either untreated or treated with 0.2 µM of 
MNNG for 24 hours.   
 
Fig.2 Tandem Affinity Purification strategy 
A: Schematic representation of the hMLH1- (upper panel) and  hPMS2-TAP (lower panel) 
constructs. The TAP-tag was inserted at the N-terminus of hMLH1 and at the C-terminus of 
hPMS2. Prot A, Protein A (IgG binding) domain; TEV, TEV protease cleavage site; CBD, 
Calmodulin Binding Domain. 
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B: Overview of the purification procedure. Black circles represent factors that specifically 
interact with the bait protein and white circles represent non-interactors (see text for 
details). 
 
Fig.3 Analysis of hMLH1- and hPMS2-interacting partners by TAP 
A: Analysis of the TAP-hMLH1 (right lane, left panel) and TAP-hPMS2 (right lane, right 
panel) interactors. TAP with extracts from corresponding parental untransfected cells 
(middle lane) was used as a negative control. One third of the final eluate from 60 mg whole 
cell extract (see Methods for details) was resolved on a SDS-polyacrylamide gel and 
visualized by silver staining. The bands corresponding to the tagged protein and its major in 
vivo interactor are indicated. M; Molecular size marker, 20 ng/band. CBD; Calmodulin 
Binding Domain. 
B: Western blot analysis. 50 µg of whole cell extract (WCE) or 33 µl of TAP eluate were 
loaded on a SDS-polyacrylamide gel and analyzed by Western blotting using specific 
antibodies against human hMLH1 and hPMS2. Extracts and eluates from parental 
untransfected cell lines 293T (left panel) and HeLa12 (right panel) were compared with 
samples from the stable cell lines TAP-hMLH1/293T (left) and TAP-hPMS2/HeLa12 (right). 
Note that the TAP-tagged hMLH1 and hPMS2 migrate according to the presence of the TAP-
tag or of the Calmodulin Binding Domain (CBD). 
 
Fig.4 Relative abundance of hPMS1 and hPMS2 in TAP eluates 
A: Silver stained SDS-PAGE gel of hMLH1-TAP eluate. The band corresponding to hPMS1 
has comparable intensity to the band corresponding to hPMS2. M: Molecular size marker, 
20 ng/band. CBD: Calmodulin Binding Domain. 
B: Western blot analysis. 50 µg of whole cell extract (WCE) from 293T and TAP-
hMLH1/293T cells or 33 µl of the final eluate from the TAP were loaded on SDS-
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polyacrylamide gel and analyzed by Western blotting using specific antibodies against human 
hPMS1 and hPMS2. 
 
 Fig.5: Co-immunoprecipitation of hPMS1-interacting partners from HeLa cell 
extracts 
A: Example of large-scale co-immunoprecipitation analysis of hPMS1. Immunoprecipitation 
was performed with 5 mg of whole cell extract and 1 µg of affinity-purified anti-hPMS1 
rabbit polyclonal antibody or purified pre-immune serum. Immunoprecipitates were analyzed 
by SDS-PAGE and visualized by Coomassie staining. M: Molecular size marker, 2 µg/band. 
B: Western blot analysis of hPMS1 immunoprecipitates. Only the purified anti-hPMS1 
antibody and not the pre-immune serum efficiently immunoprecipitates hPMS1 and 
hMLH1. 
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Table1: Proteins associated with hMLH1. Shown is a selection of proteins present specifically 
 in hMHL1-TAP eluate.
Function^ Protein Protein score* Sequence Swiss-Prot
coverage (%) acc.no.
Mismatch repair
hMLH1 7390 70 P40692
hPMS1 7143 70 P54277
hPMS2 4117 59 P54278
hMSH3 628 22 P20585
Exonuclease 1 72 6 Q5T396
Other repair Pathways
DNA-PKcs 483 9 P78527
BRCA1 202 11 Q5YLB2
SMC1A 68 10 Q14683
Proteins Import/Export
Importin alpha2 336 18 P52292
Importin beta 1 118 3 Q14974
Importin alpha 4 108 5 O00629
Importin alpha 6 70 8 O15131
Ubiquitin pathway/proteasome
PSD3 243 18 O43242
UBP2L 183 12 Q14157
Ubiquitin 172 45 P62988
IFP38 66 3 Q9BX72
DNA Helicases
BRIP1(BACH1) 3905 53 Q9BX63
SEP1(XRN1) 330 9 Q8IZH2
RuvB like1 309 22 Q9Y265
RuvB like2 76 8 Q9Y230
Heat Shock Proteins/Chaperones
Hsp60 1169 48 P10809
TCPA (TCP-1 sub.alpha) 456 23 P17987
TCPD (TCP-1 sub.delta) 192 10 P50991
Hsp90alpha(Hsp86) 94 11 P07900
Unknown Function/Hypotetical proteins
KIAA1018(fragment) 898 27 Q9Y2M0
YLPM1 (ZAP3) 184 3 P49750
AN11H (WDR68) 95 5 P61962
FLJ10178 89 9 Q9NWA6
KIAA0553 73 5 Q9UKJ3
Function^ Protein Protein score* Sequence Swiss-Prot
coverage (%) acc.no.
Metabolism of RNA/Transcription/Translation/Ribosome
EF1-alpha2 456 25 Q05639
hnRNP A1 260 15 P09651
WUGSC:H_RG054D04.1 201 14 O95036
EF-Tu 137 12 P49411
RLA0 173 16 P05388
RS3A 166 18 P61247
eIF3-p47 163 8 O00303
DDX3Y 151 10 O15523
DDX17 145 8 Q92841
RL6 134 15 Q02878
RL4 132 16 P36578
eIF3-p167 120 7 Q14152
RNMT 109 10 O94996
PheRS (SYFA) 97 9 Q9Y285
CPSF6 91 5 Q9BSJ7
hnRNP K 86 11 P61978
PRP4 85 6 O43172
SF3B-1 (SAP155) 85 5 O75533
SFRS3(SRP20) 79 18 P78406
RAE1L 85 6 P84103
ILF2(NF45) 84 11 Q7L7R3
NPM1(Numatrin) 74 12 P06748
eIF3-p66 72 6 O15371
PABPL1 66 10 Q9NTZ0
Cell cycle/Signaling/Kinases/Phospatases/Apoptosis
PP2A reg. sub A- alpha 278 19 P30153
PP2A reg. sub B-alpha 152 10 P63151
PP2A reg. sub B-beta 99 6 Q00005
P2BB catalytic sub-beta 184 19 P16298
P2BC catalytic sub-gamma 122 10 P48454
PP2A reg. sub. B-delta 99 8 Q6IN90
PDCD8 169 15 O95831
PI3K-C2alpha 160 6 O00443
Others
Angiomotin 4013 57 Q4VCS5
ATAD3A 470 25 Q9NVI7
DOCK7 460 9 Q5T1C0
PYGB 269 10 P11216
ATPalpha 953 39 P25705
ATAD3B 244 19 Q5T9A4
REC14(WDR61) 155 7 Q6IA22
HDAC2 88 12 Q92769
YTHDF3 82 14 Q7Z739
ARMCX3(ALEX3) 72 13 Q9UH62
NCOA3(TRAM1) 70 5 Q9Y6Q9
^ Derived from Swiss-Prot. database or published data.
* Mascot protein score where a value >65 was considered significant (P<0.05).
Table1: continued
Table2: Proteins associated with hPMS2. Shown is a selection of proteins present 
specifically in hPMS2-TAP eluate.
Function^ Protein Protein score* Sequence Swiss-Prot
coverage (%) acc.no.
Mismatch repair
hMLH1 4158 85 P40692
hPMS2 3601 71 P54278
hMSH2 1529 31 P43246
hMSH3 993 24 P20585
hMSH6 108 4 P52701
Exonuclease 1 164 12 Q5T396
PCNA 184 15 P12004
RFC 40kDa 82 10 P35250
Other repair Pathways
DNA-PKcs 1938 13 P78527
BRCA2 114 8 P51587
DDB1 114 8 Q16531
MMS19-like 97 97 Q5T455
Proteins Import/Export
Importin alpha2 535 22 P52292
Importin beta 1 425 12 Q14974
Importin beta3 87 10 O00410
CRM1 (XPO1) 797 17 O14980
COPB 741 24 P53618
COPG 170 4 Q9Y678
COPG2 112 7 Q9UBF2
Ubiquitin pathway/proteasome
PSD2 818 24 Q13200
PRS4 378 29 P62191
PRS10 253 14 P62333
PSD5 245 16 Q16401
PSD3 234 14 O43242
PRS6A 132 12 P17980
PRS7 108 7 P35998
Ubiquitin 127 45 P62988
CYLD 241 10 Q9NQC7
EDD 206 8 O95071
HERC2 99 3 O95714
PRS8 73 8 P62195
DNA Helicases
BRIP1(BACH1) 720 14 Q9BX63
RuvB like1 710 33 Q9Y265
RuvB like2 570 24 Q9Y230
Heat Shock Proteins/Chaperones
Hsp90alpha(HSP86) 496 16 P07900
Hsp70/7 193 18 P48741
Hsp60s2 173 22 Q96RI3
Hsp60s1 127 20 Q96RI4
Hsp75 91 2 Q12931
HSP60 954 30 P10809
Hsp70/2 745 21 P54652
TCPA (TCP-1 sub.alpha) 359 15 P17987
SSRA 164 12 P43307
TCPG (TCP-1 sub.gamma) 105 4 P49368
STIP1(HOP) 75 14 P31948
Replication/DNA metabolism
CAD(PYR1) 1718 19 P27708
MCM3 130 7 P25205
Function^ Protein Protein score* Sequence Swiss-Prot
coverage (%) acc.no.
Unknown Function/Hypotetical proteins
KIAA1018(fragment) 454 14 Q9Y2M0
DKFZp686L22104 103 21 Q68E03
FLJ16757 91 8 Q6ZMQ9
KIAA1541 88 10 Q9P1Y7
FLJ26613 87 5 Q6ZP32
DKFZp667O1117 85 5 Q5JPJ1
DKFZp586H1322 81 7 Q9H065
KIAA1729 73 11 Q9C0D4
DKFZp451I106 70 12 Q86T41
DKFZp434P055 70 13 Q8NCX0
Metabolism of RNA/Transcription/Translation/Ribosome
EF-Tu 413 24 P49411
hnRNP M 360 15 P52272
GCN1L 348 9 Q92616
RLA0 329 21 P05388
SMCA4 280 5 P51532
EF2 272 10 P13639
EEF1A 209 14 Q14222
PABP1 189 15 P11940
RL18 183 21 Q07020
RS3a 185 26 P61247
PABP3 152 11 Q9H361
RL7 137 14 P18124
WUGSC:H_RG054D04.1 129 15 O95036
RL4 101 14 P36578
Exportin T 385 11 O43592
DSRAD 93 6 P55265
U5S1 93 6 Q15029
DDX39 92 8 O00148
PRP4 83 11 O43172
hnRNP E2 80 10 Q15366
GRIPE 72 3 Q6GYQ0
eIF2-gamma 66 6 P41091
RRP44 146 8 Q5W0P7
ABCE1 134 13 P61221
DHX15 175 7 O43143
DDX46 72 11 Q7L014
Cell cycle/Signaling/Kinases/Phospatases/Apoptosis
RIF-1 isoform 4 97 3 Q5UIP0
PDCD8 90 6 O95831
PP2A reg.sub B-beta 105 6 Q00005
PP2A catalitic sub-alpha 131 12 P67775
PI3K-C2alpha 67 9 O00443
Others
ATAD3A 571 30 Q9NVI7
NSUN2 145 10 Q9BVN4
SMRA3(HIP116) 74 9 Q14527
^ Derived from Swiss-Prot. database or published data.
* Mascot protein score where a value >65 was considered significant (P<0.05).
Table2: continued
Table3: Proteins associated with hPMS1. Shown is a selection of proteins
that specifically  immunoprecipitate with the anti-hPMS1 antibody.
Function^ Protein Protein score* Sequence Swiss-Prot
coverage (%) acc.no.
Mismatch repair
hMLH1 3692 74 P40692
hPMS1 3118 70 P54277
hMLH3 94 8 Q9UHC1
RFC 40kDa 120 18 P35250
RFC 37kDa 111 11 P35249
RFC 140kDa 98 6 P35251
Exonuclease 1 65 10 Q5T396
RPA 40kDa 83 12 O15160
Other repair Pathways
BRCA2 224 10 P51587
BRCA1 78 6 P38398
MMS19-like 103 14 Q5T455
XPF 83 14 Q92889
ATR 157 9 Q13535
NONO 283 28 Q9BQC5
ATM 99 7 Q13315
RAD18 86 23 Q9NS91
RAD54B 76 13 Q9Y620
Proteins Import/Export
Importin beta3 851 24 O00410
Importin alpha 2 312 23 P52292
Importin 9 296 11 Q96P70
RANBP9 338 20 Q96S59
RANGAP1 243 29 Q96JJ2
Importin 3 184 12 O14787
Ubiquitin pathway/proteasome
 EDD 2558 34 O95071
UBP5 963 35 P45974
CYLD 183 7 Q9NQC7
UBP13 141 15 Q92995
Ubiquitin 111 58 P62988
RNF123 103 7 Q5XPI4
UBAP2L 101 7 Q9BTU3
PSD2 506 23 Q13200
PRS4 198 16 P62191
Herc2 213 8 O95714
Cullin 3 190 15 Q13618
Cullin 1 134 11 Q13616
USP9Y 102 6 O00507
RNF20 188 14 Q5VTR2
UBP26 83 15 Q9BXU7
Table3: continued
Function^ Protein Protein score* Sequence Swiss-Prot
coverage (%) acc.no.
DNA Helicases
Dna helicase B 706 23 Q8NG08
MOV10 330 14 Q9HCE1
BRIP1 159 15 Q9BX63
RECQ4 95 8 O94761
Heat Shock Proteins/Chaperones
HSP90beta 2299 63 P08238
TCPA (TCP-1sub.alpha) 543 42 P17987
Midasin 345 5 Q9NU22
HSP75 192 16 Q12931
Sacsin 182 9 Q5T9J7
Replication/DNA metabolism
PGK1 487 30 P00558
TOP1 403 18 P11387
DPOD1 169 11 P28340
MCM6 278 12 Q14566
DPOZ 229 8 O60673
POLQ 139 9 Q6VMB5
Dna Pol. Gamma sub. 1 77 4 P54098
SMC3 170 17 Q9UQE7
Unknown Function/Hypotetical proteins
WDHD1(AND-1) 537 21 O75717
RO52 (TRIM21) 513 33 P19474
MARE2 482 55 Q15555
DKFZp686E0722 377 13 Q68DX7
KIAA1018 (fragment) 349 17 Q9Y2M0
KIAA0889 295 10 Q6ZTG8
KIAA1401 285 15 Q9P2E6
Metabolism of RNA/Transcription/Translation/Ribosome
EF1-delta 517 49 P29692
RLA0 512 50 P05388
SK2L2 505 18 P42285
hNRP U 1052 40 Q9BQ09
U520 504 16 O75643
SR140 401 15 O15042
ABCF1 398 31 Q8NE71
RS8 369 50 P62241
U2AF2 362 30 P26368
eIF-5B 284 17 O60841
hnRNP M 218 18 P52272
eIF-2B 140 8 Q13144
eIF-4B 254 12 P23588
UBF-1 280 20 P17480
DHX36 261 12 Q8IYE5
PABPC4 261 16 Q5SPS6
TRRAP 224 14 Q9Y4A5
ASH1 217 10 Q9NR48
EXOSC10 213 17 Q01780
RRBP1 183 16 Q9P2E9
POLR1A 157 12 O95602
Function^ Protein Protein score* Sequence Swiss-Prot
coverage (%) acc.no.
Cell cycle/Signaling/Kinases/Phospatases/Apoptosis
SET binding factor 2 759 17 Q86WG5
SET binding factor 1 194 8 O95248
Cyclin T1 483 30 O60563
CDK9 444 38 P50750
PI3K-C2 alpha 443 15 O00443
CENP E 384 19 Q02224
CENP F 263 12 P49454
CENP J 212 15 Q5T6R5
CDC5-like 338 22 Q76N46
AKAP9 323 15 Q99996
PP2A reg. sub. A-alpha 263 22 P30153
PP2A reg. sub. A-beta 113 18 P30154
CDC42BPA 127 7 Q5VT25
CK5P2 189 12 Q96SN8
NEK1 150 15 Q96PY6
PKCB 125 18 Q9ULU4
Others
ACC-alpha 459 16 Q7Z561
ATAD 34 362 25 Q5SV23
DPH5 370 36 Q9H2P9
Dnmt1 120 9 P26358
APC 198 11 P25054
HRMT1L2 175 19 Q99873
SUP6H 175 9 Q7KZ85
Angiomotin 82 12 Q4VCS5
^ Derived from Swiss-Prot. database or published data.
* Mascot protein score where a value >65 is considered significant (P<0.05).
Table3: continued
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The mismatch repair (MMR) gene hMLH1 is mutated
in ~50% of hereditary non-polyposis colon cancers
and transcriptionally silenced in ~25% of sporadic
tumours of the right colon. Cells lacking hMLH1 dis-
play microsatellite instability and resistance to killing
by methylating agents. In an attempt to study the
phenotypic effects of hMLH1 downregulation in
greater detail, we designed an isogenic system, in
which hMLH1 expression is regulated by doxycycline.
We now report that human embryonic kidney 293T
cells expressing high amounts of hMLH1 were MMR-
pro®cient and arrested at the G2/M cell cycle check-
point following treatment with the DNA methylating
agent N-methyl-N¢-nitro-N-nitrosoguanidine (MNNG),
while cells not expressing hMLH1 displayed a MMR
defect and failed to arrest upon MNNG treatment.
Interestingly, MMR pro®ciency was restored even at
low hMLH1 concentrations, while checkpoint activ-
ation required a full complement of hMLH1. In
the MMR-pro®cient cells, activation of the MNNG-
induced G2/M checkpoint was accompanied by phos-
phorylation of p53, but the cell death pathway was
p53 independent, as the latter polypeptide is function-
ally inactivated in these cells by SV40 large T antigen.
Keywords: cell cycle checkpoint/hMLH1/methylating
agent/mismatch repair/TetOff
Introduction
Mutations in mismatch repair (MMR) genes, predomin-
antly hMSH2 and hMLH1, segregate with hereditary non-
polyposis colon cancer (HNPCC). Inheritance of a single
mutated allele of a MMR gene predisposes to precocious
cancers of the colon, endometrium and ovary. Analysis of
HNPCC tumour cells showed that repeated sequence
elements (microsatellites) in their genomic DNA are
frequently mutated (for a review see Peltomaki, 2001). As
microsatellite instability (MSI) is a hallmark of defective
MMR in all organisms tested to date, and has been shown
to be present in all tumour cell lines that have lost both
alleles of hMSH2 or hMLH1 (Boyer et al., 1995), it is
assumed that the wild type alleles of the respective MMR
genes in cells of HNPCC tumours have been lost or
inactivated by mutation. But mutations in MMR genes are
not an absolute prerequisite for MSI. In recent years, a
number of sporadic colon tumours and tumour cell lines
displaying MSI have been described that are MMR-
de®cient due to silencing of the hMLH1 promoter by
hypermethylation (reviewed in Esteller, 2002).
Once both MMR gene alleles have been inactivated, the
cell's propensity towards acquiring mutations increases,
especially in genes carrying microsatellite repeats. Should
the mutated genes be involved in the control of cell
proliferation, the mutator cell in, for example, the colonic
epithelium would be able to divide in an uncontrolled
manner and thus give rise to an adenomatous polyp. As the
cells in this benign growth acquire further mutations with
subsequent cell divisions, the adenoma would rapidly
become transformed into a carcinoma. That such a path to
transformation can be followed in vivo was demonstrated
when numerous HNPCC colon cancers were shown to
carry frameshift mutations in a run of 10 adenines within
the coding sequence of the transforming growth factor b
receptor type II (TGFbRII) gene, as well as in other genes
involved in growth control or apoptosis (reviewed in
Markowitz et al., 2002). Further support for this hypo-
thesis comes from the ®nding that adenomas of HNPCC
kindred transform to carcinomas with a much higher
frequency than those associated with sporadic disease
(Kinzler and Vogelstein, 1998), presumably due to a more
rapid acquisition of transforming mutations.
The above ®ndings help explain how the loss of MMR
might accelerate cellular transformation and tumour
progression. What is unclear to date, however, is whether
the transformation process begins only following the
inactivation of both MMR gene alleles, or whether it
commences already at the stage when only one allele is
affected or when the expression of the given MMR gene is
only attenuated, rather than shut off, such as might be the
case in cells where the hMLH1 promoter is only partially
methylated. The notion that a reduction in MMR protein
levels might promote tumorigenesis originates in studies
with Msh2+/± mice. Although the Msh2+/± embryonic stem
cells were apparently normal in terms of their MMR
capacity as measured by MSI (de Wind et al., 1995), the
heterozygous animals were cancer prone, and presented
with tumours that often still contained the wild-type Msh2
allele (de Wind et al., 1998). The propensity of the MMR
heterozygous cells to transformation would thus appear to
be linked to a process distinct from the correction of
replication errors. What might the nature of these
processes be?
In recent years, MMR defects have been linked to
several other phenomena, such as transcription-coupled
repair and recombinationÐboth mitotic and meiotic
(reviewed in Harfe and Jinks-Robertson, 2000). In
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addition, the MMR system was implicated in activation
of cell cycle checkpoints and apoptosis, as witnessed by
the increased resistance of MMR-de®cient cells to the
methylating agent N-methyl-N¢-nitro-N-nitrosoguanidine
(MNNG) or cisplatin (reviewed in Bellacosa, 2001).
Thus, while MMR+/± cells, or cells expressing low amounts
of MMR proteins, may not display a mutator phenotype,
they might have at least a partial defect in one of the above
processes, speci®cally in the DNA damage signalling
pathway, which we judged to be of the greatest relevance to
cancer. We wanted to study these processes in detail, but we
lacked isogenic cells expressing varying amounts of MMR
proteins. Cells in which the MMR defect was corrected
either by transfer of a chromosome carrying a single wild-
type copy of the mutated MMR gene (Koi et al., 1994) or its
cDNA (Risinger et al., 1998; Buermeyer et al., 1999;
Lettieri et al., 1999; Claij and Te Riele, 2002) were
unsuitable for our studies, because they express similar or
even higher amounts of the complementing MMR proteins
than MMR-pro®cient controls. Thus, in order to be able to
study the phenotypic consequences associated with reduced
levels of MMR proteins, we had to generate a new line,
preferably of epithelial origin, in which the expression of a
selected MMR gene could be regulated. We now describe
the construction and characterization of a line in which the
expression of hMLH1 can be tightly regulated by
doxycycline with the help of the TetOff system.
Results
Construction of cells with inducible hMLH1
expression
The human embryonic kidney cell line 293T is MMR
de®cient, because the hMLH1 gene in these cells is
epigenetically silenced by promoter hypermethylation
(Trojan et al., 2002). We set out to correct its MMR
defect through the expression of exogenous hMLH1 using
the TetOff expression system, which can be tightly
regulated. We ®rst generated the 293T-TetOff cell line
by stable transfection of the 293T cells with a DNA vector
encoding the tetracycline-controlled transactivator (tTA).
In the second step, we stably transfected the 293T-TetOff
cells with a vector carrying the hMLH1 cDNA under the
control of the tetracycline response element (TRE), thus
creating 293T La cells. In the absence of tetracycline, or
its more stable analogue doxycycline (Dox), the tTA
protein binds to the TRE and activates transcription of
hMLH1; conversely, addition of the drug induces a
conformational change in tTA, which loses its ability to
bind DNA and the transcription of hMLH1 is thus turned
off (Figure 1A). During the initial screening, we used Dox
at a concentration of 2 mg/ml, as recommended by the
manufacturer, but later we found that a concentration of
50 ng/ml was suf®cient to turn off the expression of
hMLH1 below the limit of detection by western blotting
(see below).
In vivo, hMLH1 interacts with hPMS2 to form the
heterodimer hMutLa, which is essential for MMR. Our
previous studies have shown that hPMS2 is unstable in the
absence of its cognate partner (RaÈschle et al., 1999).
Indeed, no hMLH1 could be detected in the extracts of
293T cells, and hPMS2 was hardly detectable (Trojan
et al., 2002). A similar situation also existed in our 293T
La clone grown in the presence of Dox, i.e. under
conditions where the hMLH1 promoter is shut off
(Figure 1B). However, expression of hMLH1 brought
about hPMS2 stabilization through the formation of
hMutLa, such that the levels of the latter protein were
Fig. 1. Inducible hMLH1 expression in 293T La cells. (A) In the Tet-Off system, hMLH1 is expressed in the absence of Dox, because the tTA factor
binds to the promoter of the expression vector and thus activates transcription. Addition of Dox to the culture medium causes a conformational change in
tTA, which leads to its dissociation from the promoter and thus to an inactivation of hMLH1 transcription. (B) Western blot analysis of cytoplasmic (CE)
and nuclear (NE) extracts of cells cultured in the absence (±) or presence (+) of 50 ng/ml Dox. hMLH1 and hPMS2 were visualized using anti-hMLH1 or
anti-hPMS2 antibodies as described in Materials and methods. Total extract (TE) of MMR pro®cient HeLa cells was used as a positive control.
(C) Stability of hMutLa. The cells were cultured without Dox (±) to induce maximal hMLH1 expression. Following the addition of 50 ng/ml Dox (+),
total cell extracts were isolated after 1, 2, 3, 4, 6 and 8 days. Western blot analysis was performed using anti-hMLH1 and anti-hPMS2 antibodies as in (B).
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comparable to those seen in extracts of MMR-pro®cient
cell lines (Figure 1B).
The expression of hMLH1 in the 293T La cells grown
in the absence of Dox was substantially higher than in any
MMR-pro®cient cell line tested by us to date (Figure 1B;
data not shown). Interestingly, this overexpression did not
appear to be toxic to the cells: we detected no increase in
the rates of apoptosis, as described for cells microinjected
with expression vectors encoding hMSH2 and hMLH1
(Zhang et al., 1999). Moreover, cells grown in the absence
or presence of Dox divided roughly once every 24 h (data
not shown), unlike HCT116 and SNU-1 cells, in which the
stable expression of hMLH1 was reported to result in
substantially slower growth rates (Shin et al., 1998). When
the expression of the transgene was turned off by the
addition of Dox, the hMLH1 and hPMS2 proteins were
present in the cell extracts in a 1:1 ratio only 24 h later
(Figure 1C) and decayed with similar kinetics. This
experiment showed that hMutLa is extremely stable, as
it was detectable in the extracts of 293T La cells even
6 days after the expression of hMLH1 was shut off.
In the following text, cells grown in the presence of
50 ng/ml Dox that do not express hMLH1 and thus lack
hMutLa will be referred to as 293T La± cells. Those
grown in the absence of Dox, which express hMLH1 and
thus contain functional hMutLa, will be referred to as
293T La+ cells.
hMLH1 expression in 293T La cells restores MMR
in vitro
Extracts of the 293T La cells were tested for MMR
activity in vitro using two different MMR assays (see
Materials and methods). No MMR activity was detected in
extracts of 293T La± cells, but as the defect could be
complemented by the addition of the recombinant wild-
type hMutLa, we concluded that this heterodimer was the
only factor missing in these extracts (Figure 2). In contrast,
extracts from 293T La+ cells were MMR pro®cient in both
assays (Figure 2). Importantly, these results showed that
the excess partnerless hMLH1 in the 293T La line does
not inhibit MMR, at least not in our in vitro system. This
differs from the situation in Saccharomyces cerevisiae,
where overexpression of MLH1 gave rise to a mutator
phenotype associated most likely with the inhibition of
MMR through the homodimerization of this polypeptide
(Shcherbakova and Kunkel, 1999; Shcherbakova et al.,
2001). The MMR pro®ciency of the 293T La+ cells in our
in vitro assay was similar irrespective of whether the
extracts were prepared from cells grown in the absence of
Dox, or 24 h after the addition of the drug (data not
shown), at which time point the ratio of hMLH1 to hPMS2
was 1:1 (Figure 1C).
Inducible hMLH1 expression restores sensitivity to
alkylating agents
In order to determine the effect of hMLH1 expression on
the sensitivity of 293T La cells to MNNG, we used
clonogenic assays to quantify the surviving fraction of
293T La± and 293T La+ cells following treatment with
5 mM MNNG. [Note that 293T La cells do not express
MGMT, the enzyme responsible for the detoxi®cation of
methylation damage (G.Marra, unpublished data). For this
reason, the experiments described below were carried out
in the absence of the MGMT inhibitor O6-benzylguanine.]
As shown in Figure 3A, 293T La+ cells were very
sensitive to killing by MNNG, and the surviving fraction
was indistinguishable from that obtained after MNNG
treatment of the related MMR-pro®cient 293 cell line. In
contrast, 293T La± cells were resistant to killing by
MNNG, just like the parental, MMR-de®cient 293T cells.
The presence of Dox in the culture medium had no effect
on the survival of any of the control cell lines used in this
study (Figure 3A).
The sensitivity of 293T La cells to MNNG was further
examined using the MTT assay, which is based on the
cleavage of the yellow tetrazolium salt MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
by the action of mitochondrial dehydrogenases to form a
violet formazan dye. As this reaction takes place only in
living cells, these can be distinguished from non-viable
cells in a simple colorimetric assay. As shown in
Figure 3B, 293T La± cells were 125-fold more resistant
Fig. 2. MMR pro®ciency of 293T La cell extracts. (A) Repair ef®-
ciency of a G/T mismatch in the M13mp2 vector carrying a strand
discrimination signal 3¢ from the mispair, using cytoplasmic extracts of
the 293T La+ and 293T La± cells, supplemented or not with recom-
binant hMutLa (see text for details). Error bars show standard errors.
(B) Correction of a G/T mismatch within a BglII restriction site of a
pGEM vector, following incubation with nuclear extracts of 293T La+
or 293T La± cells, supplemented or not with recombinant hMutLa.
The strand discrimination signal in this heteroduplex substrate was 5¢
from the mispair. Ef®cient repair resulted in the restoration of a BglII
site and in the generation of two DNA fragments that co-migrate with
those observed in the reference digest of the homoduplex molecule
carrying a bona ®de BglII site.
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to killing by MNNG than the same cells in a MMR-
pro®cient mode (i.e. 293T La+ cells).
Expression of hMLH1 in 293T La cells leads to
activation of a methylation damage induced cell
cycle arrest
To determine whether the increased sensitivity of 293T
La+ cells to MNNG resulted from induction of cell cycle
arrest and cell death, the treated 293T La+ and 293T La±
cell populations were analysed by ¯ow cytometry. As
shown in Figure 3C, 2 days after treatment with 0.2 mM
MNNG, the 293T La+ cells were mostly arrested in the
G2/M phase of the cell cycle. One day later, cells
containing sub-G1 amounts of DNA became detectable,
and this population increased with time. In contrast, no
increase in the population of cells either arrested in G2/M
or with a lower than 2n DNA content was detected in
cultures of treated 293T La± cells.
In order to further characterize the response of cells to
MNNG, we analysed the phosphorylation status of Cdc2.
As shown in Figure 4A, Cdc2 phosphorylated on Tyr15
accumulated exclusively in 293T La+ cells treated with
0.2 mM MNNG. This provides molecular evidence for a
G2/M arrest, because so long as this kinase remains
phosphorylated, entry into mitosis should be blocked. No
difference in Cdc2 phosphorylation was observed in the
extracts of MNNG-treated 293T La± cells (Figure 4A).
The above results thus show that induction of hMLH1
expression in the 293T La cells was necessary and
suf®cient to endow them with a MMR-pro®cient status,
which also enabled them to respond to DNA damage
induced by MNNG. What is presently unclear is the role of
the MMR system in this checkpoint activation. DNA
damage signalling is known to be mediated via several
protein phosphorylation cascades, which involve primarily
the DNA-dependent protein kinase (DNA-PK), or the
ataxia telangiectasia-mutated (ATM) and ATM and
Rad3-related (ATR) kinases. The downstream target of
the latter enzymes is the p53 tumour suppressor protein,
the phosphorylation of which on Ser15 is known to lead to
its stabilization and subsequent activation as a transcrip-
tion factor (Tibbetts et al., 1999). Phosphorylation of p53
has indeed been shown to take place upon MNNG
treatment, and was shown to be dependent on functional
hMutSa and hMutLa (Duckett et al., 1999; Hickman and
Samson, 1999; Adamson et al., 2002). However, as the
latter experiments were carried out with drug concentra-
tions 25- to 125-fold higher than those used in our study,
we wanted to test whether Ser15 phosphorylation also took
place in the 293T La cells treated with 0.2 mM MNNG.
These cells overexpress the SV40 large T antigen and thus
contain large amounts of stabilized p53 polypeptide. This
system is ideally suited for the study of post-translational
modi®cation of p53, as the steady-state levels of the latter
protein remain unaltered during the experiment (Tibbetts
et al., 1999). As anticipated, the p53 steady-state levels in
the 293T La cell extracts were high, irrespective of
whether hMLH1 was expressed or not, or whether extracts
of treated or untreated cells were examined (Figure 4A).
However, following MNNG treatment, phosphorylation of
p53 with a Ser15-speci®c antibody could be detected
exclusively in the MMR-pro®cient 293T La+ cells.
Notably, and in contrast to the study by Adamson et al.
(2002), where the phosphorylation of p53 became detect-
able already just minutes after MNNG treatment, the
MMR-dependent post-translational modi®cation of p53
observed in our cells peaked at 48 h, i.e. at a time point
where most cells were arrested at G2/M (Figure 3C). This
difference is probably linked with the high concentration
of MNNG (25 mM) used in the latter study, which would
be expected to introduce numerous single- and double-
strand breaks into DNA that arise through the spontaneous
loss of methylated purines and the subsequent breakage of
the sugar-phosphate DNA backbone by b-elimination at
the resulting abasic sites (Loeb, 1985). DNA strand breaks
rapidly activate the ATM/ATR kinases that subsequently
phosphorylate a number of downstream targets, one of
which is histone H2AX (Redon et al., 2002). This histone
modi®cation is thought to aid the recruitment of DNA
repair factors to the sites of damage (Paull et al., 2000).
H2AX is phosphorylated in the 293T La cells upon
Fig. 3. Sensitivity of 293T La cells to MNNG. (A) Survival of 293T
La+ and 293T La± cells following treatment with 5 mM MNNG. 293
and 293T cells were used as MMR-pro®cient and -de®cient controls,
respectively. The presence of Dox (+Dox) in the culture medium did
not affect the control cells, but had a dramatic effect on the survival of
the 293T La cell populations. (B) IC50 values of 293T La+ and 293T
La± cells. Each value represents the mean 6 SE. (C) Cell cycle pro®les
of 293T La+ and 293T La± cells treated with 0.2 mM MNNG. Shown
are representative cytometrograms of cells expressing (293T La+) and
not expressing (293T La±) hMLH1. G1, cell population in the G1 phase
of the cell cycle with a 2n DNA content; G2, cells in the G2 and M
stages of the cell cycle with a 4n DNA content; S, cells in various
stages of DNA synthesis with a DNA content between 2n and 4n.
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treatment with 0.2 mM MNNG, as witnessed by the
formation of phospho-H2AX foci (Figure 4B). However,
these foci arise in both 293T La+ and 293T La± cells soon
after treatment. Thus, damage caused by direct modi®ca-
tions of DNA at low concentrations of MNNG does not
trigger the G2/M checkpoint. The activation of the
checkpoint machinery must take place after H2AX
phosphorylation, in the second cell cycle post-treatment
(Kaina et al., 1997), and must involve the MMR system,
perhaps in conjunction with another pathway of DNA
metabolism that remains to be identi®ed. Thus, the lesions
that trigger the checkpoint machinery are distinct from
those that bring about phosphorylation of H2AX.
MMR pro®ciency and response to MNNG
treatment require different levels of hMLH1
expression
The principal goal of this study was to investigate the
phenotypic effects of reduced expression of MMR
proteins, such as might be encountered when expression
of the gene is attenuated by cytosine methylation. In order
to achieve this goal, we attempted to modulate hMLH1
expression in the 293T La cells. This could be achieved
by varying the Dox concentration in the culture media.
Thus, cells grown in the presence of 0.1, 0.2, 0.4, 0.8 and
1.5 ng/ml Dox contained steadily decreasing amounts of
hMLH1 and hPMS2, as compared with cells grown in the
absence of the drug (Figure 5A).
When we tested how this variation in the amount of
hMutLa affected MMR ef®ciency, we found that extracts
of cells expressing as little as 10% of the amounts found in
cells grown in the absence of Dox were still pro®cient in
the in vitro MMR assays. Cells cultivated with 0.1 and
0.2 ng/ml Dox showed MMR activities comparable to
those of the MMR-positive 293T La+ cells grown in the
absence of Dox, and even extracts of cells cultivated with
0.4 ng/ml Dox were still able to repair mismatches in vitro,
albeit with lower ef®ciency (Figure 5B). MMR pro®ciency
was lost only in cell extracts in which the hMLH1 and
hPMS2 proteins became dif®cult to detect by western
blotting (Figure 5A). To test whether the results of the
in vitro MMR assays were re¯ected also in the MSI
Fig. 4. Post-translational protein modi®cation and strand break process-
ing in MNNG-treated 293T La cells. (A) Phosphorylation status of p53
and cdc2 in 293T La+ and 293T La± cells 1±4 days after treatment
with 0.2 mM MNNG. P-p53, P-cdc2, phosphorylated p53 and cdc2
proteins, respectively; C, untreated control cells; b-tubulin, internal
standard used to ascertain equal gel loading. (B) g-H2AX foci forma-
tion in MNNG-treated 293T La cells. In the control cell population,
<10% of cells displayed H2AX foci. Following MNNG treatment, all
cells contained foci until 24 h post-treatment. See text for details and
Materials and methods for experimental procedures.
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phenotype of the cells, we analysed the BAT26 micro-
satellite marker, which contains a repeat of 26 deoxy-
adenosines, and which is considered to be a reliable
indicator of MSI. Because the 293T La cells are hypo-
triploid, and because this cell line was MMR de®cient for
many generations prior to our intervention, the BAT26
locus was found to be highly heterogeneous. The product
of PCR ampli®cation had on average eight peaks, and we
therefore applied the HNPCC criteria of MSI (Loukola
et al., 2001), whereby only PCR products that differed by
three or more peaks at this locus were considered to be a
sign of MSI. By these criteria, the BAT26 instability in the
cells propagated for 35 generations in 0 or 0.2 ng/ml
Dox was ~1%, whereas cells grown with 50 ng/ml Dox
displayed MSI that was ~5-fold higher (Table I). How-
ever, closer inspection of the data revealed that cells
propagated in 0 or 0.2 ng/ml Dox displayed no alleles
(0/211) that differed by more than 4 bp from the median. In
contrast, two such alleles (two out of 73; 2.7%) were found
in the cells grown with 50 ng/ml Dox (Table I, numbers in
parentheses). This suggests that MSI at the BAT26 locus
in the 293T La± cells is substantially greater than in cells
expressing hMLH1, and thus that expression of even low
amounts of hMutLa are suf®cient to correct the MMR
defect in these cells, both in vitro (Figure 2) and in vivo
(Table I).
We were interested to determine whether the low
amounts of the hMLH1/hPMS2 heterodimer that were
shown to restore MMR pro®ciency were also able to
activate the DNA damage-induced cell cycle arrest in
293T La cells. To this end, we treated the cells with 5 mM
MNNG and calculated the average doubling time over a
period of 5 days. In accordance with our previous
experiments, only cells expressing the highest amounts
of hMLH1 (i.e. 293T La+ cells grown without Dox) ceased
to grow, as suggested by their increased doubling time.
Cells grown in 0.1 ng/ml Dox were only partially affected,
and cells cultivated with 0.2 ng/ml Dox or more grew
similarly to 293T La± cells (Figure 5C). To test whether
this growth retardation was due to checkpoint activation,
we analysed the DNA content of the cells 3 days after
treatment with 0.2 mM MNNG. As shown in Figure 5D,
FACS analysis showed that only cells expressing the
highest amounts of hMLH1 (i.e. cells cultured without
Dox) displayed a strong G2/M arrest (an average of 63% of
the cells were in G2/M). The response of cells cultivated
with 0.1 ng/ml Dox was substantially weaker (~27% cells
in G2/M), and the cell cycle pro®les of cells grown with
0.2 ng/ml Dox or more were indistinguishable from those
of the untreated controls (~22% cells in G2/M). Notably,
whereas cells grown in the absence of Dox activated the
MNNG-induced G2/M checkpoint, while those grown in
Table I. Instability of the BAT26 chromosomal locus in 293T La
cells expressing varying amounts of hMLH1
Dox (ng/ml) MSI+/total % MSI
0 2 (0)/131 1.5
0.2 1 (0)/80 1.3
50 4 (2)/73 5.5 (2.7)
MSI+ clones were de®ned as those displaying more than three extra
peaks in the sequence of the PCR product. Numbers in parentheses
refer to clones with more than four extra peaks.
Fig. 5. Mismatch correction ef®ciency and MNNG-induced G2/M arrest
in cells expressing different amounts of hMLH1. (A) Dependence of
hMLH1 expression on Dox concentration. hMLH1 and hPMS2 were
visualized as described in Materials and methods. b-tubulin, internal
standard used to ascertain equal loading. (B) MMR ef®ciency of a G/T
mispair in an M13mp2 substrate carrying a strand-discrimination signal
3¢ from the mispair. Error bars show standard errors. (C) Variation in
doubling times of 293T La cells grown in the indicated Dox concentra-
tions following treatment with 5 mM MNNG. (D) FACS analysis of
293T La cell populations grown in the indicated Dox concentrations,
either untreated (Control), or 72 h after treatment with 0.2 mM MNNG
(see also Figure 3C). (E) Phosphorylation of p53 and cdc2 48 h after
treatment of cells (grown in the indicated Dox concentrations) with
0.2 mM MNNG. b-tubulin, internal standard used to ascertain equal
loading.
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0.2 ng/ml Dox failed to do so, phosphorylated forms of
p53 and cdc2 could be detected in both cell populations
(Figure 5E). The extent of cdc2 phosphorylation in
particular would predict that a detectable proportion of
the treated cells should be at the G2/M boundary. This was
clearly not the case, as judged by FACS analysis
(Figure 5D; also see Figure 3C).
Taken together, these experiments show that although
only low amounts of hMutLa are required for MMR
pro®ciency, DNA damage-induced G2/M arrest and cell
death in response to MNNG treatment require a full
complement of this heterodimer. The fact that the 293T
La+ cells arrest and die with kinetics and ef®ciency similar
to other MMR-pro®cient cells con®rms that p53, which is
inactive in these cells, is not required for either of
these processes (Hickman and Samson, 1999). Thus, the
molecular pathways controlling the MNNG-induced G2/M
checkpoint in these cells require further study.
Discussion
We show that expression of hMLH1 in 293T La cells
corrected their MMR defect in vitro and in vivo. The 293T
La+ cells were also found to be >100-fold more sensitive
to killing by MNNG than the isogenic cells lacking
hMLH1. MNNG treatment arrested the MMR-pro®cient
cells in the G2/M phase of the cell cycle, and this arrest
was entirely and solely dependent on the function of
hMLH1. This latter statement is supported by the ®nding
that expression of hMLH1 in 293T La+ cells did not affect
the transcriptional activity of other genes, as demonstrated
by Affymetrix GeneChipÔ analysis (data not shown).
This study also showed that the steady-state levels of the
hMLH1/hPMS2 heterodimer required for MMR pro®-
ciency and DNA damage response were signi®cantly
different. In earlier experiments (Lettieri et al., 1999) we
generated a cell line derived from hMSH6-de®cient
HCT15 cells, which expressed low levels (~20%) of
wild-type hMSH6. This line was MMR pro®cient, but
remained as resistant to killing by methylating agents as
the parental cell line. Similarly, a recent study described a
Msh2±/± mouse embryonic stem cell line in which the
MMR defect was largely corrected by the expression of
low levels (10% of control) of exogenous Msh2, but the
response of these cells to methylating agents was
comparable to that observed with the parental Msh2±/±
cells (Claij and Te Riele, 2002). This damage signalling
defect was suggested by the authors to be linked to poor
recognition of MeG/T mispairs, which arise through the
mispairing of O6-methylguanine (MeG) with thymine
during DNA replication (Karran and Bignami, 1996),
and which are bound less ef®ciently than bona ®de
mispairs by the hMSH2/hMSH6 (hMutSa) heterodimer
(Duckett et al., 1996). Constant loading of hMutSa sliding
clamps at MeG/T mispairs was proposed be responsible for
transmission of the DNA damage signal to the checkpoint
machinery in vivo (Fishel, 1999), and it might be expected
that this process is substantially less ef®cient in cells
expressing only low amounts of the mismatch binding
factor hMutSa. However, the amounts of hMutSa in 293T
La+ and 293T La± cells are equal, and similar to those
found in other MMR-pro®cient cells. Our results thus
extend the above hypothesis by showing that the signal
transduction process also requires the hMLH1/hPMS2
heterodimer, thought to act downstream of damage
recognition. Moreover, our result show that the recogni-
tion of MeG/T mispairs per se is insuf®cient to activate the
checkpoint machinery. The G2/M checkpoint is thought to
be controlled by the phosphoinositide-3 (PI3) kinases
ATM/ATR, which are principally responsible for the
phosphorylation of p53 on Ser15 (Osborn et al., 2002).
The MeG/T mispairs arise already during the ®rst round of
replication, yet no p53 phosphorylation is detectable until
24 h after treatment, at which point the cells are beginning
to enter the second S phase (Figure 3C; data not shown).
Notably, the peak of signalling activity coincides with
that of chromosomal rearrangements (sister chromatid
exchanges and recombinations) induced by MNNG (Kaina
et al., 1997). Thus, MMR-dependent processing of the
MeG/T mispairs that arise during the ®rst S phase
apparently does not activate the checkpoint machinery,
but leads instead to the generation of intermediates that
result in aberrant recombination events during the subse-
quent round of DNA replication, which then signal. What
the exact nature of these intermediates may be is currently
the subject of intensive studies.
The evidence presented here shows that cells with lower
than wild-type levels of MMR proteins are not pheno-
typically normal, despite being MMR pro®cient. The
observed defect in DNA damage signalling may be
relevant to cellular transformation and cancer, particularly
in epithelial cells that are rapidly proliferating and that
may be exposed to stress or carcinogens. In the colon, the
epithelial stem cells that are near the bottom of the crypts
give rise to daughter cells that begin to differentiate during
their migration towards the surface of the colon. Upon
reaching the apex of the crypt, these cells undergo
apoptosis and are shed. When the colonic epithelial cells
become damaged, they should undergo apoptosis and thus
give rise to no mutant progeny. In contrast, cells with a
defect in DNA damage signalling, such as those express-
ing suboptimal amounts of MMR proteins, would not
activate cell cycle checkpoints and apoptosis in response
to DNA damage. Instead, they might acquire mutations
that allow them to continue to proliferate and give rise to
an adenoma.
The relevance of this hypothesis to the situation in vivo
hinges on two points. First, there are currently no
experimental data documenting instances where colono-
cytes or other epithelial cells that are prone to transform-
ation express low MMR protein levels. We obtained some
evidence of lower than normal steady-state levels of
hMSH2 and increased resistance to methylating agents in
the immortalized lymphoblasts of HNPCC patients, which
are heterozygous in the hMSH2 locus, but the hMLH1±/±
cells were normal in all assays (Marra et al., 2001). It is not
known whether hMSH2 and hMLH1 levels in hetero-
zygous colonocytes of HNPCC kindred are lower than in
similar cells of normal individuals, even though some
¯uctuations might be expected. However, the recent
characterization of the hMLH1 promoter as a frequent
target of DNA hypermethylation (Esteller, 2002) implies
that there must be cells with only partially methylated
promoters, because de novo methylation of CpG islands is
a gradual process. These cells, such as the 293T La cells
grown in low concentrations of Dox (Figure 5A), would
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contain decreased levels of hMutLa and would therefore
be likely to also have a defective response to DNA
damage.
The second point concerns the nature of the endogenous
DNA damage that might trigger the transformation
process. It is conceivable that normal colonocytes which
become damaged by endogenous or exogenous DNA
modifying agents would arrest and, in cases where the
extent of the damage is beyond repair, activate cell death
processes, while those expressing reduced levels of
hMutLa would continue to proliferate and thus acquire
mutations. Although human DNA is aberrantly modi®ed
by S-adenosyl methionine and other methyl group donors,
the extent of such modi®cations might be too low to trigger
cell death. However, the deleterious effects of the
checkpoint defect could become evident also in response
to other types of DNA damage; experimental evidence
implicates the MMR system in the processing of DNA
modi®cations ranging from oxidative damage to bulky
moieties such as cisplatin and AAF (reviewed in
Bellacosa, 2001).
We have described a cell line in which the MMR status
can be controlled by the concentration of doxycycline in
the culture medium. Our current results show that the
activation of transcription of exogenous hMLH1 comple-
ments not only the MMR defect of the 293T cells, but also
reactivates their responsiveness to treatment with methyl-
ating agents, providing that the levels of the MMR proteins
are suf®ciently high to activate the DNA damage-induced
checkpoint. This fully isogenic system is clearly open to
further exploitation, and should allow us to study the
involvement of the MMR system in other pathways of
DNA metabolism, such as response to other types of DNA
damaging agents ranging from ionizing radiation to
crosslinking chemotherapeutics, where the involvement
of MMR was found to be only marginal and where it could
not be ruled out that the observed effects (or lack thereof)
were linked to a selection of an atypical clone from the
stably transfected population. The 293T La line could also
be used in the screening for substances that preferentially
kill MMR-de®cient cells. This should prove invaluable in
the treatment of tumours, both hereditary and sporadic,
with defective MMR.
Materials and methods
Cell lines
The 293T cells (a kind gift of K.Ballmer) were grown in Dulbecco's
modi®ed Eagle's medium with Eagle salts (Gibco-BRL, Gaithersburg,
MD), supplemented with 10% Tet System Approved Fetal Bovine Serum
(Clontech, Palo Alto, CA), 2 mM L-glutamine (Gibco-BRL), 100 IU/ml
penicillin and 100 mg/ml streptomycin (Gibco-BRL). For 293T-TetOff or
293T La cells, 100 mg/ml Zeocin (Invitrogen, San Diego, CA) or
100 mg/ml Zeocin and 300 mg/ml Hygromycin B (Roche Molecular
Biochemicals, Mannheim, Germany) were added, respectively.
Plasmid construction
The pTetOff-Zeo plasmid was constructed by ligation of the following
DNA molecules: the ®rst, coding for tTA, was obtained by digestion of
pTetOff (Clontech) with XhoI (New England Biolabs, Beverly, MA)
followed by ®lling-in with dCTP and dTTP using the Klenow fragment of
DNA polymerase I (New England Biolabs). The second, coding for
Zeocin resistance protein, was obtained by digestion of pVgRXR
(Invitrogen) with BamHI (New England Biolabs) followed by ®lling-in
with dGTP and dATP. The pTRE2-hMLH1 plasmid was generated by
subcloning hMLH1 cDNA (a kind gift of R.Michael Liskay) into the
BamHI and NotI sites of pTRE2 (Clontech).
Calcium phosphate transfections
One day before transfection, 250 000 cells were plated in 6-well plates in
3 ml of cell culture medium. The cells reached ~50% con¯uency on the
day of transfection. Three hundred microlitres of solution A (250 mM
CaCl2) was carefully mixed with 15 mg DNA and 300 ml of solution B
(140 mM NaCl, 50 mM HEPES, 1.4 mM Na2HPO4 pH 7) in an Eppendorf
tube. Exactly 1 min after mixing, 300 ml of the precipitation cocktail was
added to the medium. The plates were incubated for 4 h at 37°C. The
medium was then removed, the cells were washed with phosphate-
buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4´7H2O, 1.4 mM KH2PO4) and fresh cell culture medium was
added.
Generation of the 293T La cell line
293T cells were transfected with pTetOff-Zeo using the calcium
phosphate method (see above). The selection of stable cell lines was
initiated 2 days later using 400 mg/ml Zeocin. After 3 weeks, ~50 colonies
were isolated and screened by transient transfection with pTRE2-Luc
(Clontech) for the expression of luciferase in induced and noninduced
cells (with or without 2 mg/ml Dox; Clontech). The clone with the lowest
background and high induction of luciferase (293T-TetOff) was then
transfected with pTRE2-hMLH1 and pTK-Hyg (ratio 15:1). Selection of
stable cell lines was initiated 2 days post-transfection using 400 mg/ml
hygromycin-B. After 3 weeks, ~160 colonies were isolated and their
extracts were screened by western blotting using antibodies against
hMLH1, hPMS2 and b-tubulin. The clone 293T La was selected for
further study, as it displayed the highest induction of hMLH1 in the
absence of Dox, and no background expression with 2 mg/ml Dox.
Regulation of hMLH1 expression
293T La cells were grown in the presence of 50 ng/ml Dox to keep
hMLH1 expression turned off; fresh Dox was added every second day. To
induce hMLH1 expression, the cells were transferred to a Dox-free
medium, and the cells were cultivated for at least 6 more days. To obtain
cells completely free of hMLH1, cells grown in the absence of Dox were
kept for a least 7 days in a medium containing 50 ng/ml Dox. To obtain
intermediate levels of hMLH1, the cells were cultivated with 1.5, 0.8, 0.4,
0.2 or 0.1 ng/ml Dox for at least 7 days.
Preparation of total protein extracts for western blots
Cells were harvested, transferred to a 1.5 ml Eppendorf tube and washed
twice with PBS. Cell lysis was performed on ice in 50 mM Tris±HCl pH 8,
125 mM NaCl, 1% NP-40, 2 mM EDTA, 1 mM phenylmethylsulfonyl
¯uoride, 13 complete protease inhibitory cocktail (Roche Molecular
Biochemicals) for 25 min. Insoluble material was pelleted by
centrifugation at 18 000 g for 3 min at 2°C. Protein concentration was
determined using the Bradford assay (Bio-Rad, Munich, Germany).
Western blot analyses
The primary antibodies used in this study were: anti-hMLH1
[PharMingen, San Diego, CA), 1:2000 in TBST (20 mM Tris±HCl
pH 7.4, 150 mM NaCl, 0.1% Tween-20 with 2.5% non-fat dry milk],
hPMS2 (Calbiochem; 1:500), b-tubulin, p53 (Santa Cruz Biotechnology;
1:1500 and 1:2000, respectively), cdc2 (Upstate Biotechnology;
1:1000) and phospho-p53-Ser15, phospho-cdc2-Tyr15 (Cell Signalling
Technology; 1:1000 and 1:5000, respectively). The proteins (20±50 mg)
were denatured, reduced, separated by SDS±PAGE (7.5±12.5%) and
transferred to Hybond-P PVDF membrane (Amersham Pharmacia
Biotech) according to standard protocols (Sambrook et al., 1989). The
membranes were blocked with 5% non-fat dry milk in TBST for 60 min,
incubated with primary antibodies for 60 min, washed three times with
TBST for 10 min, incubated with the peroxidase-conjugated secondary
antibody (anti-mouse IgG, 1:5000 in TBST with 2.5% non-fat dry milk)
for 60 min and washed three times with TBST for 10 min.
Immunoreactive proteins were detected using enhanced chemilumines-
cence (ECL; Amersham Pharmacia Biotech).
Indirect immuno¯uorescence experiments
Cells grown on coverslips were treated or mock-treated with MNNG
(0.2 mM end concentration) and incubated for 6, 12 and 24 h (Figure 4B).
Foci of phosphorylated histone H2AX were visualized using an anti-
phospho-H2AX rabbit polyclonal antibody (Upstate Biotechnology) at
+4°C, over night, at a dilution of 1:100. The procedure was as described
previously (Kleczkowska et al., 2001). To allow direct comparisons, all
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the cells were treated and processed simultaneously, and all the images
were obtained using the same magni®cation, brightness and contrast
settings.
MMR assays
The cell extracts were prepared as described previously (Marra et al.,
2001; Nystrom-Lahti et al., 2002). Two different in vitro assays were
used. The ®rst, adapted from Holmes et al. (1990), is based on a circular
3¢ 193 bp DNA molecule containing a G/T mismatch within a unique
BglII recognition site, a single-strand nick 369 nucleotide residues 5¢ from
the mismatch in the G-containing strand, and a unique BsaI site. This
molecule is refractory to cleavage with BglII, unless the mispair is
corrected to an A/T. Thus, the unrepaired heteroduplex digested with both
endonucleases gives rise to only a single fragment of 3¢ 193 bp, whereas
the repaired homoduplex is cleaved into two fragments of 1¢ 833 and
1¢ 360 bp (Nystrom-Lahti et al., 2002).
The second method, originally described by Thomas et al. (1991),
makes use of an M13mp2 DNA heteroduplex containing G/T mismatch
within lacZa complementation gene, obtained by hybridizing single-
stranded viral (+) DNA with the replicative form I (±) strand. The repair is
directed to the (±) strand by the presence of a nick. The method was
described in detail elsewhere (Marra et al., 2001). In the complementation
studies, extracts were supplemented with puri®ed recombinant hMutLa
(0.1 mg).
MTT assays
Two thousand cells/well were plated in 96-well plates, treated the next
day with various concentrations of MNNG (Sigma; diluted in dimethyl
sulfoxide and stored at ±20°C in the dark) and incubated for 5 days. Then,
20 ml of MTT solution (5 mg/ml MTT; Sigma; in PBS, sterile ®ltered) was
added, and the plates were incubated for 4±5 h at 37°C. One volume of
lysis solution was then added (20% SDS, 50% dimethylformamide
pH <4.7), and the plates were incubated overnight at 37°C. The
solubilized formazan was quanti®ed at 570 nm, using the Versamax
microplate reader (Molecular Devices, Sunnyvale, CA). The optical
density values were plotted against logarithm of MNNG concentrations
and IC50 values were calculated from the regression curve.
Colony-forming assays
Cells in log phase (50±80% con¯uent) were treated with 5 mM MNNG,
harvested after 2 h, and 200 or 2000 cells per duplicate were plated in
10 cm plates. Colonies were counted after 15±20 days of incubation.
Survival was calculated as the ratio of the number of colonies from
treated versus untreated samples.
Doubling time assessment
Cells (35 000) were plated in 35 mm plates. The cell number was
determined daily for 4 days. The doubling time was calculated from the
numbers of cells between the ®rst and the fourth day after plating.
Cell cycle analyses
Cells (both attached and ¯oating) were harvested, counted, washed with
PBS, ®xed with 70% ethanol and stored up to 1 week at 4°C. The cells
were then washed once with PBS, incubated in PBS containing RNase A
(100 mg/ml, Sigma) for 1 h at 37°C, stained with propidium iodide
(20 mg/ml, Sigma) and incubated on ice in the dark for 30 min. DNA
content was analysed by Coulter Epics Altra Flow Cytometer (Beckman
Coulter, Inc., Fullerton, CA). DNA cell cycle analysis software
(MultiCycle, Phoenix Flow Systems, Inc., San Diego, CA) was used to
quantify cell cycle distribution.
MSI analysis
293 La cells grown with 50, 0.2 and 0 ng/ml Dox were subcloned, and
grown independently for 35 generations. The chromosomal DNA was
extracted using the TRI Reagent (Molecular Research Center, Lucerne,
Switzerland). MSI was assessed at the mononucleotide repeat locus
BAT26. PCRs were carried out in a total volume of 25 ml containing
~100 ng of genomic DNA, as described by Loukola et al. (2001). The
PCR products were diluted 1:4 and 0.5 ml was added to 10 ml deionized
formamide (including 0.5 ml GS size standard 400 ROX), denatured at
95°C for 5 min, chilled on ice and loaded on a 96-capillary ABI PRISM
3700 DNA Analyzer (PE Applied Biosystems). MSI was de®ned as the
occurrence of novel alleles that differed by 63 nucleotides from the
control (Loukola et al., 2001).
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Abstract
DNA mismatch repair (MMR) defects bring about a strong mutator
phenotype and microsatellite instability (MSI). In an attempt to exploit
MSI in cancer therapy, we constructed expression vectors carrying a
thymidine kinase/blasticidin deaminase fusion gene downstream from a
(C)12 or an (A)26 microsatellite and stably transfected these constructs into
human cells in which the MMR status could be regulated by doxycycline.
We now show that ganciclovir-resistant clones arising through frameshifts
in the (C)12 microsatellite were 20 times more frequent in cells in which
MMR was inactivated. This difference may be exploited in gene therapy
of tumors with MSI, which represent a substantial proportion of cancers
of many different tissues.
Introduction
A substantial proportion of tumors of different organs displays
MSI1, a phenotypic trait characterized by a large increase in the
frequency of frameshift mutations within repeated sequence elements,
the so-called microsatellites. This anomaly is caused by inactivation
of the postreplicative MMR system, which normally corrects strand
misalignments arising in these repeats during DNA replication (1). In
hereditary nonpolyposis colon cancer kindred, which represents 5%
of colon cancer patients, the MMR defect and MSI are linked to
inherited mutations in genes encoding MMR proteins. In 10% of
sporadic colon cancers, MSI arises as a result of epigenetic silencing
of the MMR gene hMLH1 (2, 3), and an ever-increasing number of
reports describe MSI also in cancers of head and neck, lung, prostate,
breast, bladder, and other tissues (reviewed in Ref. 4). Past attempts to
identify agents able to selectively kill MSI cells largely failed. Upon
treatment with a range of DNA damaging agents, substantial differ-
ences in the response of MMR-deficient and -proficient cells were
observed only for cisplatin, which kills MMR-proficient cells3-fold
more efficiently than MMR-deficient ones (5) and for SN1-type meth-
ylating agents, where the difference is 100-fold (6, 7). MMR-
deficient cells were reported to be more sensitive to killing by CCNU
than MMR-proficient controls (8), but this difference appears to be
limited to only a subset of MMR-deficient cell lines. Thus, in an
attempt to identify a more general approach toward the therapy of
MMR-deficient tumors, we set out to exploit the MSI phenotype. In
cultured human cells established from these tumors, MSI was reported
to be two to three orders of magnitude higher than in control lines. We
plan to introduce into the cells a toxin-encoding gene, the ORF of
which is preceded by a labile microsatellite sequence such that the
gene is out-of-frame (Fig. 1A). If the microsatellite undergoes inser-
tion or deletion mutagenesis, the toxin ORF should in a given number
of events be shifted into the correct reading frame; the construct
should thus express the functional toxin polypeptide, and the trans-
duced cell should be killed. This experimental strategy should result
in an efficient elimination of MMR-deficient cells, whereas MMR
proficient cells in which the microsatellite remains stable should be
unaffected. However, before deploying the above strategy, we needed
to establish an experimental system that would permit us to reliably
test the relative stability of a variety of microsatellite repeats in
MMR-proficient and -deficient cells. The critical characteristics of the
ideal repeat should be its high stability in the former cells and
substantial instability in the latter. The mutation frequencies of several
microsatellites have been previously studied, using a variety of assays
(9–12). However, in these studies, two major problems were encoun-
tered. First, it could not be excluded that the repeats acquired muta-
tions already during the lengthy selection of the stable transfectants.
Second, the studies did not use isogenic pairs of MMR-proficient and
-deficient cell lines such that it was impossible to exclude the effects
on the mutation frequency of other genetic defects present in these
cells. Indeed, Hanford et al. (9) described extensive variation among
microsatellite mutation rates of different clones of the same cell line.
We now describe a system that successfully overcomes these draw-
backs by making use of a strictly isogenic cell pair and a reporter
system that allows for the elimination of mutated transfectants before
the initiation of the experiment.
Materials and Methods
Cell Lines. 293T L cells were derived from the hMLH1-deficient human
embryonic kidney 293T cells by stable transfection with a vector carrying the
hMLH1 cDNA under the control of the inducible Tet-Off expression system
(7). The cells were grown in DMEM with Eagle salts (Life Technologies, Inc.,
Gaithersburg, MD), supplemented with 10% Tet System Approved Fetal
Bovine Serum (Clontech, Palo Alto, CA), 2 mM L-glutamine (Life Technolo-
gies, Inc.), 100 IU/ml penicillin, 100 g/ml streptomycin (Life Technologies,
Inc.), 100 g/ml Zeocin (Invitrogen, San Diego, CA), and 300 g/ml hygro-
mycin B (Roche Molecular Biochemicals, Basel, Switzerland). To obtain cells
completely free of the MMR protein hMLH1 (293T L), the cells were
transferred for at least 7 days to a medium containing 50 ng/ml DOX (Clon-
tech). Fresh DOX was added every second day. To induce hMLH1 expression
(293T L), the cells were transferred to a medium without DOX, the medium
was changed the following day, and the cells were cultivated for at least 6 more
days. Expression of hMLH1 in these cells fully restored MMR proficiency (7).
Vector Construction. The pSBCTKBSD vector (13) containing the fusion
gene encoding thymidine kinase and blasticidin deaminase was used as a
template for a PCR reaction in an assay consisting of 1 Cloned PFU buffer,
1 M forward primer, 1 M reverse primer, 200 ng of template DNA, 0.2 mM
deoxynucleoside triphosphates and 2.5units/50l reaction Pfu turbo DNA
polymerase (Stratagene, La Jolla, CA). The primers (Microsynth, Balgach,
Switzerland) were as follows: forward no-repeat, TGG CCA GGA TCC ACC
ATG ATT GAA GAA TTC ATT GAA CAA GAT GGA TTG CAC GCA GG;
Received 8/14/03; revised 10/2/03; accepted 10/16/03.
Grant support: UBS AG (to P. C.) and from the European Community Grant
QLG1-CT-2000-001230 (to J. J., Z. S.).
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
Present address: Zuzana Storchova, Department of Pediatric Oncology, The Dana-
Farber Cancer Institute, Boston, Massachusetts.
Requests for reprints: Josef Jiricny. Phone: 41-1-634-8910; Fax: 41-1-634-8904;
E-mail: jiricny@imr.unizh.ch.
1 The abbreviations used are: MSI, microsatellite instability; BSD, blasticidin deami-
nase; DOX, doxycycline; GANC, ganciclovir; MMR, mismatch repair; ORF, open read-
ing frame; TK, thymidine kinase; TKBSD, thymidine kinase/blasticidin deaminase fusion
gene.
8113
forward (C)12, TGG CCA GGA TCC ACC ATG ATT GAA CCC CCC CCC
CCC ATT GAA CAA GAT GGA TTG CAC GCA GG; forward (A)26, TGG
CCA GGA TCC ACC ATG ATT GTC AAA AAA AAA AAA AAA AAA
AAA AAA ATT GAA CAA GAT GGA TTG CAC GCA GG; and reverse,
TAC TCG CTC GAG TCA ATG TAT CTT ATC ATG TCT GGA TCG. The
PCR cycle was as follows: 98°C for 3 min, (98°C for 1 min, 69°C for 1 min,
and 72°C for 5 min)30, 72°C for 10 min. The PCR products were digested with
BamHI and XhoI (both New England Biolabs, Beverly, MA) and cloned into
the corresponding sites of pcDNA3 (Invitrogen), creating pcDNA3-TKBSD,
pcDNA3-(C)12TKBSD, and pcDNA3-(A)26TKBSD vectors.
Isolation of Stable Transfectants. pcDNA3-TKBSD, pcDNA3-
(C)12TKBSD, and pcDNA3-(A)26TKBSD vectors were digested with BglII
and DraIII (both New England Biolabs) and subjected to preparative gel
electrophoresis. The fragments containing the TKBSD fusion gene were iso-
lated and used for transfection of 293T L cells using the FuGENE reagent
(Roche, Basel, Switzerland). Selection was initiated 2 days after transfection
with 10 g/ml blasticidin S (Invitrogen). After 2–3 weeks, stable clones were
isolated and additionally propagated with blasticidin (100 g/ml).
Mutagenesis Assays. The selected clone, carrying the microsatellite re-
peat/TKBSD fusion stably integrated in the genome, was grown without or with
50 ng/ml DOX in a 6-well plate in a medium containing 100 g/ml blasticidin
for 7 days. At this time point, the cells grown in the presence of DOX were
completely free of hMLH1 and thus MMR-deficient, and cells grown without
DOX remained MMR proficient. The high concentration of blasticidin in the
medium ensured elimination of cells with frameshifted inserts. The blasticidin
was then removed and the cells were additionally propagated without or with
DOX in a 6-well plate. As the doubling time is 24 h, the cells were split
every 2 days in a ratio 1:4 to maintain a constant cell number. In the absence
of blasticidin, cells in which the TKBSD fusion gene was inactivated by
frameshift mutagenesis (or otherwise) survived. Immediately upon blasticidin
withdrawal and at the selected time points (4, 8, and 13 days, 4, 8, and 13
generations), 1  105 or 5  104 cells were plated into 10-cm dishes in 10 ml
of medium containing 30 M GANC (Sigma, St. Louis, MO) to score for
mutant (GANC-resistant) cells. At the same time, 300 cells were plated in a
medium without GANC to assess plating efficiency (control). After 2 weeks of
incubation, the colonies were stained with Giemsa (Fluka, Buchs, Switzerland)
and counted (see Fig. 1C for a schematic outline of the experiment).
MSI Analysis. Chromosomal DNA from the GANC-resistant colonies was
extracted using the TRI reagent (Molecular Research Center, Cincinnati, OH).
The vector DNA sequence containing the repeat was amplified by PCR under
the following conditions: 1 Taq buffer, 1 M forward primer, 1 M reverse
primer, 300 ng of template DNA, 0.2 mM deoxynucleoside triphosphates, and
2 units/50 l reaction TaqDNA polymerase (New England Biolabs). The
following primers (Microsynth, Balgach, Switzerland) were used: forward
(GCG GTA GGC GTG TAC GGT G), reverse (CCA GTC CTC CCG CCA
CGA CC). The PCR procedure was as follows: 95°C for 2 min (95°C for 1
min, 60°C for 1 min, and 72°C for 1 min 20 s)25, 72°C for 10 min. The PCR
products were purified, and the DNA regions containing the repeats were
sequenced using the primer GTA CGT AGA CGA TAT CGT CG on an ABI
PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA).
Results and Discussion
The experimental system intended for use in gene therapy of tumors
with MSI is based on transduction of the tumor cells with a vector
carrying a toxin gene that is out-of-frame because of the insertion of
a microsatellite immediately downstream from its AUG start codon
(Fig. 1A). The inherent instability of the microsatellite in MMR cells
should result in restoration of the correct reading frame in a given
percentage of the transduced cells and thus in expression of the toxin
and cell death. However, for the purposes of the present study, we
decided to invert this strategy by making use of an in-frame reporter/
toxin combination that allows for a more accurate estimation of
mutation frequencies and is free of artifacts (Fig. 1, B and C). The
reporter gene construct was a fusion of BSD from Aspergillus terreus
and TK from Herpes simplex virus (13). This fusion gene was pre-
ceded by a microsatellite repeat, which was inserted immediately
downstream from the start codon, but which maintained the correct
reading frame of the fusion gene. For the initial experiments, we chose
Fig. 1. A, scheme of a gene therapy approach designed to target MSI cells. The microsatellite repeat puts the toxin out of the correct reading frame, and thus the vector produces
no functional polypeptide. In a MMR cell, the toxin gene may be reverted into its correct reading frame through MSI, and the cell will be killed. In contrast, the repeat should remain
stable in cells with functional MMR. B, the constructs used in this study. The (C)12 and (A)26 microsatellites or a control DNA sequence without a repeat were inserted downstream
from the start codon of the TKBSD fusion protein while keeping the ORF in its correct reading frame. C, scheme of the test assay (see also “Materials and Methods”). 293T L cells
were transfected with constructs shown in B, and stable clones were isolated using blasticidin selection. The selected clones were then grown in two separate subcultures: in the
MMR-proficient (L, without DOX) and -deficient (L, with DOX). After 4, 8, and 13 days (which corresponds to4, 8, and 13 cell generations, respectively), the cells were treated
with GANC and plated to select for TK mutants.
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the (A)26 and (C)12 repeats, together with a control construct that
carried no repeat (Fig. 1B). The BSD protein confers resistance
against blasticidin, which permits the selection of clones carrying the
nonmutated construct stably integrated in the genome. Inducing MMR
deficiency in one-half of the cells by adding DOX to the culture
medium and propagating the cells independently in a MMR-deficient
or -proficient mode for several generations without selection allows
for mutations within the repeat to occur. Addition of GANC to the
medium then eliminates cells in which no frameshifting occurred (Fig.
1C). Thus, by counting the surviving TK (GANC-resistant) colonies,
we can calculate the mutation frequency in a cell population that
consisted initially exclusively of TK cells (i.e., without preexisting
mutants), all carrying the vector integrated in the same genomic
sequence context and in a strictly isogenic genetic background.
Before initiating this study, we had to check the integrity of the
stable clones carrying the reporter constructs, more specifically, the
integrity of the Tet-Off system that controls the inducible expression
of hMLH1. As shown in Fig. 2A, the 293T L cells and the clone
stably transfected with the pcDNA3-(C)12TKBSD vector [denoted
293T L(C)12TKBSD] expressed both hPMS2 and hMLH1 in sim-
ilar amounts. In the presence of DOX, the transcription of hMLH1
was shut off, which resulted in the depletion of the hMLH1/hPMS2
heterodimer (7); these cells are denoted 293T L(C)12TKBSD. The
selected clones carrying the pcDNA3-(A)26TKBSD and pcDNA3-
TKBSD vectors, 293T L(A)26TKBSD and 293T L TKBSD, re-
spectively, behaved similarly (data not shown).
Results of the mutagenesis assays (“Materials and Methods”) indi-
cated that the (C)12 repeat remained stable in the MMR-proficient
293T L cells (Table 1 and Fig. 2, B and C). The TK gene remained
in-frame, and upon addition of GANC, most of the cells were killed.
In contrast, frequent frameshift mutations within this repeat in a
MMR-deficient background gave rise to a20-fold higher number of
GANC-resistant clones in which the TKBSD gene was shifted out-of-
frame (Fig. 2, B and C). The number of GANC-resistant colonies
increased with time in both MMR-proficient and -deficient back-
grounds, but the fold-difference remained relatively stable (Fig. 2C).
In contrast to (C)12, the (A)26 repeat was labile in both MMR-
proficient and -deficient backgrounds, displaying only 2 fold dif-
ference in stability (Fig. 2, B and C, and Table 1).
To confirm that the GANC-resistant phenotype resulted from a
mutation in the reporter construct, we sequenced the DNA regions
containing the repeat and its close proximity. Microsatellite frame-
shifts were detected in all of the 293T L samples sequenced (30 of
30). Only 1 frameshifts were observed in the (C)12 repeat and 1
or, less frequently, 2 frameshifts in the (A)26 repeat (Fig. 2D).
Fig. 2. Differences in repeat stability in isogenic
293T L cells. A, Western blot analysis of total cell
extracts of 293T L (C)12TKBSD cells cultured in
the absence (L, expressing hMLH1/hPMS2) or
presence (L, not expressing hMLH1/hPMS2) of
50 ng/ml DOX. The extracts of 293T L cells are
shown as the positive control. (See Ref. 7 for
experimental details.) -Tubulin was used to ascer-
tain equal gel loading. B and C, comparison of
repeat stabilities in isogenic MMR-proficient
(L) and -deficient (L) cells. B, example of a
typical result of an assay described in Fig. 1C. Cells
were grown for 8 days without blasticidin, treated
with GANC, plated, and the GANC-resistant colo-
nies (GANCr) were stained and counted after 2
weeks. Control, cells plated without GANC to es-
timate plating efficiency (see “Materials and Meth-
ods”). C, numbers of GANC-resistant colonies
were adjusted, using plating efficiency, for 5 104
plated colony-forming cells, and plotted for each
time point. Each data point represents the mean of
five independent experiments; error bars show SD.
D, MSI analysis. Left panel, original sequence
without mutations; right panel, loss of one repeat
unit.
Table 1 Average fold-differences in the number of GANC-resistant colonies in
MMR-deficient versus proficient backgrounda
Days without
selection
293T L
(C)12
TKBSD
(A)26
TKBSD TKBSD
4 29.5 (17) 1.6 (0.1) 1.4 (0.1)
8 17.1 (3.9) 2.1 (0.3) 1.2 (0.1)
13 19.2 (2.8) 2.6 (0.2) 1.6 (0.1)
a The values shown in the table were calculated by dividing the number of GANC-
resistant colonies in the MMR-deficient background by the number of GANC-resistant
colonies in the MMR-proficient background at each time point (4, 8, and 13 days) for each
individual experiment. Shown are average values for each time point from five independ-
ent experiments. See also “Materials and Methods.” Numbers in parentheses show SEs.
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Although most of the DNA samples isolated from the GANC-resistant
MMR-proficient cells also contained 1 or 2 microsatellite frame-
shifts, other types of mutations (3 of 30) were also detected (data not
shown) in agreement with previous studies (9). In control clones not
containing a repeat within the reporter gene, the construct remained
relatively stable and we did not detect significant differences in
stability between MMR-proficient and -deficient backgrounds (Fig.
2C and Table 1). The above information is invaluable for the design
of the therapeutic out-of-frame vector (Fig. 1A). In theory, only a
fraction of frameshift mutations should lead to the restoration of the
correct reading frame because of the possibility of both insertions and
deletions. Our data demonstrate that deletions of a single repeat unit
of a given microsatellite repeat predominate. Taking this evidence into
account, it should be possible to design vectors with a high propensity
toward shifting into the correct reading frame, i.e., by having the toxin
gene insert in the vector in a 1 reading frame in cases where it is
preceded by a mononucleotide repeat.
Microsatellite mutation frequencies measured in our MMR-defi-
cient cells (Fig. 2C and Table 2) roughly corresponded to those
described by others (9, 14, 15). However, the relative differences
between MMR-proficient and -deficient cells were somewhat smaller:
20-fold in our system as compared with 16–340-fold as described
by Hanford et al. (9) or 25–100-fold as described by Kahn et al. (12).
However, the latter studies compared mutation frequencies of MMR-
deficient colon carcinoma cells either with those of unrelated MMR-
proficient colon carcinoma cells or even with those of MMR-profi-
cient cancer or normal cells of different type. It has been well
documented that cells acquire a plethora of mutations during trans-
formation. Some of these mutations might inactivate cell cycle check-
point pathways, which might allow DNA replication in the presence
of DNA damage, and thus permit the accumulation of additional
mutations even in a MMR-proficient background. Indeed, Boyer and
Farber (16) found a 75-fold difference in the mutation frequency of
the same microsatellite in MMR-proficient normal human fibroblasts
and fibrosarcoma cells. Clearly, genetic differences between cells of
different origin make a direct comparison of mutation frequencies
very difficult.
A recent study (10) used the human MMR-deficient colon cancer
cells HCT116 and their MMR-proficient counterparts (HCT116Chr3)
where the MMR defect was corrected by chromosome 3 transfer.
These two cell lines, although not isogenic, are more closely related
than those used in the studies cited above. Interestingly, the observed
30-fold difference in the stability of a (CA)13 microsatellite is quite
close to that of the (C)12 repeat examined in our study.
The 20-fold difference in the stability of the (C)12 microsatellite
between MMR-proficient and -deficient cells is lower than might have
been anticipated from the results of earlier studies, however, given the
extremely low mutation frequency in the MMR-proficient cells, it is
likely to be therapeutically exploitable. Moreover, it is highly likely
that analysis of a larger number of mononucleotide and dinucleotide
repeats will identify a sequence with a substantially higher therapeutic
index. Thus, exploitation of the MSI phenotype, which is currently
estimated to segregate with 15% of colon cancers, may represent a
valid approach toward combating these tumors and, more importantly,
their metastases.
One of the major challenges of tumor therapy is acquired resistance
to treatment. Because the MSI phenotype is linked with defective
MMR, the only chance the transduced cell has to escape death is either
to stop replicating, which would in itself lead to tumor regression, or
to silence the transcription of the transgene. The latter scenario is
unlikely because gene silencing requires as a rule many cell divisions
and because the microsatellite repeat tested in our study was unstable
after only four replication cycles. Even if this problem should arise, it
could be overcome by repeated transductions. It is therefore likely that
the problem of resistance will not pose a substantial threat to this
approach.
The study described above represents but an initial step toward this
goal. As the environment of cells in tumors differs dramatically from
that in cell culture, it will be necessary to carry out in vivo experiments
using, in the first instance, human tumor xenografts in nude mice.
Should these experiments meet with success, the transducing vector
will be remodeled to carry the suicide gene out-of-frame, which would
be moved into the correct reading frame through selective frameshift
mutagenesis in MSI cells, as shown in Fig. 1A. In a gene therapy
setting, most cells in solid tumors are not transduced and it is likely
that not each cell will mutate the microsatellite. But as tumor cells are
in close contact, it is anticipated that the suicide gene will exert a
bystander effect, which should bring about the death not only of the
transduced cell that acquired the frameshift mutation but also of a
number of surrounding cells (17). A complete eradication of a tumor
expressing TK has been reported, although only 10% of the tumor
cells expressed the enzyme (17). Cytosine deaminase, another suicide
gene frequently used in gene therapy trials, has been reported to be
effective even if only 2% of the tumor cells were transduced (18), and
strategies causing even more effective bystander effects are being
developed (19). The system described in this study should permit the
identification of the most effective microsatellite/enzyme/prodrug
combination that could then be further developed for therapeutic use.
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5.Conclusions and future perspectives 
 
5.1. The role of hMLH3 in MMR 
Our data represent the first report on the variable expression levels of hMLH3 in human 
cell lines and its possible epigenetic inactivation by promoter hypermethylation. We also 
confirmed, by immunoprecipitation experiments, the in vivo interaction between hMLH1 
and hMLH3. An interesting observation was the different stability of hMLH3 in Sf9 and in 
human cells. While the protein needs the presence of hMLH1 when expressed in insect 
cells, it is instead stable in hMLH1-deficient cells, suggesting the requirement of additional 
interacting partners in vivo, to mediate its stabilization. We thus plan to use the Tandem 
Affinity Purification method to identify proteins in complex with hMLH3 and so to further 
characterize the role of hMLH3 or hMutLγ in human cells. Most importantly, we could 
demonstrate an in vitro activity of hMLH3 in MMR. The contribution of hMLH3 to MMR 
seems to be marginal thus the significance of this contribution in vivo is questionable. 
Interestingly, parallel to our observation, Lipkin et al. demonstrated the contribution of 
Mlh3 to tumour suppression in the mouse. In summary, more data is needed to clarify the 
role of hMutLγ in vivo, especially regarding its role in colon cancer. 
 
5.2 Identification of interacting partners of hMLH1 and 
hPMS2 by Tandem Affinity Purification 
We used the Tandem Affinity Purification (TAP) technique to identify novel interacting 
partners of hMLH1 and hPMS2. Our analysis resulted in the identification of several 
known interacting partners of hMLH1 and/or hPMS2, thus validating the method, and 
revealed the presence of numerous, previously undescribed, proteins in complex with one 
or both MutL proteins. We grouped these proteins into functional groups and we set out to 
characterize some of these interactions further. Remarkably, we identified the BRCA1-
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interacting protein 1 (BRIP1 or BACH1), recently described as FancJ, in complex with 
hMutLα. This interaction was validated by reciprocal immunoprecipitation and it is of 
particular interest. BRIP1 was shown to have DNA helicase activity and it has been 
implicated in the repair of double strand breaks. Notably, the helicase involved in human 
MMR, if any, still remains to be identified and we are currently investigating the possible 
role of BRIP1 in MMR or related-processes. 
In addition, we validated by immunoprecipitation analysis the interaction between hMLH1 
and Angiomotin. Angiomotin, a recently identified protein involved in the promotion of 
angiogenesis, is present in the cells in two forms, a high molecular weight (p130) and a 
lower molecular weight (p80). Interestingly, only the p130 form seems to bind to hMLH1. 
Immunofluorescence experiments showed Angiomotin to be localized in the cytoplasm of 
293T cells, we thus assume that hMLH1 might assist Angiomotin in its function rather then 
the contrary. We intend to start collaboration with Prof. Lars Holmgren, (Karolinska 
University Hospital, Stockholm) to investigate this unexpected cytoplasmic role of 
hMLH1. 
The finding of Importin α2 in complex with hMLH1 and hPMS2 points to a role of this 
protein in the nuclear import of hMutLα. Importin α2 belongs to the family of 
karyopherins, a group of proteins devoted to the nuclear import of polypeptides containing 
a sequence called nuclear localization signal (NLS). Both hMLH1 and hPMS2 were shown 
to possess a NLS in their sequence so that the possibility that Importin α2 is the molecule 
involved in their nuclear translocation is attractive and will probably be one of our future 
subjects of investigation. 
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5.3 Identification of hPMS1 interacting partners by large-
scale immunoprecipitation 
The analysis of the interacting partners of hPMS1 brought us to the identification of several 
proteins. Among these the presence of several factors belonging to the ubiquitin-pathway is 
of particular interest, suggesting that hPMS1 might undergo such a post-translational 
modification. We investigated this possibility and demonstrated that hPMS1 is in fact poly-
ubiquitinated in untreated cells. This could be a relevant finding for a possible role of 
hPMS1 in human cells. Interestingly, recombinant hPMS1 lacked any MMR activity in 
vitro. We are now investigating whether the activity of hPMS1 in the repair process is 
dependent on its ubiquination. 
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